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In the field of surgery, a wide range of different imaging modalities are applied for pre-operative 
diagnostics, intraoperative guidance and post-operative follow-up. For diagnostics and follow-
up, mainly X-ray, computed tomography (CT), magnetic resonance imaging (MRI), positron 
emission tomography (PET) or single-photon emission computed tomography (SPECT), and 
ultrasound (US) are routinely employed. These modalities have been significantly improved over 
the past decades and allow, each with its own advantages and disadvantages, for high resolution 
imaging with a broad supply of information relevant to the standard care of treatment. However, 
despite these highly advanced modalities, a major limitation in imaging today is the inability 
to specifically distinguish pathology from healthy tissue at a cellular and functional level. In 
particular, it remains a major challenge to distinguish tumors from normal tissue, or infections 
from sterile inflammation. Consequently, there is a pressing need for novel advanced imaging 
modalities that can reliably discern pathologies from healthy tissue and other diseases.
Imaging during surgery is far less evolved than the imaging applied for pre-operative diagnostics 
and post-operative follow-up. For centuries, surgeons have relied mainly on visual and tactile 
information. Tumor borders, for example, are difficult to recognize by a surgeon and microscopic 
invasive carcinoma in the margins of the surgical specimen are only detectable through 
postoperative histopathological analysis. Moreover, microscopic disease is still invisible for the 
surgeon. Frozen sections collected and analyzed during surgery may provide the surgeon with 
information on the radicality of resection, but this method is indirect and the information is 
limited only to the small site of tissue where a biopsy was taken. Clearly, the development of 
strategies to improve visualization during surgery and, thereby, to improve detection, precision 
of resection, and radicality would greatly improve the prognoses for patients in many different 
diseases. 
Fluorescence ImagIng
Fluorescence imaging or optical imaging is an elegant imaging modality that is currently rapidly 
evolving. Fluorescence imaging works as follows. Electrons in a fluorescent molecule become 
excited as soon as this molecule is exposed to light of a specific wavelength. When these electrons 
fall back into their normal energy state, fluorescent light of a slightly longer wavelength is emitted. 
This emitted light can be detected with a specialized charge-coupled device (CCD) camera. All 
human tissues show a certain degree of auto-fluorescence, especially in the visible light range 
with wavelengths of 400-600 nm. However, particular fluorophores emit stronger signals that 
can be distinguished from the auto-fluorescence of human tissue. The best-detectable signals are 
derived from fluorophores that emit light in the near-infrared range (NIR; 700-1000 nm). This 
is due to the fact that the longer wavelengths allow for maximal tissue penetration, whereas tissue 
autofluorescence is minimal in the NIR range.1 NIR fluorescence imaging has a high signal-
to-background ratio compared to other imaging modalities. Importantly, fluorescence imaging 
has several other favorable qualities, such as high spatial resolution, low costs, no involvement 
of radiation, and the possibility of real-time measurements.1 The NIR signal has a maximum 
penetration depth of 2 cm, which makes fluorescence imaging suitable for the examination of 
surfaces and superficially located structures.2 
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A broad spectrum of fluorescent dyes is available and several of these dyes have been clinically 
approved, namely fluorescein isothiocyanate (FITC; 518 nm), indocyanin green (ICG; 790 nm) 
and IRDye800CW (800 nm). 
targeted ImagIng
In targeted imaging, a contrast agent is used that is specifically taken up at the site of interest, 
allowing for site-specific imaging. In this way, information can be gathered regarding the 
localization of a certain disease process and biological activity. The extent of the pathology and 
its exact anatomical location can be pointed out as such. Targeted imaging can be achieved 
by conjugating an imaging agent, such as a radionuclide or a fluorophore, to a molecule that 
specifically targets a proteinaceous or non-proteinaceous receptor present on the target of interest. 
The targeting molecule can be virtually any molecule that specifically binds to the target of 
interest, for example an antibody, an antibody fragment, or a clinically available pharmaceutical 
such as an antibiotic. Targeted imaging can be performed with both fluorescence imaging and 
other imaging modalities, such as PET/SPECT scanning, CT, MRI and US.3-5 The sensitivity 
and specificity of targeted imaging depends, in addition to the targeting probe and the imaging 
device itself, largely on the receptor that is targeted. The level and pattern of expression of the 
receptor in both diseased tissue and healthy tissue will strongly impact on the target-to-normal 
tissue (T/N) ratio for the respective signal. Therefore, it is of importance to have a thorough 
understanding of the receptor intended for targeting and its expression level in the course of a 
certain disease process and within the individual patient.
Targeted fluorescence imaging can in principle be applied in two ways, namely intraoperatively 
for surgical guidance and direct feedback, or peri-operatively as a diagnostic modality and for 
follow-up. Intraoperative real-time fluorescence imaging is likely to improve detection and 
surgical elimination of pathologic tissue. This requires the use of fluorescently labeled probes 
targeted against biomarkers that are expressed by the target cells. With the help of these probes 
and an appropriate CCD camera, it is possible to detect in real-time a signal emitted from 
the diseased tissue and to convert this signal into an image depicted on a monitor for surgical 
feedback. In this way surgeons will be able to operate using their own tactile information combined 
with additional visual, functional, molecular-based information in the operating theater. Using 
fluorescence imaging, residual and/or metastatic disease can be visualized during surgery and 
appropriate action can be taken. Over the last decade, real-time intraoperative fluorescence 
imaging has been performed successfully in animal studies using many targets in many different 
diseases. Importantly, tumor spots as small as 0.3 mm that are not visible to the naked eye, 
can be visualized with fluorescence intraoperative imaging in vivo as has been shown in animal 
models.6,7 Very recently, early clinical trials in oncology were performed with success, and routine 
implementation of this imaging modality for certain cancer types has been recommended.8-11 
Notably, the number of probes that are allowed for use in patients by organizations like the Food 
and Drug Administration (FDA) and European Medicines Agency (EMA) is still limited, and 
does not at all cover the need for applications to fight the wide range of diseases that could benefit 
of intraoperative fluorescence imaging.
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In peri-operative imaging, the use of targeted fluorescence imaging may be of particular value 
for the non-invasive detection of infections that have great impact on health care management 
and costs. Due to the high resolution of fluorescence imaging and the high sensitivity and 
specificity as a result of the targeted component, infectious agents may be detected at an earlier 
stage than is presently possible. This will facilitate early treatment, and prevent major damage. 
Altogether, it can be concluded that fluorescence imaging potentially allows for fast and easy 
bedside monitoring prior to and after surgery.
scope oF thIs thesIs
As outlined in the afore-going paragraphs, targeted fluorescence imaging holds great promise 
for improved peri-operative diagnostics and intraoperative accuracy. Therefore, the research 
described in this thesis was aimed at the identification of targets, targeting agents and fluorescent 
probes potentially suitable for clinical use in different disease states, namely cancer, gynecological 
pathology and infection.
part I. optIcal targeted ImagIng: target selectIon
Part I of this thesis is focused on intraoperative imaging in the field of intestinal malignancies 
and gynecological pathology. 
Colorectal peritoneal carcinomatosis (PC), the abdominally disseminated form of colorectal 
cancer, is an end-stage form of colorectal cancer with high morbidity and mortality. This 
disease is currently treated surgically with extensive cytoreduction, followed by hyperthermic 
intra-abdominal chemotherapy (HIPEC).12 The radicality of cytoreduction is related to overall 
survival.13 Therefore, major improvement can be expected from fluorescence guidance during 
cytoreduction, visualizing the submillimeter tumor spots that currently remain undetected. 
Chapter 2 of this thesis gives a systematic overview and discussion of potential biomarkers in 
colorectal cancer that could be used as targets for fluorescent probes. Furthermore, a systematic 
approach is suggested for the selection of potential targets in colorectal cancer through a novel 
scoring system - TArget Selection Criteria (TASC) - that may aid in the successful development 
of new targeted probes. 
In chapter 3, six clinically relevant biomarkers are presented that could serve as targets for 
intraoperative imaging of colorectal PC during the HIPEC procedure. These potential targets 
were investigated in tissue from patients with colorectal PC using immunohistochemistry (IHC). 
Four promising biomarkers were selected using the scoring system described in chapter 2, and 
newly synthesized probes targeted to these biomarkers were investigated in vivo for feasibility of 
intraoperative colorectal PC imaging.
Related to colorectal PC is PC of ovarian cancer. Similar to colorectal PC, this disease is associated 
with high morbidity and mortality, and the current curative treatment is mainly surgical in 
the form of cytoreduction.14 Also here, surgical cytoreduction could be greatly improved by 
intraoperative fluorescence targeted imaging. In chapter 4 of this thesis, the application of 
targeted imaging in ovarian cancer is discussed. Recently, the feasibility of targeted intraoperative 
fluorescence imaging in PC of ovarian cancer was demonstrated by targeting the folate receptor-
alpha (FR-α).8 
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In ovarian PC, often (neo)adjuvant chemotherapy is administered and/or a second surgical 
intervention is needed. Therefore, it is relevant to know what the effect of chemotherapy is on 
biomarker expression in ovarian cancer. This was investigated for the FR-α in patient-derived 
samples and the results are described in chapter 5. 
Apart from FR-α, the folate receptor-beta (FR-β) may be a suitable biomarker for targeting in 
both ovarian cancer and colorectal cancer as suggested in previous studies. Therefore, expression 
of FR-β in ovarian, breast and colorectal cancer was investigated by IHC on patient tissue and 
the relation with disease characteristics and with FR-α expression was analyzed as documented 
in chapter 6. 
The treatment of another more benign gynecological disease, endometriosis, which tends to 
spread through the abdominal cavity with debilitating effects could also benefit from intra-
operative targeted imaging for improved cytoreduction and thus surgical outcome. Although 
endometriosis is regarded as a benign disease, it can resemble a disseminating malignant disease 
with substantial morbidity. As in PC, the success of surgery depends heavily on the extent of 
cytoreduction. Chapter 7 reports on the investigation of potential targets for intraoperative 
imaging in endometriosis. In this particular study, the expression patterns of different biomarkers 
was evaluated by IHC in samples of patients with endometriosis, and the TASC scoring system 
for target selection was used to determine suitability for targeted imaging.
part II. ImagIng oF BacterIal InFectIons
Bacterial infection is a frequently occurring problem in the field of surgery, both as a disease 
that requires surgery, as well as a post-operative complication in the form of wound infection or 
infection of implanted biomaterials. As bacterial cells differ both biochemically and structurally 
from the cells of their human host, targeted imaging seems an attractive approach for the fight 
against bacterial infections where major improvements can be expected from intra- and peri-
operative targeted imaging. However, the currently available imaging modalities suffer from 
difficulties in detecting bacterial infections at an early stage. Moreover, it has remained hard 
to reliably distinguish bacterial infections from other pathologic disease states such as sterile 
inflammation. This clinically relevant topic is therefore addressed in part II of this thesis. 
In chapter 8, the current status of targeted imaging for the specific detection of bacteria is 
outlined in a systematic literature review, and a first definition of the respective TASC criteria is 
given.
To design a bacteria-specific probe capable of detecting infections through fluorescence imaging, 
the antibiotic vancomycin was conjugated to the NIR fluorescent molecule IRDye800CW. 
The rationale of this approach was that vancomycin will bind to most Gram-positive bacteria, 
thereby targeting the vast majority of infections encountered in the surgical field. Feasibility of 
targeted fluorescence imaging using this probe named vanco-800CW was tested in an infectious 
myositis model in mice and, subsequently, in a novel human post-mortem model for biomaterial 
infections. The results of these studies are described in chapter 9, showing proof-of-principle for 
the highly specific detection of bacterial infections with a ‘glowing antibiotic’. 
A summary of the results of studies described in this thesis is given in chapter 10. This chapter 
also highlights the overall conclusions and future perspectives for further research and clinical 
implementation are presented.
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Peritoneal carcinomatosis (PC) of colorectal origin is associated with a poor prognosis. 
However, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy 
is available for a selected group of PC patients, which significantly increases overall survival 
rates up to 30%. As a consequence, there is substantial room for improvement. Tumor 
targeting is expected to improve the treatment efficacy of colorectal cancer (CRC) further 
through 1) more sensitive preoperative tumor detection, thus reducing overtreatment; 2) 
better intraoperative detection and surgical elimination of residual disease using tumor-
specific intraoperative imaging; and 3) tumorspecific targeted therapeutics. This review 
focuses, in particular, on the development of tumor-targeted imaging agents. A large 
number of biomarkers are known to be upregulated in CRC. However, to date, no validated 
criteria have been described for the selection of the most promising biomarkers for tumor 
targeting. Such a scoring system might improve the selection of the correct biomarker for 
imaging purposes. In this review, we present the TArget Selection Criteria (TASC) scoring 
system for selection of potential biomarkers for tumor-targeted imaging. By applying TASC 
to biomarkers for CRC, we identified seven biomarkers (carcinoembryonic antigen, CXC 
chemokine receptor 4, epidermal growth factor receptor, epithelial cell adhesion molecule, 
matrix metalloproteinases, mucin 1, and vascular endothelial growth factor A) that seem 
most suitable for tumor-targeted imaging applications in colorectal cancer. Further cross-
validation studies in CRC and other tumor types are necessary to establish its definitive 
value.
IntroductIon
Patients with colorectal cancer (CRC) have an estimated 5-year survival, varying from 
approximately 90% in patients with stage I disease (Dukes A) to approximately 10% in patients 
with metastatic disease (Dukes D).1 Peritoneal carcinomatosis (PC) is a common form of end-
stage colorectal cancer (CRC), affecting 10% to 15% of patients at the time of primary surgery 
and accounting for 25% to 35% of the recurrences of CRC.2 PC has a median survival of 5 to 7 
months without treatment.3-5 
Since the last decade, selected stage IV CRC patients with PC are treated with hyperthermic 
intraperitoneal chemotherapy (HIPEC). This procedure consists of flushing the intra-abdominal 
cavity with heated chemotherapy peri-operatively after primary cytoreduction. HIPEC improves 
the median survival to 13 to 63 months, with a 5-year survival varying from 19% to 51%.6–10 
However, further improvement is still desirable. 
A more extensive surgical cytoreduction is associated with an increase in survival.11,12 Furthermore, 
because penetration of chemotherapeutic drugs into peritoneally located tumor tissue is only 
superficial (limited to 1-2 mm), optimal cytoreduction by removing all visible tumor noduli is an 
essential prerequisite for the HIPEC procedure.13–15
The limited survival in stage IV CRC asks for a more vigorous approach to improve prognosis. 
Current research is mainly focused on tumor-targeted imaging and therapy for diagnosis, 
treatment, and follow-up because these are expected to yield tumor-specific and thus stronger 
diagnostic and therapeutic effects. Therefore, objective identification of suitable tumor biomarkers 
for diagnostic and therapeutic purposes seems appropriate. 
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Furthermore, tumor-targeted imaging can aid in identification of metastatic disease and in 
detection of recurrent disease. In this review, we emphasize tumor-targeted imaging because 
targeted therapeutics demand an entirely different approach for a meta-analysis.
A large number of biomarkers have been reported to play an important role in CRC. However, 
a limited number of these markers are suitable for tumor targeting based on characteristics 
such as, for example, expression rates. In literature, few objective data on how to determine the 
suitability of a potential target are available. Therefore, we set out to design a novel scoring system 
for classification and selection of biomarkers for tumor targeting applications. CRC is used as 
a clinical example for development and initial testing of this novel scoring system. With the 
emphasis on diagnostic and intraoperative imaging, we identified the most promising markers 
for tumor targeting in CRC using the scoring system. 
In conclusion, in this review, we provide an overview of potential biomarkers for tumor targeting 
in CRC, supported by a newly designed TArget Selection Criteria (TASC) scoring system.
methods
Design of the TASC Scoring System 
Seven most important target characteristics selected based on the literature were summarized and 
granted 0 to 6 points, in order of importance. Subsequently, the selection system was tested by 
scoring a number of random biomarkers. Cutoff values were determined, and the scores were 
slightly adjusted where necessary to assure realistic outcomes. Finally, the selection system was 
further validated by testing a wide spectrum of biomarkers based on a publication of Cardoso 
et al.16
Literature Search Methods
Cardoso et al.16 presented a table of genes found to be upregulated in CRC compared with 
normal colon tissue, as confirmed in three or more articles. The initial literature search query 
was based on this extensive table of genes. In addition, based on this table, we analyzed all genes 
mentioned for overexpression of the related protein because protein expression is not always 
synchronously upregulated, using Swiss-Prot and PubMed from 1985 to May 2010 (Figure 1). 
Furthermore, we included a number of proteins that were not mentioned in the table of Cardoso 
et al. but were otherwise described in the literature to play a significant role in CRC. 
Finally, a systematic search of literature was performed, with PubMed as the main database, using 
the following search terms: the name of the protein + “immunohistochemistry” + “colorectal 
cancer,” and the name of the protein + “imaging” + “colorectal cancer,” or variations of these 
terms, from 1985 to May 2010.
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2P 
Cardoso et al.16 
Genes upregulated in CRC reported 
in ≥3 articles. 
128 genes 
Proteins upregulated in CRC 
16 proteins 
Is the protein product of the gene also upregulated in CRC?  
(As confirmed by immunohistochemical analysis, reported in 
literature.) 
Total of analysed proteins 
29 proteins  
(table 2) 
Proteins already reported as target for 
imaging purposes, which are 
upregulated in CRC (as reported in 




Figure 1. Selection of biomarkers upregulated in colorectal cancer (CRC)
target selectIon: IntroducIng tasc
A tumor biomarker can be defined as a distinguishable component present on the tumor cell or 
secreted by a tumor cell to the surrounding stromal tissue. Such a biomarker is often a target in 
biologic interactions, e.g., the combination of CXC chemokine receptor 4 (CXCR4) as target 
of SDF-1. Alternatively, a biomarker can be used as a target for a synthetic substrate, which can 
be a single molecule, antibody, or others. Such a substrate can be conjugated to a diagnostic or 
imaging agent or a drug for clinical application purposes. 
To our best knowledge, a scoring system to identify the most ideal target characteristics has never 
been explicitly described or developed or even validated. However, a number of favorable target 
features can be logically extracted from literature so far. On the basis of these characteristics, we 
propose a novel scoring system for target selection in particular for imaging purposes, the TASC. 
The TASC score is based on the seven most favorable target characteristics that are granted points 
if it applies to the marker (Table 1).




I Extracellular protein localization
Bound to cell surface (receptor) 5
In close proximity of tumor cell 3
II Diffuse upregulation through tumor tissue 4
III T/N ratio > 10 3





V Previously imaged with success in vivo 2
VI Enzymatic activity 1
VII Internalization 1
Total: maximum 22
Potential target ≥ 18
Table 1. The TASC. A biomarker is granted points for seven factors (I-VII). A total score of 18 or higher indicates that 
the biomarker is potentially suitable for tumor-targeted imaging purposes.
These characteristics are as follows: I) extracellular biomarker localization, either on the cell 
membrane or in close proximity of the tumor cell; II) expression pattern; III) tumor-to-healthy 
tissue ratio (T/N); IV) percentage of positive tumors; V) reported successful use of the biomarker 
in in vivo imaging studies; VI) enzymatic activity; and VII) internalization (Figure 2). 
We will briefly explain these seven individual characteristics: 
I—A target must be easily accessible by an agent, administered either systemically or 
intraperitoneally. For effective targeting, as little as possible barriers should be between the 
agent and its target. As a consequence, most conveniently, the marker is present on the cell 
surface. Alternatively, the expression of the target in the extracellular tumor matrix may also be 
adequate for imaging purposes. In our opinion, the extracellular localization of the target, either 
membrane-bound or near the tumor cell, is one of the most important factors and is therefore 
weighted substantially in the TASC system. Extra points are given to a cell membrane bound 
target because it is expected that membrane-bound targets more specifically emit signal from the 
tumor cell than soluble targets. 
II—In the best scenario, the target is expressed by all tumor cells. However, in reality, this is very 
rare because cancer cells have the reputation of being heterogenic.17 Also acceptable is a marker 
that is evenly distributed throughout the tumor tissue. High sensitivity to detect all tumor tissue 
is essential; therefore, this factor also has a significant power in TASC. 
III—The expression of the biomarker should be minimal in normal tissue. In modalities like 
positron emission tomography (PET) and single photon emission computed tomography 
(SPECT) scanning, a tumor-to-healthy cell (T/N) ratio of greater than 10 is considered 
sufficient.18 
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In fluorescence imaging, a minimal T/N ratio has not yet been described but is expected to be 
comparable to the previously mentioned modalities on the basis of its detection sensitivity and 
specificity. 
IV—It is highly preferable that the use of a particular biomarker is of value for large patient 
populations rather than only small groups of “special” patients. Overexpression of the target in 
most patients increases clinical applicability of a tumor-targeted agent. 
V—Previous use of a biomarker in in vivo imaging indicates suitability of the marker for imaging 
purposes in other diseases; in this case, CRC.
VI—Although not an absolute condition for a target, (extracellular) enzymatic activity in and 
around the tumor tissue offers the possibility of applying locally activated imaging agents, 
so-called smart probes, increasing the signal-to-background ratio.19
VII—It is reported in the literature that internalization of the probe-target complex in the tumor 
can lead to intracellular accumulation of the imaging agent, which improves the signal and leads 
to a more optimal T/N ratio.20 For this reason, internalization is granted points in the selection 
criteria.
Figure 2. The TASC. The blue flag represents the selected biomarker. I. Extracellular localization of the biomarker, cell 
membrane-bound, or in close proximity of tumor cell. II. Diffuse up-regulation of the target throughout tumor tissue. 
III. T/N ratio greater than 10. Blue cells represent tumor cells; normal cells are green. IV. Up-regulation of the biomarker 
in most patients. V. A biomarker that has previously successfully been used in in vivo imaging studies. VI. Enzymatic 
activity facilitating the use of activatable probes. Shown are cleaving enzymes (yellow) that activate the imaging agent
VII. Internalization of probe for accumulation of imaging agent.
Selecting a target that meets up to all of these conditions is challenging. In most cases, it is not 
necessary to meet all criteria. 
A total score of 21 or 22 implies that a marker has a high potential for use as a target for imaging 
tracers in vivo. If a marker scores 18 or higher, it is considered to be a potential target. Markers 
with a score of less than 18 seem less suitable for targeted imaging modalities and require more 
research to evaluate their potential. 
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possIBle target candIdates In colorectal cancer
It is well known that it can be difficult to distinguish cancer cells from its normal surroundings 
because of the many similarities between malignant cells and normal cells. Furthermore, tumors 
are mutually heterogenic. However, what most cancer cells have in common and what separates 
them from normal cells is uncontrolled growth, resulting in a high nutritional uptake. An 
alternative property is the ability to invade normal tissue and metastasize. In this respect, it 
is not surprising that the potential targets presented in this review support these phenotypic 
characteristics. The biomarkers reported for CRC can roughly be divided into the following 
groups:
•	 Proteins necessary for high cancer cell metabolism and proliferation rate: epidermal growth 
factor receptor (EGFR), folate receptor-alpha (FR-α), transforming growth factor (TGF), 
vascular endothelial growth factor (VEGF).
•	 Proteins with regulatory functions in the extracellular matrix: carbonic anhydrase (CA) IX, 
collagen, matrix metalloproteinases (MMPs), osteonectin (SPARC). 
•	 Cell adhesion and signaling molecules: cadherin 3, carcinoembryonic antigen (CEA), 
CD44, CXCR4, epithelial cell adhesion molecule (EpCAM), integrins.
•	 Cytokines/chemokines and their corresponding receptors, involved in metastasis: CXCR1, 
CXCR2, CXCR4, CXC chemokine ligands (CXCLs).
•	 Miscellaneous: cathepsin, inducible nitric oxide synthase (iNOS), mucin 1 (Muc1), 
neutrophil gelatinase–associated lipocalin (NGAL) also called lipocalin-2 (LCN2), tumor-
associated glycoprotein 72 (TAG-72).
These potential targets are summarized in Table 2. As is shown in this table, several potential 
target candidates can be identified; however, currently, a limited number of matching clinically 
approved agents are available for application in humans (Table 3). 
Some targets have T/N ratio of less than 10. However, it should be noted that some targets 
internalize the imaging agent more rapidly in tumor cells compared with normal cells.18 
This leads to an accumulation of the conjugated imaging agent, which may compensate the 
signal for the lower T/N ratio, as with FDG-PET imaging.18,20
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Target Clinical ly  approved l igand In cl inical  tr ia l  
CEA Arcitumomab, altumomab  
CXCR4 AMD3100 BKT-140, AMD11070, MSX-122 
EGFR Cetuximab, Panitumumab, 
Nimotuzumab 
Necitumumab, Zalutumumab 
EpCAM Edrecolomab, Catumaxomab (anti-
EpCAM x anti-CD3) 
Adecatumumab, Tucotuzumab 
Folate receptor-alpha Folate  
Integrin  MoaB PF-04605412 (mAb against 
α5β1integrin), Etaracizumab (mAb 
against αvβ3integrin)  
Muc1 Pemtumomab 90Y-hPAM4 
TAG-72 Anatumomab mafenatox, 
Minretumomab 
 
VEGF Bevacizumab, Ranibizumab  
	  
Table 3. Clinically approved ligands for the biomarkers mentioned in Table 2.
WhIch BIomarKers meet the targetIng crIterIa?
When applying the proposed TASC score (Table 1) to the biomarkers mentioned in Table 2, 
not all requirements can be objectified by data from literature. Most often, expression rates and 
pattern are unknown; therefore, it would be interesting to focus future research on target finding 
on these aspects. The following six targets have a score greater than 17 points and can therefore be 
considered most promising in CRC (Table 4): EpCAM (20 points), CXCR4 (20 points), Muc1 
(18 points), MMPs (18 points), EGFR (20 points), and CEA (19 points). In this section, we 
discuss these targets in more detail, including the status of these biomarkers in targeted imaging. 
VEGF-A scores 17 points, which implies less potential as a target. However, given the extensive 
experience in VEGF-A–targeted imaging, this biomarker was, nevertheless, considered to be 
promising and is therefore given attention in this section. 
Epithelial Cell Adhesion Molecule 
EpCAM is a cell surface receptor, which is involved in cell adhesion and is expressed on most 
epithelial cells. EpCAM is upregulated on several epithelial cancers, including CRC. The expression 
of EpCAM in CRC is more than 80%.21–23 Paradoxically, a higher expression of EpCAM on 
tumor cells is associated with increased tumor cell migration.23 Eder et al.24 successfully imaged 
EpCAM-expressing tumors in mice, using an antibody fragment targeting EpCAM conjugated 
to radionuclide, for PET imaging. 
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Edrecolomab and catumaxomab are clinically approved antibodies directed at EpCAM (Table 
3) and tested for therapeutic use. However, so far, no obvious therapeutic advantage has been 
reported for these agents.25–28 To our best knowledge, these antibodies have not yet been used 
for in vivo imaging of EpCAM. When applying TASC to EpCAM; the total score of 20 points 
comes about as followed: EpCAM is cell membrane bound (5 points), diffusely upregulated (4 
points), has a high T/N ratio (3 points), is upregulated in more than 79% of the CRC patients 
(5 points), has been previously imaged with success in vivo (2 points), and is able to internalize 
a compound (1 point).21,22,29 
CXC Chemokine Receptor 4 
CXCR4 is a cell surface receptor involved in homing of hemopoietic stem cells and lymphocytes 
to the bone marrow, but it is also associated with metastatic spread in several types of cancer, 
including CRC. CXCR4 is expressed in approximately 70% of the colorectal tumors.30 
Imaging of CXCR4 has recently attracted attention of many different research groups. 
Nimmagadda et al.31,32 reported imaging of CXCR4 in tumor-bearing mice using a radionuclide-
labeled anti- CXCR4 monoclonal antibody (mAb) using SPECT/CT scanning. Recently, 
the same group also succeeded in imaging CXCR4 expressing tumors in mice with the use 
of AMD3100, a clinically approved molecule that selectively binds to CXCR4 (Table 3), 
conjugated to a radionuclide.32 AMD3100 is a clinically approved agent that is most promising 
in harvesting hemopoietic stem cells from the bone marrow. Alternatively, CXCR4-targeting 
peptides conjugated to a radionuclide or a fluorophore have been reported.33,34 Misra et al.35 
labeled stromal-derived factor-1 alpha (SDF-1α), a ligand ofCXCR4, to a radionuclide for 
myocardial infarction imaging purposes. 
When applying TASC, CXCR4 is granted 20 points based on its expression in CRC. 
Vascular Endothelial Growth Factor-A 
VEGF is an epithelial growth factor that is most extensively known for its ability to induce 
angiogenesis. Angiogenesis in turn is considered one of the primary markers in tumor 
diagnostics.36 There are four VEGFs, namely VEGF-A, -B, -C, and -D. VEGF-A is the most 
important subtype. When tumor cells become hypoxic, VEGF-A expression is upregulated.36 
VEGF-A is partly membrane bound, but it also diffuses through the interstitial cell space. The 
latter potentially limits broader use as a target. However, the highest VEGF-A concentrations 
are observed close to the source of expression, inducing the creation of new blood vessels to the 
hypoxic tumor areas.37 
VEGF-A is upregulated in more than 56% to 78% of all colorectal tumors.38,39 
Multiple groups have successfully imaged VEGF-A expression in tumors induced in animals 
using a VEGF-A antibody conjugated to an imaging agent. Imaging has most commonly been 
performed with bevacizumab (Avastin; Roche), a clinically approved therapeutic anti-VEGF-A 
mAb, which was made suitable for imaging by conjugation to a radionuclide.40–44
In a clinical imaging study, Scheer et al.40 did not find a significant correlation between VEGF-A 
expression and a positive SPECT signal, which may imply that the used tracer was not specific 
enough. Furthermore, a study in melanoma patients with bevacizumab conjugated to a 
radionuclide by Nagengast et al.44 yielded more promising results. 
When applying TASC to VEGF-A, a total of 17 points are granted. This low score is mainly 
caused by the fact that the largest proportion of VEGF-A is not membrane bound and by the 
expression in a relatively low percentage of patients with CRC. However, because of the recent 
results in various imaging modalities, as described above, VEGF-A can be considered a potential 
target for future imaging purposes and is therefore worth to be included in this overview. 
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Mucin 1
Muc1 is a cell surface receptor that plays a role in protection and lubrication of epithelial surfaces 
in luminal structures. This receptor is also involved in signal transduction in cell adhesion and 
antiadhesion mechanisms. Overexpression of Muc1 is often found on malignant cells. In CRC, 
Muc1 is expressed on approximately 50% of the tumors.45,46 
Different groups have successfully imaged Muc1 in tumor-bearing mice using muc1-targeted 
monoclonal antibodies or aptamers conjugated to a radiopharmaceutical.47–53 The use of 
monoclonal antibodies directed to Muc1 conjugated to a radionuclide has already been described 
in patients with bladder and pancreatic cancer.54–56 Medarova et al.57 described the use of a dual-
modality imaging agent by conjugating a Muc1-targeting peptide to fluorophore Cy5.5 for 
fluorescence imaging and to iron oxide nanoparticles for magnetic resonance (MR) imaging. This 
probe was tested in mice bearing human pancreatic cancer with good imaging results for both 
modalities. Muguruma and Ito58 proved the ability to endoscopically detect tumors by using a 
fluorescent antibody–based tracer targeting Muc1, in freshly resected specimens of gastric cancer. 
A different approach for tumor imaging is a two-step pretargeting technique using a bispecific 
antibody. An antibody directed to both Muc1 and the used radiopharmaceutical is administered 
on which the radiopharmaceutical is administered subsequently. The radiopharmaceutical 
binding site of the circulating antibody can be blocked, thus yielding a higher tumor-to-
background ratio.59 Promising results were obtained in breast cancer patients with bispecific 
antibody-based PET scanning.60 
The total TASC score for Muc1 in CRC is 18 points. 
Carcinoembryonic Antigen
CEA is a glycoprotein that plays a role in cell adhesion. In healthy adults, hardly any CEA is 
found; however, CEA is strongly expressed in CRC (>90%)61–64 and is one of its best studied 
tumor markers. CEA is also measurable in blood, but by far, the highest concentration of CEA 
is found at the tumor site. CEA imaging using a CEA-directed antibody or antibody fragment 
conjugated to a radionuclide has extensively been described in animal studies and in patients, 
without showing disadvantages of having simultaneous high serum and tumor CEA levels.65–70 
Yazaki et al.71 fused CEA-antibody fragments conjugated to a radionuclide to albumin for a 
more specific tumor uptake. Technetium 99m (99mTc) arcitumomab is a commercially available 
antibody fragment directed to CEA conjugated to 99mTc, which is used in the CEA scan. 
However, in comparison to FDGPET, 99mTc arcitumomab offers little convincing advantages 
in the detection of CRC.72,73 The use of CEA-antibody fragment–based radiotracers for guided 
surgery has also been described.68,70,74
As well as in Muc1 targeting, the two-step pretargeting system using a bispecific antibody has 
been described in animal studies and in patients for CEA.75,76
Few studies are available on fluorescence imaging for targeting of CEA. Fidarova et al.77 described 
the use of an anti-CEA mAb conjugated to a fluorophore for the detection of metastatic CRC in 
mice. Kaushal et al.78 showed the use of an anti-CEA mAb conjugated to a fluorophore, in intra-
operative detection of colorectal tumor deposits, with good in vivo results. 
When applying TASC to CEA in CRC, the total score is 19 points. 




MMPs are zinc- and calcium-dependent endoproteases that are upregulated in the tumor 
environment and are capable of degrading proteins in the extracellular matrix. MMPs are 
upregulated in 30% to 95% of colorectal tumors, depending on the type of MMP (Table 2).45,79–82
Several groups have targeted MMPs in vivo by using fluorescent or radiolabeled specific MMP-
inhibitors.83–86 One study reports using a radiolabeled mAb for in vivo targeting of MMP1, an 
MMP subtype.87 Because MMPs have proteolytic activity, this target is ideal for activatable probes. 
The advantage of activatable probes is that they greatly reduce background signal. Several studies 
demonstrate the in vivo use of proteolytic beacon coupled to a fluorophore, which emits a signal 
after cleavage by MMP.88,89 MMPsense is a commercially available MMP-dependent activatable 
fluorescent probe, successfully tested in in vivo models.90 Veiseh et al.91 describe the in vivo use of 
chlorotoxin, a small peptide derived from snake venom that interacts with MMP2, conjugated to 
the fluorophore Cy5.5, for potential intraoperative imaging. Lepage et al. synthesized a contrast 
agent containing gadolinium chelate, which is cleaved by MMP. On cleavage, this agent is less 
soluble in water and remains at the tumor site. Good in vivo results have been demonstrated 
for MR imaging using this protease-modulated contrast agent.92–94 Aguilera et al.95 developed 
activatable cell penetrating peptides (ACPPs) that enter the cell after cleavage by MMP. The 
ACPPs were labeled with Cy5.5 for fluorescence imaging, with gadolinium chelate for MR 
imaging, or with both for dual imaging.96 These ACPPs were further improved by conjugation 
to large molecule dendrimers, which improved tumor uptake and thus the emitted signal.97,98
MMPs granted an average of 18 points in CRC when applying TASC, depending on the subtype. 
Epidermal Growth Factor Receptor 
EGFR is a cell surface receptor involved in processes such as cell proliferation, differentiation, 
adhesion, and migration. EGFR is upregulated in different types of cancer, including skin, 
breast, ovary, bladder, prostate, kidney, head and neck, and non–small cell lung cancers.99,100 In 
colorectal cancer, EGFR is upregulated in approximately 80% of the tumors.101,102 
EGFR has been extensively imaged by radionuclide- or fluorophoreconjugated antibodies. Most 
often, cetuximab, a clinically approved anti-EGFR antibody, is used.103–107 In 1994, Dadparvar 
et al.108 administered radionuclide-labeled anti-EGFR antibodies to patients with intracranial 
neoplasms for SPECT scanning. Although promising results were obtained, to our knowledge, 
no sequel was given to this radiopharmaceutical. Also, a few studies described the use of 
panitumumab in vivo, which is the second clinically approved antibody directed at EGFR.109,110 
Variants using antibody fragments or affibodies have been described in animal studies.111,112
Alternatively, EGF, the natural ligand of EGFR, is also used in vivo as an imaging agent, 
conjugated to mainly fluorophores or quantum dots.113–115 Goetz et al.116 described a fluorescent 
anti-EGFR antibody capable of imaging human CRC tissue, which is not only successful in 
in vivo imaging results but also potentially useful in endoscopy. Hama et al.117 described an 
alternative two-step pretargeting model, using nonfluorescent biotinylated cetuximab as first 
antibody, followed by a neutravidin-BODIPY-FL fluorescent conjugate. The latter binds to the 
first antibody by a neutravidin-biotin binding. The concept was tested in vivo in a PC model. A 
10-fold signal amplification was found, leading to high tumor-to-background ratios and good 
detection of lesions as small as 0.8 mm. 
The TASC score of EGFR in CRC adds up to 20 points. 










	  Table 4. The biomarkers that score 18 or more points when applying TASC. These biomarkers are regarded most 
promising for tumor-targeted imaging in colorectal cancer. *VEGF-A scores 17 points but was nonetheless included 
based on the broad experience with this marker for imaging purposes.
dIscussIon
TASC needs to be validated in other cancer types and adjusted where necessary. 
It should be pointed out that TASC is designed as a directive which can help gain objectivity 
and extra insight in target selection. Future validation studies and adjustments, to our 
opinion, will improve TASC to make it more broadly applicable to various types of cancer. 
Immunohistochemical analysis of collected tumor specimens is a relatively easy way to determine 
applicability of a target. In the case of a promising target, further validation is needed by 
testing a target-directed imaging probe in vitro, for proof of concept and specific binding, and, 
subsequently, in appropriate tumor mouse models in vivo. 
Expression of a target may depend on tumor stage. For example, CXCR4, EGFR, and VEGF 
are associated with more advanced tumor stages and metastasis in CRC.118–120 However, MUC1 
is also generally expressed in T1 CRC tumors.46 Therefore, such a target may also be of value in 
early CRC detection. 
conclusIons
In PC of colorectal origin, tumor-targeted imaging may yield better diagnostic and therapeutic 
results. A large number of tumor biomarkers are upregulated in CRC. However, there is no 
objective system for selecting their clinical applicability in targeted imaging applications. In 
this review, we introduce a novel scoring system for target selection for imaging purposes, the 
TASC. When applying TASC to biomarkers for CRC, we found that the most potent targets 
for imaging are CXCR4, VEGF-A, Muc1, MMPs, EGFR, EpCAM, and CEA based on their 
scoring. Clearly, the ideal target for imaging purposes does not exist; moreover, by using the 
TASC system, we propose a novel guideline in tumor targeting for selecting appropriate targets 
for imaging purposes. 
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Introduction: Peritoneal carcinomatosis (PC), i.e. peritoneal dissemination of cancer, is a 
common form of disseminated colorectal cancer (CRC) accompanied with poor prognosis. 
Outcome may be improved through tumor-targeted intraoperative optical imaging and 
resection. We evaluated the expression of six biomarkers in CRC that may serve as possible 
targets for imaging, and tested these markers in vivo.
Methods: Immunohistochemical staining (IHC) was performed on tumor tissue of 14 
patients with colorectal PC for expression of the tumor biomarkers CXC chemokine 
receptor 4 (CXCR4), epidermal growth factor receptor (EGFR), epithelial cell adhesion 
molecule (EpCAM), folate receptor-alpha (FR-α), hypoxia inducible factor-1alpha (HIF-
1α) and vascular endothelial growth factor-A (VEGF-A). Fluorescently labeled antibodies 
directed to CXCR4, EGFR, EpCAM and VEGF-A were used for imaging colorectal tumor 
deposits in vivo, using both a laboratory imaging system and a clinical multispectral 
fluorescence camera.
Results: VEGF-A and EpCAM appeared to be the most strongly expressed targets, showing 
diffuse and homogeneous expression in all samples. EGFR was expressed in 11/13 patients, 
with varying intensity and homogeneity. Membrane-bound EGFR was found in only 5 
patients. CXCR4 and HIF-1α were expressed in 13/14 patients. CXCR4 was expressed 
diffusely while HIF-1α showed focal expression. FR-α was expressed focally in 5/14 patients. 
Fluorescence imaging using antibody-based probes targeting CXCR4, EGFR, EpCAM and 
VEGF-A in a xenograft PC mouse model showed clear delineation of tumor spots, especially 
for VEGF-A and EGFR. 
Conclusion: For clinical translation of optical image-guided surgery, VEGF-A currently 
seems to be the most promising and straightforward imaging target in colorectal PC.
IntroductIon
Peritoneal carcinomatosis (PC), i.e. peritoneal dissemination of cancer, is a common form of 
end-stage colorectal cancer (CRC) and has a poor prognosis.1-4
Hyperthermic intraperitoneal chemotherapy (HIPEC) significantly improves survival in a 
selection of patients.5 In the HIPEC procedure the abdominal cavity is flushed with heated 
chemotherapy after radical surgical cytoreduction. However, although HIPEC significantly 
improves survival, further improvement is necessary, since survival remains limited to a median 
time period of 12-32 months.5
It has been demonstrated that more extensive cytoreduction is associated with improved survival.6,7 
In addition, survival may be improved by more effective chemotherapeutic treatment during the 
HIPEC procedure, preferably combined with more extensive surgical cytoreduction.8 Surgical 
cytoreduction may benefit from better intraoperative visualisation of small tumor deposits that 
are difficult to detect. For this purpose, intraoperative tumor-specific fluorescence imaging was 
developed in animal models, and was recently proven to be feasible in patients.9,10
The HIPEC procedure itself may be ameliorated by adding tumor-specific therapeutic agents 
to conventional chemotherapeutics. Ideally, tumor-specific agents interfere with essential tumor 
cell pathways by antagonizing ligands, while leaving healthy cells unharmed. An example is the 
monoclonal antibody bevacizumab (Avastin®), which specifically targets VEGF-A and as such 
interferes with tumor angiogenesis.11 
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A tumor-targeted approach for therapy or imaging necessitates the identification of useful 
tumor-specific biomarkers in order to obtain highly efficient and successful tumor visualisation 
and killing. Recently, our group presented the Target Selection Criteria (TASC) as a new 
methodology to help determine which biomarkers are suitable for targeted imaging.12 To apply 
TASC, information regarding the expression pattern of a biomarker is necessary. However, little 
is known about biomarker expression rates and expression patterns in colorectal PC. For this 
reason, we set out to analyze six biomarkers that are often mentioned in the literature for their 
role in CRC and their potential for tumor-targeted imaging in vitro and in vivo: CXC chemokine 
receptor 4 (CXCR4), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule 
(EpCAM), folate receptor-alpha (FR-α), hypoxia inducible factor-1alpha (HIF-1alpha) and 
vascular endothelial growth factor-A (VEGF-A).10,13-26
CXCR4 and its ligand CXCL12 (stromal derived factor, SDF-1) play a pivotal role in chemotaxis 
and cell adhesion.27 In cancer, upregulation of CXCR4 is associated with a higher frequency of 
metastatic disease.28 CXCR4 is expressed in colorectal cancer as well as in other types of cancer 
such as breast and ovarian cancer.18,29 AMD3100 (Plerixafor, Mozobil®) is a clinically approved 
drug that binds specifically to CXCR4 and blocks its activity.30
EGFR (also named HER1 or ErbB1) is a cell-surface receptor known for its role in cell growth, 
differentiation, and cell proliferation in both normal cells and malignant cells. Furthermore, in 
cancer, EGFR overexpression is associated with angiogenesis, metastasis and an overall impaired 
survival.31 Cetuximab, a monoclonal antibody directed against EGFR, is used for patients in the 
treatment of CRC.32
EpCAM is a transmembrane protein that is upregulated by many epithelial carcinomas, including 
CRC.20 EpCAM is involved in cell-cell adhesion in normal epithelial cells and is linked with cell 
cycle and proliferation in tumor cells.33 The monoclonal antibody edrecolomab (Panorex®) has 
earlier been approved for clinical use in CRC, but is no longer available for the treatment of 
cancer.34
FR-α is involved in cellular uptake of folate, necessary for DNA synthesis. FR-α is expressed 
in different types of cancer, including ovarian, endometrial, breast, lung, renal, kidney, brain 
and colorectal cancer.19,35 In 2011, the first study describing intraoperative tumor-targeted 
fluorescence imaging in patients with ovarian cancer was published by our group using a folate-
based imaging agent targeting the FR-α.10
HIF-1α is overexpressed under hypoxic conditions and induces, after dimerization with HIF-
1β, a broad spectrum of hypoxia-response proteins, allowing cells to survive under hypoxic 
conditions.13 In CRC, as well as in other tumor types, expression of HIF-1α is associated with 
proliferation, angiogenesis, metastasis, therapy resistance, and worse prognosis.13,14
VEGF comprises a group of growth factors that play a key role in angiogenesis.36 VEGF-A, 
the most important subtype, is one of the proteins upregulated by the HIF-1 pathway and 
is associated with invasive tumor growth and metastasis.37 VEGF-A can be targeted with 
bevacizumab (Avastin®), which is recently approved for clinical application in CRC. 
In this study, we focus on the selection of targets for tumor-targeted imaging in PC of colorectal 
origin both in immunohistochemical analysis as well as in vivo, with the emphasis on image-
guided surgery. In this article, we describe an immunohistochemical analysis of colorectal 
PC human specimen in combination with the application of a new methodology (TASC) to 
determine the best targets for intraoperative tumor-targeted imaging in PC of colorectal origin. 
These targets were further validated by testing antibody-based fluorescence probes in an in vivo 
xenograft mouse model.





Tumor samples were obtained from the databank of the Department of Pathology and Medical 
Biology, University Medical Center Groningen (UMCG). Tissue of fourteen patients was 
analyzed, consisting of tumor nodules excised during cytoreductive surgery followed by HIPEC 
for PC of colorectal origin from 2006 to March 2009. All tissue had been excised before 
administration of peri-operative chemotherapy. This group consisted of 5 men and 9 women, 
with a mean age of 53 years (± 11.0). The specimens were fixed by 10% formalin and embedded 
in paraffin. 
All data were anonymized and the study was conducted in accordance with the Declaration of 
Helsinki principles and with the rules and regulations posed by the Institutional Research Board 
(IRB) of the UMCG.
Immunohistochemistry
Antibodies for CXCR4, EGFR, EpCAM, HIF-1α and VEGF-A staining were purchased (Table 
1). Antibody for FR-α staining (mAB343; 1.8 mg/ml) was kindly provided by professor P.S. Low 
(Purdue University, West Lafayette, Indiana, USA).
Sections (3 μm) were deparaffinized with xylene, rehydrated with ethanol, and rinsed with 
distilled water according to standard procedures. One section was used for analysis of one 
biomarker only. Of one tumor sample, serial sections were used where possible. Antigen retrieval 
for the different antibodies was performed (Table 1). Endogenous peroxidase was blocked 
in 0.3% H2O2 in phosphate-buffered saline (PBS) for 30 minutes and, in the case of HIF-
1α and VEGF-A, endogenous biotin was blocked using a Blocking Kit (Vector Laboratories, 
Burlingame, USA). In case of EGFR staining, endogenous peroxidase activity was blocked for 15 
min in a buffer solution pH5.8 containing 0.3% hydrogen peroxide. Subsequently, the sections 
were incubated with the primary antibody during 1 hour at room temperature, except for FR-α 
and HIF-1α. FR-α was incubated for 3 hours at room temperature and HIF-1α and EGFR 
were incubated overnight at 4° Celsius. The sections were then incubated with a secondary and 
tertiary antibody where appropriate (Table 1). The sections with FR-α staining were incubated 
with mouse MACH3 (Biocare Medical, Concord, USA). The sections with EGFR staining were 
amplified using the Novolink kit (Leica, The Netherlands). Peroxidase activity was developed 
with 3,3-diaminobenzidine. Slides were counterstained with haematoxylin, mounted and 
coverslipped.
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CXCR4 Ab 2074 (Abcam) 1:50 None GARPO 
(Dako) 
RAGPO (Dako) 
EGFR Clone 31G7 (Zymed, 
Invitrogen) 
1:30 Prot K (0.15mg/ml), 5 
min 
- - 
EpCAM BerEp4 (Dako) 1:100 Protease 0,1%, 30 min  RAMPO 
(Dako) 
GARPO (Dako) 
FR-alpha  MAb343 1,8 mg/ml  1:500  Pascal autoclave (Dako)  -  -  
HIf-1alpha  Clone H1 alpha 67 
(Neomarkers)  










ABC complex  
(Dako) 
 
Analysis of the results
All slides were independently analyzed by one researcher (MvO) and one pathologist (JB) blinded 
to the study results. For EGFR staining, one patient had to be excluded after staining because no 
tumor cells were found on the slide and no replacement material was available. 
The slides were semi-quantitatively scored according to: - (no staining), + (weak staining in >10% 
of the tumor cells), ++ (moderate staining in >10% of the tumor cells), +++ (strong staining 
in most tumor cells). Furthermore, we analyzed whether samples showed a diffuse staining 
pattern (i.e., staining throughout the sample) and whether staining was homogenous (i.e., the 
same intensity throughout the sample). Additionally, EGFR staining was scored for membrane 
expression, as is described in the literature for HER2 expression in gastric cancer: - (no staining), 
+ (weak membrane reactivity, in part of the membrane, in >10% of the tumor cells), ++ (weak 
to moderate complete or basolateral staining of the membranes in >10% of the tumor cells), +++ 
(moderate to strong complete or basolateral staining of the membranes in >10% of the tumor 
cells).38 In cases of different grading, the sample was discussed among the two observers until 
agreement was reached. Positive and negative control tissues were included as usual.
Table 1. Immunohistochemical procedure. Used primary, secondary and where applicable tertiary antibodies; antibody 
dilution; and antigen retrieval are given.




I Extracellular protein localization
Bound to cell surface (receptor) 5
In close proximity of tumor cell 3
II Diffuse upregulation through tumor tissue 4
III T/N ratio > 10 3





V Previously imaged with success in vivo 2
VI Enzymatic activity 1
VII Internalization 1
Total: maximum 22
Potential target ≥ 18
Table 2. The TArget Selection Criteria (TASC) scoring system. This scoring system was introduced in a review by 
van Oosten et al.12 A marker is scored for seven factors. An added score of ≥ 18 suggests potential marker suitability for 
targeted imaging purposes.
Target Selection Criteria (TASC) scoring
In Table 2, the Target Selection Criteria (TASC) scoring system as described by our group is 
depicted. In short, a marker is scored for seven characteristics. A total score of ≥ 18 suggests that 
the biomarker has a high potential to be suitable for targeted imaging purposes. The seven factors 
were selected on the basis of relevance for imaging purposes; details are described elsewhere.12
Labeling of antibodies
Human CXCR4 (Clone 12G5) mouse IgG2A monoclonal antibody and human EpCAM 
(Clone 158210) mouse IgG2A monoclonal antibody were purchased (R&D Systems, 
Minneapolis, USA). EGFR directed cetuximab (Erbitux®, Merck, The Netherlands) and 
VEGF-A directed bevacizumab (Avastin®, Roche, The Netherlands) were kindly provided by 
the hospital’s pharmaceutical department. All antibodies were labeled with IRDye-800CW-
NHS ester according to manufacturers orders (Li-COR Biosciences, Nebraska, USA). In short, 
IRDye-800CW-NHS ester was dissolved in dimethylsulfoxide (DMSO; 0.24 mg/mL). Buffer 
(Na2HPO4, pH8.4, 0.1M) and IRDye-800CW-NHS ester were added to the desired antibody. 
The dilution was shaken for 1 hour at room temperature in the dark. Subsequently, the dilution 
was centrifuged three times in centrifugal filters (Amicon Ultra 0.5 mL 100K Centrifugal filters, 
Millipore) at 9000 RCF with PBS for 4 minutes at 5˚ Celsius. The end product was dissolved 
to the appropriate volume with PBS. This procedure was followed for all different antibodies. 
According to a recent published report from our group a dye:protein ratio was approximated to 
be 3.5.39
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Cell culture
The human colorectal cell line HCT116 and human glioblastoma cell line U87 were used, 
because of known expression of respectively EpCAM, VEGF-A and EGFR, or CXCR4 
in vivo.40-43 Because CXCR4 is described to be expressed in U87, but at low levels, presence of 
CXCR4 in tumor spots after fluorescence imaging in vivo, was confirmed by IHC as described 
below. 
HCT116, stably transfected with a plasmid for luciferase expression for the ability of 
bioluminescent tumor evaluation (HCT116.luc; Caliper Life Sciences), was cultured in Roswell 
Park Memorial Institute medium (RPMI; Lonza, Switzerland) + 10% foetal calf serum (FCS; 
Lonza, Switzerland) until an amount of 80x 106 tumor cells was obtained. U87 (ATCC HTB-
14) cells were transfected with plasmid pCMV-d2EGFP using Fugene 6 (Roche, Indianapolis, 
USA) in order to produce an intrinsic green fluorescent protein (GFP) signal. Transfected cells 
(U87.gfp) were selected by culturing in the presence of 1µg/ml G418 (Invitrogen, California, 
USA). U87.gfp was cultured in Dulbecco’s Modified Eagle Medium (DMEM; Lonza, Basel, 
Switzerland) + 10% FCS until an amount of 20x 106 cells was obtained. Both cell lines were 
cultured at 37°C.
Animal model
All procedures were carried out in compliance with the Guide for the Care and Use of Laboratory 
Animal Resources (1996), and were approved by the local Animal Care and Use Committee. 
Each newly conjugated fluorescent agent was tested in 6 week old nude mice. Tumor xenografts 
were established by intraperitoneal inoculation with 2x 106 HCT116.luc suspended in 200µl of 
PBS in a total of 9 mice. An intraperitoneal injection with 5x 106 U87.gfp cells suspended in 200 
μl of PBS was done in a total of 3 mice. 
Probe administration 
After 4 weeks for the HCT116.luc inoculated mice and after 7 weeks for the U87.gfp inoculated 
mice, the mice were injected with 100 mg probe, in accordance with a previously reported 
study.39 The probe was injected intravenously in the tail vein under isoflurane gas anaesthesia. 
In one mouse, a retro-orbital injection was performed (cetuximab probe group) due to failure of 
tail vein injection. Overall, 3 mice received bevacizumab-800CW, 2 mice received cetuximab-
800CW, 2 mice received anti-CXCR4-800CW and 3 mice received anti-EpCAM-800CW. One 
mouse of the HCT116.luc group and one mouse of the U87.gfp group received no probe and 
served as negative control.
Surgery
Based on earlier obtained pharmacokinetic data,39 surgery was performed four days after probe 
administration. All surgery was done under general anaesthesia and mice were sacrificed using 
barbiturate (Euthanasate®, Apharma, The Netherlands) directly after imaging. Ten minutes prior 
to surgery, all mice with HCT116.luc tumors (n=12) were given an intraperitoneal injection 
with D-luciferin (Caliper Life Sciences, Alameda CA, USA) at a dose of 150 mg/kg that was 
allowed to distribute for 10 minutes. 
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In the HCT116.luc model, the mice were imaged with an IVIS Spectrum (Caliper Life Sciences) 
under general anaesthesia using bioluminescence imaging. Bioluminescence served as an “in 
vivo” gold standard for the presence of tumor tissue, and was applied to assess correlation with 
the fluorescence data.44,45 In the mice inoculated with U87.gfp, the GFP signal served as an 
internal control.
First, bioluminescence imaging (excitation block, emission open, illumination 1s) and imaging 
of the green fluorescent protein signal (excitation 465nm, emission 520nm, illumination 3s) 
was performed. Subsequently, near-infrared fluorescence imaging was performed to detect 
IRDye800CW specific probe signal (excitation 710nm, emission 800nm, illumination 3-10s). 
All mice were imaged both alive with intact skin and during surgery, after a midline laparotomy. 
All organs and tumor tissue were imaged ex vivo for both bioluminescence and fluorescence.
The mice were imaged with an IVIS Spectrum (binning 4, field of view 6.5-21.2, F-stop 1-2) 
and with a clinical multispectral fluorescence camera (SurgOptix T3-platform©, SurgOptix BV, 
The Netherlands).10,46
Microscopic analysis of excised tissue
All excised tissue, both tumor and organs, were fixed in formalin and subsequently embedded 
in paraffin. Presence of the targeted marker and presence of tumor tissue were confirmed using 
immunohistochemical staining as described above. 
Software analysis
All IVIS Spectrum data was processed using Living Image 3.2 (Caliper Life Sciences). Tumor 
to background (T/B) ratios were calculated by drawing regions of interest (ROIs) onto images 
containing both tumor and healthy tissue after excision. Correction for background signal was 
done by extracting signal of the black background from the actual signal; in this article referred 
to as net intensity.
results
Immunohistochemical analyses
The expression rates of CXCR4, EGFR, EpCAM, FR-α, HIF-1α, and VEGF-A are summarized 
for each individual patient in Table 3. Furthermore, the overall results are shown in Table 4, 
including the staining pattern and staining in adjacent healthy tissue. Representative images of 
the immunohistochemical analyses are depicted in Figure 1.
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Marker  Number of patients 
with expression  
(n=14) 
Number of patients with 
moderate to strong 
expression 
(n=14) 
Pattern of staining  Expression in 
adjacent normal 
tissue  
EGFR 5/13 (11/13) 4/13 (8/13) 
Membrane expression is 
focal, cytoplasm staining 
varies from homogeneous 
diffuse to focal 
Moderate in bowel 
epithelia. Weak in 
stromal tissue.  
 
CXCR4 13/14 10/14 Diffuse 
Weak to moderate 
in bowel epithelium  
HIF-1α  13/14 10/14 Focal  Weak in fatty tissue  
EpCAM  14/14 14/14 Diffuse  
Strong in bowel 
epithelium  
FR-α  5/14 1/14 Focal  None  
VEGF-A 14/14 14/14 Diffuse 
Moderate in 
stromal tissue and 
bowel epithelia. 
	  
Table 4. Number of patients with positive marker expression in tumoral tissue with immunohistochemical analysis. 
Pattern of expression in tumor tissue and expression in adjacent normal tissue is described. In case of EGFR expression, 
membrane expression is counted. Cytoplasm + membrane expression is given between bars.
CXCR4
Thirteen out of 14 patients (93%) showed expression of CXCR4, varying from weak to strong. 
Ten patients (71%) had moderate to strong (2+/3+) expression, whereas tumor tissue from one 
patient showed no expression at all. Intensity of expression in different tumor samples from the 
same patient did not vary strongly.
Overall, CXCR4 expression was mainly cytoplasmic, with stronger expression seen near the cell 
membrane compared to the center of the cell. Hardly any nuclear expression was observed. 
Expression throughout tumor tissue was diffuse, and in most cases homogeneous. In some small 
areas expression was slightly weaker, but overall staining was clearly present throughout the 
tumor. 
The epithelial border of healthy colon showed expression of CXCR4, albeit weaker than tumor 
tissue. Stromal tissue surrounding the tumor tissue was negative or only very weakly positive for 
CXCR4 expression. 
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A B  C 
D E F 
Figure 1. Immunohistochemical staining for (A) EGFR, strong intensity, (B) CXCR4, moderate intensity, 
(C) HIF-1alpha, moderate intensity, focal expression, (D) EpCAM, strong intensity, (E) FR-alpha, moderate 
intensity, focal expression and (F) VEGF-A, strong intensity of peritoneal carcinomatosis tissue of colorectal origin. 
Representative images are shown. Magnification 10x.
EGFR
Cytoplasmic EGFR staining was observed in 11 out of 13 patients (85%), ranging from weak 
to strong, with staining patterns varying from diffuse and homogeneous to focal staining. When 
exclusively considering membrane staining, only 5 out of 13 patients were positive (38%), again 
with varying intensity. Most membrane staining was found at the basolateral cell membrane. 
One patient showed exclusive membrane staining, without cytoplasmic staining. Interestingly, 
tumor material of this patient showed 3+ membrane staining, which was almost exclusively in 
squamous morules, which were formed in the tumor. When taking membranous staining and 
cytoplasmic staining together, 11/13 patients showed EGFR expression. In all positive cases, 
staining in tumor tissue was higher than in surrounding normal tissue. Apart from tumor tissue, 
normal bowel epithelia also showed positive staining, mainly cytoplasmic.
EpCAM
EpCAM was expressed in all tumor samples (14/14, 100%), with strong intensity and a diffuse, 
homogeneous staining pattern in more than 90% of the tumor cells in all patients. Staining 
was most dominantly cytoplasmic, but in many samples the staining was so intense that it was 
difficult to discriminate nuclei. Most staining was located near the cell membrane, both apical 
and basolateral.
In adjacent healthy tissue, strong expression was seen in the epithelial border of the bowel. This 
expression was, in contrast with tumor tissue, mainly at the basolateral membrane.
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FR-α
FR-α was expressed in 5 out of 14 patients (36%). In four patients, expression was weak while 
one patient showed moderate expression. In all FR-α positive patients, only a minority of tumor 
cells showed expression and staining had a focal pattern throughout the sample. FR-α was 
dominantly expressed at the apical cell membrane, although also a weak to moderate diffuse 
cytoplasmic expression was found. In adjacent normal tissue, no staining was seen.
HIF-1α
HIF-1α was expressed in 13 out of 14 patients (93%), with moderate to strong expression in 10 
out of 14 patients (71%). HIF-1α showed focal expression and severe heterogeneity of staining 
intensity within one tumor sample, between different tumor nodules of the same patient, and 
between patients. One patient showed no HIF-1α expression at all. Expression of HIF-1α was 
mainly cytoplasmic, but in three patients some nuclear expression was observed as well. In 
adjacent normal tissue hardly any HIF-1α was detected. In a few cases, very weak staining of 
fatty tissue or nuclear staining in individual cells of normal bowel epithelia was detected, as 
described before.14 
VEGF-A
VEGF-A was strongly expressed in all tumor samples (14/14, 100%), with strong intensity and 
a diffuse, homogenous staining pattern in more than 90% of tumor cells. VEGF-A expression 
was mainly cytoplasmic, with stronger staining near the cellular membrane, and the highest 
intensity on the apical side. In adjacent tissue, staining was moderate in bowel epithelium, and 
weak strings of staining were visible in stromal tissue. All staining in normal tissue was weaker 
than the weakest intensity of staining in tumor tissue.
Target Selection Criteria (TASC) Scores
The characteristics and individual scores as defined by TASC are depicted for the analyzed 
biomarkers (Table 5). All biomarkers have previously been imaged in vivo (human and/or animal). 
None of the selected markers have enzymatic activity, whereas target-mediated internalization is 
described of four of six biomarkers. Of the six biomarkers, CXCR4, EpCAM and VEGF-A have 
a score ≥18, indicating potential for tumor-targeted imaging, while HIF-1α and FR-α both have 
a score of 11 points. The EGFR score depends on the positivity of IHC staining that is counted: 
in case of exclusive membrane staining EGFR scores only 8, while a score of 17 is reached if 
overall staining is taken into account.
In vivo imaging
Based on the results described above, anti-CXCR4-800CW, anti-EpCAM-800CW, bevacizumab-
800CW and cetuximab-800CW were selected for in vivo testing in mice. Four days after injection 
of the fluorescent probe, surgery was performed. Imaging was done with both an IVIS Spectrum 
and a clinical multispectral fluorescence camera. With all four probes, intraperitoneal tumor 
spots were clearly distinguishable from surrounding tissue (Figure 2). Tumor spots as small as 0.5 
mm could be detected with all tested probes by both the IVIS Spectrum and the intraoperative 
camera (Figure 3).
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CXCR4  Membrane bound12  In vivo22 Not described  Yes12  18  
T/N ratio not 
convincing >10 
based on this IHC 
staining  
HIF-1α  Mainly intracellular
13 
 




Not described  Not described  11   
EpCAM  Membrane bound12  In vivo26  Not described  Yes12  21   
FR-α  Membrane bound12  In patients10  Not described  Yes12  11   
EGFR  Membrane bound12  In patients24  Not described  Yes12  8 (17)  
T/N ratio not 
convincing >10 





partly secreted12  
In patients21,49  Not described  Not described  18   
	  
Table 5. Biomarker TArget Selection Criteria (TASC) scores. For each marker analyzed in this study, a TASC score was 
assessed using the scoring system mentioned in Table 2. Also biomarker characteristics, derived from the literature and 
relevant for calculation of the TASC score are mentioned.
During surgery, the clearest signal originated from cetuximab-800CW and bevacizumab-800CW. 
When compared to the bioluminescent signal or GFP signal, there was an accurate overlap, 
suggesting that all signal was tumor specific (Figure 2). However, with anti-CXCR4-800CW, a 
minority of the tumor deposits did not show probe specific signal, even when bright fluorescent 
spots were removed from their proximity (Figure 2, lower panel, green arrows).
In all cases, tumor tissue emitted a stronger fluorescence signal than healthy tissue and organs 
(Figure 4). Tumor to normal tissue (T/N) ratios were calculated for the intraperitoneal tumors 
(Figure 5). Except for anti-EpCAM-800CW, all tumors gave a T/N ratio higher than 1, with 
a maximum of 17.2 for cetuximab-800CW in comparison to healthy tissue. Anti-EpCAM-
800CW had a relatively low T/N ratio compared to bevacizumab-800CW, anti-CXCR4-800CW 
and cetuximab-800CW, i.e. a tumor to muscle ratio of 2.8 versus respectively 6.8, 6.8 and 17.2. 
Besides, anti-EpCAM-800CW yielded overall the lowest tumor signal intensity, with a maximal 
net intensity of 1.2x10-3 (Figure 4).
To confirm that all fluorescent tissue consisted of tumor cells, the excised tissue was microscopically 
analyzed. All excised fluorescent nodules were histologically confirmed to contain tumor tissue 
and to express the targeted markers CXCR4, EpCAM and VEGF-A. Because of extensive 
description of EGFR upregulation in HCT116 xenografts in mice in the literature, no control 
IHC for EGFR was performed.42,47







































































































Figure 2. Fluorescence and bioluminescence signal in tumor spots after intravenous administration of fluorescently 
labeled antibodies. Upper panel: Near-infrared fluorescence (NIRF) signal after VEGF-A targeting by bevacizumab-
800CW versus intrinsic bioluminescence signal. Second panel: NIRF signal after EGFR targeting by cetuximab-800CW 
versus intrinsic bioluminescence signal. Third panel: NIRF signal after EpCAM targeting by anti-EpCAM-800CW 
versus intrinsic bioluminescence signal. Lower panel: NIRF signal after CXCR4 targeting by anti-CXCR4-800CW 
versus intrinsic GFP signal. The green arrows indicate tumor spots that did not emit a NIRF signal.
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Figure 3. Fluorescence signal of a bevacizumab-800CW targeted tumor spot with a clinical fluorescence camera 
system. Pseudocolor (left) and fluorescence image (right) are depicted. The tumor spot is depicted by the orange arrow.
dIscussIon
In the current study, we analyzed six biomarkers known to play a role in peritoneal carcinomatosis 
from colorectal origin. Most potential targets for imaging purposes were selected based on IHC, 
i.e. CXCR4, EGFR, EpCAM and VEGF-A. Fluorescent targeted probes directed to the most 
favourable markers, produced by labeling commercially available (preferably clinically grade) 
antibodies with a near-infrared clinical approved fluorophore, were intravenously administered 
in mice with intraperitoneal colorectal tumor deposits. The investigated biomarkers will be 
discussed below in order of suitability for future clinical use.
VEGF-A expression has previously been described to be upregulated in primary colorectal 
cancer.16,48 However, expression in PC of CRC was so far unknown. We found a diffuse staining 
pattern and strong intensity in all patient samples analyzed. Clinical imaging studies have been 
reported with radioactive labeled bevacizumab in positron emission tomography, with different 
results.21,49 As Nagengast et al. found successful VEGF-A related imaging of melanomas in patients, 
Scheer et al. could not find evident correlation between antibody accumulation and VEGF-A 
expression in patients with colorectal liver metastasis. Furthermore, the use of bevacizumab-
800CW in mice has also been described recently, resulting in detection of submillimeter tumor 
nodules in vivo.39 Moreover, a feasibility study has been initiated to study the use of bevacizumab-
800CW in patients with breast cancer (UMCG, Groningen, the Netherlands; www.clinicaltrials.
gov NCT01508572). 






















































A B  
C D 
Figure 4. Signal intensity of intraperitoneal tumors and healthy tissue ex vivo of (A) Bevacizumab-800CW treated 
mice, (B) Cetuximab-800CW treated mice, (C) Anti-CXCR4-800CW treated mice and (D) Anti-EpCAM-800CW 
treated mice. Tumors and healthy tissue were imaged with the IVIS Spectrum ex vivo. Signal intensity was corrected for 
background (net intensity).
Our reported data are concordant with previous studies with bevacizumab-800CW, showing 
clear visualization of colorectal tumors using this fluorescent probe. The high expression of 
VEGF-A in PC of CRC by IHC staining and the clear visualization of tumor spots in mice using 
bevacizumab-800CW in combination with the broad experience of bevacizumab in numerous 
patients combined with its description in the literature as a potentially suitable imaging agent, 
do make VEGF-A a highly favourable target of PC in CRC.
EGFR suits many favourable target characteristics, such as being membrane bound and being able 
to facilitate internalization. In addition, the availability of a clinical approved antibody targeting 
EGFR may facilitate safe and quick introduction in the clinic. It has been shown previously that 
EGFR is a promising target in radiologic imaging of cancer in patients and in optical imaging 
in animals.24,50 In our study, we observed similar positive results of optical imaging in mice using 
cetuximab-800CW in colorectal PC, showing bright and specific localization of all tumor spots. 
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However, in this study, membrane-bound EGFR, which is the common way to score for the 
EGFR (family HER1-4) expression,38 was found in only a minority of patients with PC of CRC 
(38%). It might be argued that for imaging purposes, cytoplasmic staining should be scored for 
EGFR expression instead of membrane staining, similar to other markers. In this case, expression 
of EGFR was found in 85% of the investigated patients. However, EGFR expression still was 
found not to be homogeneous in many patients, possibly complicating targeted imaging in a 
surgical setting because of the risk of missing EGFR-negative tumor tissue. 
EpCAM showed a diffuse homogeneous staining pattern with strong intensity, similar to previous 
studies on CRC.20,51 EpCAM has been described to be expressed at the basolateral cell membrane 
in normal epithelial tissue.20,52 We observed EpCAM expression in tumor tissue both at the apical 
and at the basolateral membrane, consistent with other studies reported in the literature.20,52 
When applying the TASC methodology, EpCAM is the most promising target in this study 
based on its overall score of 21. However, strong EpCAM expression was also observed in the 
epithelial border of normal bowel tissue, which is consistent with the literature.20 Theoretically, 
strong expression of EpCAM in the epithelial border of normal bowel might hamper fluorescence 
imaging intra-abdominally in humans, as a signal from healthy tissue is undesirable. However, 
the limited penetration depth of the fluorescent agent probably greatly, if not totally, reduces the 
signal derived from the normal bowel epithelium and thus might not have an impact on detection 
of PC in CRC.53 Interestingly, although EpCAM is overexpressed in many cancer types, little is 
known on EpCAM as a target for fluorescence imaging. To our best knowledge, only two groups 




































Figure 5. Ratio of tumor tissue versus healthy tissue ex vivo. The ratio was calculated by dividing the tumor signal 
intensity by the healthy tissue intensity. Fluorescence signal was corrected for background signal (net intensity). 
Respectively, the blue bar represents VEGF-A targeting, the orange bar EGFR targeting, the green bar CXCR4 targeting, 
and the purple bar EpCAM targeting.
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In our study, tumor imaging targeting EpCAM appeared to be feasible, consistent with the 
study of Sun et al. and Hall et al. However, more background signal was observed in the mice 
compared to the EGFR and VEGF-A targeting, resulting in lower T/N ratios (Figure 5). This 
effect might be explained by the fact that the antibody used was a mouse antibody, which could 
have bound to normal mouse tissue by their Fc-regions. If this is the case, it can be argued that 
when fluorescently labeled humanized antibodies, like bevacizumab-800CW and cetuximab-
800CW, are used for imaging of tumor tissue in patients, it might be less efficient than in mice 
as described here.
CXCR4 was expressed moderately to strong in 71% of the patients with PC. When applying 
TASC, CXCR4 scores 18, indicating its suitability as an imaging target. Favourable imaging 
characteristics of CXCR4 are the diffuse expression pattern and the fact that CXCR4 is 
membrane-bound. Moreover, target-mediated internalization has been described for CXCR4, 
potentially leading to an increased tumor-to-background ratio in imaging applications.26 
In CXCR4 imaging in vivo, we found a lower concordancy between near-infrared fluorescence 
detection and the detection of intrinsic GFP signal of the tumor tissue, indicating that not all 
GFP-positive tumor nodes showed probe specific fluorescence signal. No explanation was found 
for this, moreover because CXCR4 presence was detected afterwards in all investigated tumor 
nodules by IHC, with similar intensity of CXCR4 in all regions. One hypothesis is that the used 
dosage was not sufficient to reach all CXCR4-positive tumor cells.
The least favorable biomarkers in CRC, based on both expression levels and the overall TASC-
score, respectively 11 and 14, are FR-α and HIF-1α. 
HIF-1α was, like CXCR4, expressed moderately to strong in 71% of the patients with PC, with 
an overall presence in 93% of the patients. However, HIF-1α was only focally expressed, which 
is highly unfavorable in imaging, as tumor tissue may be missed. 
Although FR-α is reported to be upregulated by different types of cancer,56 we found weak to 
moderate expression in only 35% of the patients, combined with a focal staining pattern. Shia 
et al. report similar numbers, with FR-α expression in 33% of primary colorectal tumors and in 
44% of metastasis.19
Because of a priori poor imaging suitability of FR-α and HIF-1α in colorectal PC, no in vivo 
imaging attempt was done in this study.
In summary, this clinical translational study combines immunohistochemical analysis and the 
Target Selection Criteria (TASC) methodology to show that CXCR4, EpCAM and VEGF-A 
are potential targets for intraoperative tumor-targeted imaging purposes in patients with PC 
of colorectal cancer. It was confirmed in vivo that targeting these markers allows intraoperative 
guidance for visualization of small tumor spots, and thereby potentially allowing more extensive 
cytoreductive surgery. VEGF-A targeting showed to be most effective in vivo. EGFR had a lower 
TASC score, based on a membranous pattern, and therefore seems less suitable for imaging in 
PC of colorectal cancer. Even when cytoplasmic staining is taken into account and despite the 
clear tumor visualization in mice, EGFR should probably be regarded as a less potential target for 
intraoperative tumor-targeted imaging specifically in colorectal PC due to the inhomogeneous 
pattern of EGFR expression in the tumor tissue resulting in a maximal TASC score of 17. 
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Based on our and previous observations, further confirmation of the clinical applicability of 
fluorescent labeled agents for intraoperative tumor-targeted imaging should start with VEGF-A 
and CXCR4 (respectively bevacizumab and AMD3100), in that order, to confirm the applicability 
of targeting these biomarkers in PC of colorectal origin for surgical guidance. EpCAM seems a 
very promising biomarker for clinical targeting. However, unfortunately no clinically approved 
antibody or other pharmaceutical solely targeting EpCAM is currently available. EGFR is a 
promising biomarker for targeting in general, but might be less suitable for targeting in colorectal 
PC, based on the IHC data in this study.
Currently, in the cytoreductive stage before the HIPEC procedure, the surgeon relies for surgical 
cytoreduction solely on what is seen by the naked eye and palpated by the surgeons own tactile 
senses. We observed that fluorescence intraoperative guidance highly improves visualization of 
tumor-spots during surgery, comparable to our clinical feasibility study recently reported in 
ovarian cancer10 and therefore, the usage of intraoperative fluorescence guidance in colorectal 
PC may majorly improve overall cytoreduction. Consequently, a drastic improvement in overall 
survival might be achieved in this patient population through the validation and introduction of 
optical image-guided surgery.12
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aBstract
Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field 
of research that is on the verge of clinical implementation. As each tumor has its unique 
biological profile, selection of the most promising targets is essential. In this review, we 
focus on target-finding in ovarian cancer, a disease in which fluorescence imaging may be 
of value in both adequate staging and in improving cytoreductive efforts, and as such may 
have a beneficial effect on prognosis. Thus far, tumor-targeted imaging for ovarian cancer 
has only been applied in animal models. For clinical implementation, five most prominent 
targets were identified: folate receptor alpha (FR-α), VEGF, EGFR, CXCR4 and MMP. 
These targets were selected based on expression rates in ovarian cancer, availability of an 
FDA-approved antibody or substrate, aimed at the target and the likelihood of translation 
to human use. 
The purpose of this review is to present requirements for intraoperative imaging and to 
discuss possible tumor-specific targets for ovarian cancer, prioritizing for targets with 
substrates ready for introduction into the clinic.
IntroductIon
The detection and management of cancer has benefited greatly from the development of sensitive 
imaging modalities. CT, MRI, PET, SPECT and ultrasound all have unique advantages in 
visualizing tumors, and technical improvements such as multimodality systems (PET/CT, PET/
MRI) have led to increasing efficiency and sensitivity and detailed 2D and 3D images. However, 
these modalities are not suitable for real-time feedback during surgery. In diseases with a peritoneal 
spreading pattern, such as ovarian cancer, cytoreduction is of eminent importance. Intraoperative 
fluorescence imaging aiding the surgeon in detection of (metastatic) tumor deposits may improve 
resection rates and thus positively influence prognosis. As tumor-targeted fluorescence imaging 
is on the verge of clinical implementation, we set out to provide an overview of useful imaging 
targets in ovarian cancer. In this review, the possible targets for intraoperative imaging in ovarian 
cancer will be evaluated. First, we illustrate the importance of improved tumor visualization 
during ovarian cancer surgery, and we describe the basics of fluorescence imaging. Subsequently, 
the development of tumor-specific tracers for ovarian cancer towards clinical introduction is 
discussed. 
methods
PubMed was used as primary database for search queries. The general search method was based 
on the full name and abbreviation for each target discussed, and on combinations of the following 
search terms: gynecologic cancer, ovarian cancer/carcinoma, intraoperative imaging, fluorescence 
imaging. In order to maximize search results, we did not prioritize for presence of the search 
terms in title, abstract or key words. Relevant articles were selected and examined, including 
a screening identifying possibly relevant citated reports. Only papers written in English were 
considered for citation in this review. There was no limitation on publication date, but emphasis 
was put on articles published in the last decade. 
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ImagIng In oVarIan cancer
Ovarian cancer, of which epithelial ovarian cancer (EOC) is the predominant histology, is a 
major cause of mortality in women, ranking the fifth most common cause of death from cancer.1 
Because of late onset of symptoms 75% of women are diagnosed with advanced disease and 
five-year survival rates for stage IV are only about 30%.2 In advanced disease, the degree of 
cytoreduction is one of the most important prognostic factors.3-5 Given the improved survival 
associated with complete resection of all visible disease6,7, debate is ongoing whether this is a more 
appropriate definition for optimal cytoreduction than the current standard of residual disease 
<1 cm.8,9 The size of residual disease after cytoreduction is also of importance for penetration 
of adjuvant systemic or intraperitoneal chemotherapy into tumor nodules10-13, highlighting the 
importance of a thorough inspection of the abdomen for metastases.
Pre-operative imaging offers a guideline for the multidisciplinary team and in particular the 
surgeon. However, the accuracy of CT-scanning for adequate staging is around 75%14-16, and 
depending solely on CT may thus result in over- or undertreatment. In discriminating benign 
from malignant masses, PET/CT is superior to other modalities, with an accuracy rate of 92%, 
compared to 75% and 83% for MRI and ultrasound respectively.16 For detection of large peritoneal 
metastases, CT and MRI are equally sensitive, up to 100%.17 Adding diffusion-weighted MRI 
to conventional MRI improves the detection sensitivity of peritoneal metastases.18,19 The greatest 
difficulty is the detection of very small tumor deposits in peritoneal carcinomatosis, which 
are missed by the above mentioned modalities in 20-30% of cases but are pivotal for accurate 
staging.20 Laparoscopic staging is an attractive, less invasive option for staging, and is considered 
safe in early stage ovarian cancer.21 In more advanced stages however, adhesions may impede 
thorough inspection of all abdominal quadrants.22 Therefore, current guidelines recommend 
exploratory laparotomy as the only fully reliable staging method.23,24 As an adjunct to this, 
intraoperative optical imaging for in vivo tumor detection could be of value for both improving 
adequate staging and cytoreduction. Real-time fluorescence imaging provides high sensitivity 
and resolution, illustrated by preclinical studies that report detection resolutions of 0.3 mm in an 
ovarian cancer xenograft model in mice.25 
IN VIVO Fluorescence ImagIng
Intraoperative imaging is only successful if the tumor-specific signal derived from the targeted 
optical contrast agent is clearly discernible from the background, leading to low false negative 
and false positive rates of detection. As all tissues have some degree of autofluorescence, the signal 
from the fluorescent agent is impeded to some extent, especially in visible light wavelengths 
(400-750 nm). In this respect, the use of near-infrared (NIR) fluorescent dyes (750-1000 
nm) is advantageous for in vivo imaging because surrounding tissues generally absorb little of 
the emitted signal and light in the NIR spectrum does not compete with fluorescence in the 
visible light spectrum.26 Moreover, near-infrared fluorescence (NIRF) has reduced scattering 
properties compared with fluorescence detection in the visible light spectrum, combined with 
high sensitivity and specificity. NIRF imaging therefore gives a high signal at the target site while 
surrounding tissues emit little to no signal. As this so-called high signal-to-background ratio 
(SBR) is preferable, development of imaging agents is centred on the NIR wavelengths.27 The 
spectrum of fluorescent agents in the near-infrared range is broad, but only one has been FDA-
approved for human use: indocyanin green (emission ~820 nm).28,29 
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Although fluorescein (emission ~518 nm) is also FDA-approved30, the emission wavelength of 
this agent is not within the range of the near-infrared spectrum. New promising dyes, such as 
IRDye 800CW (emission ~805 nm), are currently in preclinical testing for toxicity.31 
In regards to the detection device, emitted NIRF signals cannot be perceived with the naked 
eye. Therefore, a sensitive multispectral near-infrared camera system is needed to simultaneously 
detect the fluorescence and the color signal and process it into one image. The ideal intraoperative 
camera system is light, portable, and easily operated with high data processing speed and detailed 
imaging properties. To date, only a few clinically approved intraoperative camera systems and 
laparoscopic fluorescence cameras have been described. These workable fluorescence camera 
systems are extensively described in references 32-35.
tumor-specIFIc targets For Fluorescence ImagIng
The ideal marker for tumor-targeted intraoperative NIRF imaging is tumor-specific, clinically 
approved, safe, and non-toxic. Also, the marker needs to be easily conjugated to a NIRF dye.36 
In the following paragraphs, we will elaborate on five targets that are promising candidates for 
tumor-specific fluorescence imaging in ovarian cancer. This review is limited to agents that 
are already FDA-approved for therapeutic or diagnostic imaging purposes, thus facilitating 
introduction into the clinic within the next five years. 
Folate receptor
The folate receptor (FR) is one of the most promising targets in EOC. The transmembrane 
receptor consists of four isoforms, of which the FR-α is present on malignant cells, while the 
FR-β is located on activated macrophages.37 FR-γ and FR-δ are reported to play a role in 
regulatory T-cells.38 In general, folate receptor-alpha (FR-α) is overexpressed by approximately 
40% of human cancers, but expression rates vary greatly between tumor types.39 Since FR-α 
is overexpressed in EOC in 72-97%, both in primary tumor tissue and in metastatic tumor 
deposits40,41, applications targeting FR-α can be applied in a large group of patients without 
prior screening for expression of the target. The advantages of folate as a biomarker are that it is 
binding to FR with high affinity, it is inexpensive, can be easily coupled to other substances and 
has little or no toxicity.42
Folate and folate-conjugates are quickly internalized in the cell via receptor-mediated endocytosis 
within two hours.43 The macromolecule inside the endosome remains intact and can therefore 
fully exert its function inside the cell.43,44 This led to the development of a broad variety of 
folate-targeted conjugates such as chemotherapeutic agents and radioactive tracers.44-48 Studies 
with 111In-DTPA-folate as an imaging agent clearly show uptake in ovarian cancer, as well 
as in the kidneys, where FR-α is expressed on cells in the proximal tubule under physiologic 
conditions.49,50 Subsequently, a 99mTc-based folate-tracer, EC20, was developed by Endocyte Inc. 
(www.endocyte.com). This tracer is cleared more rapidly from the body.51,52 
Farletuzumab (MORAb-003) is an antibody with high affinity for FR-α that has been evaluated 
preclinically and is currently being introduced in the clinic for therapeutic purposes.53-55 
Furthermore, an imaging study using radiolabeled 111In-DOTA-MORAb-003 reports excellent 
biodistribution and tumor visualization, both in mice and in patients.56 
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In short, FR-α is a promising target in EOC, and the above mentioned FR-α targeted agents 
provide sensitive visualization of tumor tissue. This leads us to believe that folate conjugated to 
a fluorescent dye could be suitable for in intraoperative imaging in FR-α expressing tumors, a 
concept that has been already reported in a preclinical study in mice.57
hYpoxIa related proteIns
Hypoxia plays an important role in the development and aggressiveness of several types of solid 
tumors, including EOC.58 Tumors develop hypoxic areas when blood supply becomes inadequate 
in rapidly proliferating tissue. Moreover, hypoxic tumors show more aggressive behaviour and 
appear to have a worse prognosis, due to a greater potential to metastasize, a decreased response 
to cell damage due to inactivation of the tumor suppressor gene p53, and increased resistance to 
both radio- and chemotherapy.59-61 In instances of low oxygen pressure, hypoxia-inducible-factor 
1 (HIF-1) is expressed, of which the alpha subunit (HIF-1α) affects several regulatory processes 
such as apoptosis and proliferation, through modulation of more than 100 hypoxia related genes 
and their hypoxia responsive elements (HREs). 62-65 Two of these are of special significance in the 
context of intraoperative imaging in EOC. Both the epidermal growth factor receptor (EGFR) 
and the vascular endothelial growth factor receptor-1 (VEGFR-1) are upregulated by HIF-1α in 
EOC66,67, and could be suitable targets for imaging applications for two reasons. First, given that 
most ovarian cancers are diagnosed in a late stage when the tumor is already of reasonable size, it 
is realistic to assume that there are areas of hypoxia and thus involvement of hypoxia inducible 
genes. This is confirmed by genomic and proteomic testing of patient material.68-70 Second, 
hypoxic tumors tend to metastasize more rapidly and the associated hypoxia inducible genes can 
be detected in the primary tumor as well as in metastatic tumor deposits.71 This implies that their 
protein products or even at the cellular level, their HREs, may serve as a target in intraoperative 
imaging to visualize both the primary tumor and foci of disseminated disease. 
Vascular endothelIal groWth Factor
Vascular endothelial growth factor (VEGF), an important regulator of angiogenesis and vascular 
permeability is involved in various steps of normal ovarian function as well as carcinogenesis.62,72,73 
VEGF-related growth factors and receptors form primary signaling pathways in tumor 
angiogenesis and have been implicated as regulators of angiogenesis and disease progression in 
EOC through proliferation, cell survival and metastasis.73,74 Triggering this so-called ‘angiogenic 
switch’ by overexpression of a potent angiogenic growth factor is an important step in the growth 
and dissemination of EOC. VEGF activates two high affinity transmembrane tyrosine kinase 
cell surface receptors, VEGFR-1 and VEGFR-2, which stimulate intracellular signaling cascades 
leading to endothelial cell recruitment, activation, proliferation and survival, as well as increasing 
vascular permeability.62 Of all VEGF subtypes, the VEGF-A ligand and VEGFR-2 receptor seem 
to play a particularly prominent role in EOC.75 
Several studies are now focused on the value of VEGF-inhibition in the treatment of EOC.76 
Apart from therapeutic relevance, some of these agents could also be used for tumor-targeted 
imaging. 
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In this light, we will focus on bevacizumab (Avastin®, F. Hoffmann-La Roche Ltd, Basel, 
Switzerland), a promising drug that has already been useful in several conventional imaging 
applications such as PET-scanning. Bevacizumab is a humanized monoclonal antibody which 
binds to, and neutralizes VEGF-A, preventing its association with endothelial receptors and, 
as a consequence, inhibiting angiogenesis. Inhibiting microvascular outgrowth is believed to 
slow down the growth of all tumor tissue, including metastatic sites. Recent clinical trials report 
bevacizumab to prolong progression free survival in EOC.77-80 
Bevacizumab itself can be conjugated to radioactive substances for application in PET-imaging. 
This was illustrated in a murine ovarian tumor xenograft model, in which bevacizumab conjugated 
to 111Indium or 89Zirconium showed clear tumor uptake on microPET-imaging.81 Subsequently, 
111In-bevacizumab SPECT-imaging can clearly visualize tumor lesions in melanoma patients.82 
These developments suggest that bevacizumab may also be conjugated to NIR fluorescent dyes 
and as such provide a fluorescent agent for intraoperative imaging of tumor activity.
Apart from targeting VEGF-A, fluorescence imaging of the VEGF-receptor has also been shown, 
using a single chain fusion protein (scVEGF) coupled to the fluorescent dye Cy5.5.83
Although VEGF-guided imaging seems promising, its specificity could be limited by the fact 
that VEGF is also scavenged in fluids and thus ascites and serves as an important survival factor 
for healthy cells experiencing chemical or physical stress.84-88 Possibly, the presence of VEGF-A 
in ascites might hamper the detection of tumor spots in vivo. However, considering the high 
expression of VEGF in tumor tissue, the signal-to-background ratio may be sufficient to 
distinguish the strong tumor-related signal from the much weaker signal from healthy tissues. 
This assumption was illustrated in the above mentioned murine model with radiolabeled 
bevacizumab81, although it should be taken into account that the murine peritoneum does not 
excrete human VEGF-A. Moreover, during cytoreduction, the abdomen is thoroughly inspected, 
consecutively focusing on specific regions of interest – i.e. the abdomen, pelvis, diaphragm, liver 
capsule – and VEGF-expression in other tissues will probably not interfere with imaging of this 
specific region. Furthermore, ascites can be drained during surgery for improving detection. 
epIdermal groWth Factor receptor
Members of the epidermal growth factor (EGF) family and the associated receptor, EGFR, play 
a significant role in ovarian cancer as the majority of epithelial ovarian cancers express high levels 
of the EGFR.89-91 This overexpression of EGFR is an independent factor for poor outcome and 
low survival rates.92-94 The EGFR superfamily is made up of four distinct but structurally similar 
tyrosine kinase receptors. Upregulation leads to cell proliferation, differentiation, migration, 
adhesion, protection from apoptosis, and transformation.95
A few EGFR-targeted monoclonal antibodies are already available in the clinical setting, including 
cetuximab and panitumumab.96 These are used in therapeutic regimes, but may also prove 
useful for imaging purposes. Panitumumab, either radiolabeled or in its pure form, conjugated 
to indocyanine green (ICG) has been shown to yield excellent optical imaging signals when 
used in a mouse model.97,98 Radiolabeled cetuximab for tumor-targeted imaging has also been 
successfully used in murine tumor models.99,100 To date, no clinical studies have been performed 
using an EGFR-antibody for this type of tumor-targeted imaging. However, the existence of 
FDA-approved antibodies and promising preclinical data may lead to rapid translation into the 
clinic.Because EGFR is not only expressed by cancer cells but also by healthy cells, one might 
suggest that tumor-specific imaging using EGFR as a target is impossible. 
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However, expression rates in tumor tissue are 20-50 times higher than in the surrounding healthy 
tissue.101 This makes the signal-to-background ratio large enough for sensitive tumor-targeted 
imaging. As such, EGFR can also be regarded as a potential target for intraoperative imaging in 
ovarian cancer.
cxcr4-cxcl12
Dissemination of disease in EOC starts with the loss of cell adhesion molecules and degradation 
of the extracellular matrix after which migration of tumor cells commences.102 In this process, 
there is a key role for matrix metalloproteinases (MMPs) and several chemokine-receptor pairs, of 
which the CXC receptor 4 (CXCR4) and its chemokine CXCL12 or stromal cell derived factor 
1 (SDF-1) are among the most well-studied.103 Many of the mechanisms governing the structure 
and migration of cells are influenced and disrupted by hypoxia and HIF-1 (for a comprehensive 
review, see reference 102). Although not specific for ovarian cancer, both MMP and CXCR4-
CXCL12 indicate areas of disseminated disease and are therefore worth exploring as possible 
targets for intraoperative imaging. 
Several chemokine-receptor pairs are expressed in tumors cells, as well as by the surrounding 
stroma.103,104 The CXCR4-CXCL12 axis supports chemotaxis of tumor cells to the metastatic site 
and subsequent hatching and proliferation. In ovarian cancer, the CXCR4-CXCL12 pathway 
seems to have a more prominent role than other chemokine-receptor pairs and portends a worse 
prognosis.105-108 CXCR4 and CXCL12 staining was demonstrated in 59% and 91% of ovarian 
tumor cells, respectively, while no expression was seen in healthy tissue.109 Upon binding to 
CXCR4, CXCL12 is internalized and the receptor recycled to the cell surface where it is ready for 
further action within 15 minutes.107 Overexpression of CXCL12 was found in ascites, inducing 
the migration of tumor cells and contributing to peritoneal dissemination.109,110 
Visualization of CXCR4 on the cell membrane was shown in vitro by using a CXCR4 directed 
fluorophore. 111 For in vivo targeting, both the receptor and the chemokine can be targeted by a 
monoclonal antibody, which in itself can be conjugated to an imaging agent. In a mouse model, 
a CXCR4 radiolabeled antibody was successfully used for tumor visualization in SPECT/CT-
scanning.112 For PET-scanning, the CXCR4 antagonist ADM3100 conjugated to 99mTc proved 
useful in locating tumor xenografts in mice.113 
matrIx metalloproteInases
Matrix metalloproteinases (MMPs) degrade several components of the extracellular matrix and 
are associated with tumor progression and metastasis. Several subtypes, among which MMP1, 
MMP2, MMP7 and MMP9 are overexpressed in EOC.114-119 CXCL12 is known to activate 
MMP2 and MMP9 in ovarian cancer, further contributing to the dissemination of tumor cells.120
A few preclinical studies have been conducted on near-infrared fluorescent imaging of MMP 
activity in cancer, using so-called ‘smart activatable probes’ that are activated by MMPs.121-123 
Although these probes are not yet suitable for human use, they could play an important role 
in the future development of ovarian cancer targeting. These results indicate that substantial 
progress is being made in visualization of MMP and CXCR4 activation and expression in EOC. 
These factors could possibly find their way to the clinic as targets for tumor-specific imaging in 
ovarian cancer.
Proefschrift Marleen 18-12-2013.indd   79 18-12-13   20:05
80
dIscussIon
The greatest potential of intraoperative fluorescence imaging in EOC lies in improved detection of 
metastatic tumor deposits, leading to more complete cytoreduction. Additionally, intraoperative 
fluorescence imaging may be valuable in other gynecologic malignancies and in a broader range of 
oncologic diseases. As many tumor types express the biomarkers mentioned in this review, albeit 
to different degrees; these tumor-targeted contrast agents could potentially be applied in a broad 
spectrum of diseases. Overexpression of FR-α is seen in 40% of human cancers, including breast, 
lung, renal and brain cancer,37 however, there is great variation in expression patterns between 
tumor types.39 Hypoxia has been shown to occur in several types of solid tumors, including 
gynecologic cancers such as cervical124 and endometrial carcinoma,125 and is in the vast majority 
of cases correlated with worse survival rates. HIF-1α, VEGF and EGFR are all overexpressed 
in endometrial cancer.125 Furthermore, treatment with cetuximab has been shown to inhibit 
tumor growth and peritoneal dissemination in a mouse model for endometrial cancer.125,126 These 
findings suggest that contrast agents targeting hypoxia-induced gene products such as VEGF 
and EGFR could also be of value in the surgical treatment of endometrial cancer with peritoneal 
dissemination. In cervical cancer, peritoneal dissemination is rare, limiting the application of 
tumor-targeted contrast agents for the purposes of cytoreductive surgery. However, these agents 
may be successful in identifying parametrial disease, especially in the laparoscopic setting, as 
MRI and CT perform poorly in staging of advanced disease, with sensitivity rates of 53% and 
42%, respectively.127
Although the concept of intraoperative tumor-targeted imaging is promising, more research is 
needed to define the value of each independent target. In the development of possible tumor-
targeted agents, specificity and sensitivity of the agent for its target are of utmost importance. The 
variable expression of biomarkers, not only between tumor types but also within a solid tumor, 
may call for a combination of tumor-targeted agents in order to obtain high sensitivity rates. In 
addition, fluorescent agents with varying wavelengths could be used to localize various active 
biomarkers using multispectral fluorescence imaging. Conversely, a panel of agents with the same 
wavelength may provide the most comprehensive image of tumor activity. 
Apart from evaluating the value of each independent tumor-targeted contrast agent, attention 
needs to be focused on development of commercially available user-friendly and safe intraoperative 
camera systems and laparoscopic fluorescence cameras. 
conclusIon
Treatment of advanced epithelial ovarian cancer (EOC) primarily consists of surgical cytoreduction 
followed by chemotherapy. As the extent of cytoreduction greatly influences prognosis, detailed 
detection and resection of metastatic and residual tumor tissue during surgery is a necessary 
prerequisite to improve patient survival. New techniques such as intraoperative optical imaging 
using highly specific tumor-targeted fluorescent optical agents combined with sophisticated 
camera systems can help improve cytoreductive efforts. Preclinical and translational studies will 
determine the efficacy of such an approach in the near future. 
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aBstract
Background: Folate receptor alpha (FR-α) has been identified as a potential target in 
ovarian cancer for diagnostic and therapeutic purposes, based on its overexpression in 
serous epithelial ovarian carcinoma. The effect of chemotherapy on FR-α expression may 
be important in the applicability of FR-α directed agents in residual tumor tissue. The 
objective of this study was to assess FR-α expression in ovarian carcinoma and to evaluate 
whether FR-α expression is altered by chemotherapy. 
Materials & Methods: FR-α expression was analyzed by semi-quantitative scoring of 
immunohistochemical staining on tissue microarrays (TMAs) from a database containing 
361 ovarian cancer tissue samples, of which 210 serous and 116 non-serous carcinoma (35 
missing). Serous carcinoma samples included 28 matched samples with tissue from primary 
surgery and interval debulking surgery, and 12 matched samples with tissue from primary 
surgery and surgery for recurrent disease. 
Results: FR-α expression was seen in 81.8% of serous ovarian cancers versus 39.9% of non-
serous carcinomas (p<0.001). In matched serous carcinoma samples, no significant change 
in FR-α expression in vital tumor tissue after chemotherapy was observed (p=0.149). FR-α 
expression was not a prognostic marker of progression free survival (p=0.755) or overall 
survival (p=0.710). 
Conclusion: FR-α was expressed in the majority of serous ovarian tumors, although >50% 
of cases showed only weak expression. Chemotherapy did not decrease expression rates in 
remaining vital tumor tissue, indicating that folate-targeted agents may have a place in the 
treatment for ovarian cancer, before as well as after chemotherapy. Furthermore, FR-α status 
did not influence survival. 
IntroductIon
Ovarian cancer is the leading cause of death among gynecologic malignancies in the western 
world.1 Because of late onset of symptoms, 75% of the patients are diagnosed with advanced 
disease. Prognosis in stage III and IV remains poor with 5-year survival rates of around 30%.2 
Novel approaches to improve survival include the development of tumor-targeted diagnostic 
agents and drugs. In ovarian cancer, the folate receptor alpha (FR-α) seems promising for tumor-
targeting, as overexpression of FR-α is seen in 72-97% of serous epithelial ovarian tumors.3-5 
Folic acid is used for synthesis of nucleotide bases and is under physiological conditions 
taken up by cells by the reduced folate carrier (RFC).6 A second mode by which folic acid 
can be internalized, is via the high-affinity folate receptor (FR), of which the alpha isoform 
is overexpressed in ~40% of solid tumors, including ovarian, renal, lung and breast cancers.5 
Uptake of folate and folate-conjugates occurs via receptor-mediated endocytosis.7 Since the 
macromolecule inside the endosome remains intact, it can fully exert its function inside the 
cell.7,8 After endocytosis, the FR is recycled back to the cell surface where it can again bind 
circulating folate. The high affinity of folate for the FR combined with the rapid recycling of 
the receptor makes this receptor an attractive factor for targeted diagnostics and therapy. In 
the last decade, several FR-targeted substances have been developed. SPECT-scanning using the 
radionuclide 111In-DTPA-folate showed a strong signal originating from ovarian tumors, as well 
as from the kidneys, but no uptake in benign tumors.9,10 
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Subsequently, interest shifted towards a 99mTc-based folate-tracer because of its shorter half-life 
and lower production costs.11 FR-α targeted chemotherapy with farletuzumab (MORAb-003), 
an antibody with high affinity for FR-α, is currently under investigation in the first clinical 
trials.12-14 Furthermore, a clinical trial is being carried out evaluating the combination of EC145, 
an FR-α targeted drug, with Doxil compared with Doxil alone for platinum resistant ovarian 
cancer (PRECEDENT study; identifier no. NCT00722592; www.clinicaltrials.gov).
The possibilities for FR-targeted diagnostics and therapeutics seem promising, but applicability 
depends entirely on FR-expression by the target tissue. Chemotherapy, either (neo)adjuvant or 
intraperitoneal, is a vital part in the treatment for ovarian cancer. Therefore, the relevance of FR-α 
targeted agents depends on whether chemotherapy influences FR-α expression on remaining 
vital tumor tissue. Previous studies show that FR-α is overexpressed on the majority of primary 
ovarian tumors, however, the effect of chemotherapy has only been described once, reporting no 
significant change in FR-α expression.3 To address this question in more detail, we analyzed FR-α 
expression in ovarian cancer tumor samples obtained at primary surgery as well as in samples 
obtained directly post-chemotherapy at interval debulking surgery, and in samples from surgery 
for recurrent disease. In addition, we evaluated the impact of FR-α expression on survival. 
materIals & methods
Patient tissue samples
Ovarian cancer specimens were collected from the databank of the University Medical Center 
Groningen (UMCG). Since 1985 all clinicopathological and follow-up data of epithelial 
ovarian cancer patients treated at the UMCG are prospectively stored in a database. Tumor 
samples from 361 patients were assembled on a tissue microarray. Borderline and non-epithelial 
malignancies were excluded. Treatment for all patients consisted of surgery followed by adjuvant 
chemotherapy (platinum-based regimens; since 1995 supplemented by taxanes). Staging was 
performed surgically, according to the FIGO (International Federation of Gynaecology and 
Obstetrics) classification.15 All patient data were anonymized and all studies concerning this 
databank were conducted in accordance with the Declaration of Helsinki principles and with the 
rules and regulations posed by the medical ethical research board (IRB) of the UMCG. 
Sample preparation and immunohistochemistry
For previous studies, tissue microarrays (TMAs) were constructed (de Graeff et al., 200616). In 
order to determine whether these were suitable for quantification of FR-α expression, it was 
necessary to evaluate the homogeneity of the FR-α staining. For this purpose, ten randomly 
selected ovarian tumor samples were stained for FR-α following the immunohistochemical 
procedure described below. Uniform staining was observed throughout tumor tissue in these 
samples, indicating the feasibility of using TMAs for further analyses.
The previously constructed TMAs were cut into 3 μm sections and  fixed  on  coated  glass 
slides. Sections were deparaffinized with xylene, rehydrated through a graded series of ethanol 
and rinsed well in distilled water. Antigen retrieval was achieved by heating in a high pressure 
cooker (Pascal, Dako) in a Target Retrieval Solution (Dako) for 1 minute at 125 °C and cooled 
down to 90 °C without venting of pressure. Slides were cooled down to room temperature and 
rinsed with phosphate buffered saline (PBS). 
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After blocking endogenous peroxidase in 0.3% H2O2 in PBS for 30 minutes, sections  were 
incubated with the monoclonal antibody mAB343 (1.8 mg/ml; a generous gift from prof. P.S. 
Low, Endocyte Inc.) in a 1:500 dilution in 1% BSA/PBS solution for 3 hours at room temperature. 
After washing with PBS, the sections were incubated with mouse MACH3 (Biocare Medical). 
Peroxidase activity was visualized with 3,3-diaminobenzidine and slides were counterstained 
with haematoxylin, mounted with mounting medium and coverslipped. 
External validation
In order to validate the staining technique, one TMA (55 samples; 4 cores each) was stained in 
the laboratory of P.S. Low. The similar results as ours indicate validity of the staining protocol. 
Histological analysis
TMAs were graded for FR-α staining using the following criteria: x = no tumor cells in TMA 
core or missing core; 0=no staining; 1=weak staining; 2=moderate staining; 3=strong staining 
according to a previously published study.3 A sample was considered positive when at least 25% 
of the tumor cells showed staining. All samples with < 2 representative cores were excluded. 
First, all cores were judged separately. Second, one mean score was appointed to each sample, 
consisting of four cores. This score was based on the most frequent staining intensity observed 
in the sample. For additional analyses, cases were subdivided in a ‘low staining’ group (score 0 
or 1) and in a ‘high staining’ group (score 2 or 3). Scoring was performed, after training, by the 
primary researcher (LMAC) and by the pathologist (JB). In case of different grading, the cores 
were discussed in a general meeting until consensus was met.
Statistical analysis
Descriptive statistics were calculated for variables of interest. Histology type and FR-α expression 
were compared using the chi-square test. Matched samples were compared using the Wilcoxon 
signed-rank test. For survival analyses, progression free survival was defined as the time from 
primary surgery until either death due to ovarian cancer or last follow-up. Survival curves 
were generated using Kaplan-Meier analysis. FR-α expression was tested as a prognostic factor 
according to a Cox proportional hazards model. All statistical analyses were carried out using 
the SPSS 16.0 software package for Windows (SPSS Inc., Chicago, USA). For all tests, p-values 
<0.05 were considered statistically significant.
Image capture
Images shown in this paper were acquired using a Leica DM400B microscope and a Leica 
DFC320 digital camera (Leica Microsystems GmbH, Wetzlar Germany). 
results
Patient characteristics
Baseline characteristics of the 361 patients included in the database are presented in Table 1. 
Of these 361, histology was unknown in 35 cases. Of the remaining 326 patients, 386 tumor 
samples were available, of which 295 obtained during primary surgery, 63 during interval surgery 
and 28 during surgery for recurrent disease. 




	   All tumors (n=361) 
Age (mean, min-max, SD) 57.5 16-89 SD 13.2 
Age; grouped n % 	  
< 58 years old 168 46.5 	  
≥ 58 years old 192 53.2 	  
Missing 1 0.3 	  
Tumor type n % 	  
Serous adenocarcinoma 210 64.4 	  
Other 116 35.6 	  
- Mucinous adenocarcinoma 40 12.3 	  
- Endometrioid adenocarcinoma 51 15.6 	  
- Clear cell carcinoma 22 6.8 	  
- Undifferentiated 3 0.9 	  
Missing 35 	   	  
FIGO-stage n % 	  
Stage I 70 19.4 	  
Stage II 30 8.3 	  
Stage III 205 56.8 	  
Stage IV 54 15.0 	  
Missing	   2 0.6 	  
Grade n % 	  
Grade I 57 15.8 	  
Grade II 96 26.6 	  
Grade III 160 44.3 	  
Undifferentiated 15 4.2 	  
Missing	   33 9.1 	  
Rest tumor after primary surgery n % 	  
Yes 224 62.0 	  
No  125 34.6 	  
Missing 12 3.3 	  
Size of rest tumor  n % 	  
< 2 cm 168 46.5 	  
≥ 2 cm 163 45.2 	  
Missing 30 8.3 	  
Progression free survival (months)   	  













Table 1 – Patient characteristics
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Of the 326 cases with known histology, 210 cases (64.4%), were serous carcinomas and 116 
cases (35.6%) were of all other histologic subtypes of which mucinous and endometroid 
adenocarcinoma were the most prevalent (12.3 and 15.6%, respectively). 
In the group of serous carcinomas, 28 matched cases contained tumor tissue from both primary 
and interval debulking surgery, and 12 cases contained tumor tissue from both primary and 
recurrent surgery. Only seven matched cases for primary and interval debulking surgery could be 
identified in the subgroup of non-serous carcinomas.
FR-α expression
Samples that contained less than two representative cores were excluded. Representative FR-α 
scores (Figure 1) could be obtained in 278 tumor samples (72%), of which 216 from primary 
surgery, 39 from interval debulking surgery and 23 from surgery for recurrent disease.
Of the 216 primary tumor samples, 71.8% showed FR-α expression and 28.2% was negative. 
Grade was not correlated to FR-α expression (p=0.374).
An overview of FR-α expression subdivided into histology is shown in Tables 2 and 3. 
Of the primary serous carcinomas, 18.2% was negative; 53.3% showed weak staining, 23.0% 
moderate staining and 5.5% strong staining. Interval debulking tumor samples showed negative 
expression in 7.9%, weak staining in 44.7%, moderate staining in 39.5% and strong staining in 
7.9%. 
Figure 1. FR-α expression in a representative sample. A – no expression (0); B – weak expression (1); C – moderate 
expression (2); D – strong expression (3)
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Recurrent tumors were negative in 18.8% while 43.8% showed weak staining, 25.0% moderate 
staining and 12.5% strong staining. 
Primary non-serous carcinomas showed no staining in 60.8%, weak staining in 27.5%, moderate 
staining in 9.8% and strong staining in 2.0%. 
Using the chi square test, a significantly higher staining was observed in the primary serous 
carcinomas compared to non-serous carcinomas (p<0.001).
The combined group of moderate and strong staining (scores 2-3) showed 28.5% FR-α expression 
in serous primary tumors, versus 45.9% (p=0.035) of tumor samples at interval debulking and 
33.3% of recurrent tumors (p=1.000).
FR-α expression pre- and postchemotherapy
Twenty-eight cases within the group of serous carcinomas contained matched samples for both 
primary and interval debulking surgery. All patients had received either three or six cycles of 
chemotherapy, either platinum-based (50.0%) or platinum/taxane (46.4%). Nearly all patients 
had advanced disease (FIGO stage III-IV; 96.5%). Characteristics of this subgroup of patients 
are shown in Table 4. Comparison of staining scores using the Wilcoxon Rank test showed no 
difference in FR-α expression (p=0.149) in remaining vital tumor tissue. Similarly, no significant 
difference was found when comparing staining scores grouped into low expression (score 0 or 1) 
and high expression (score 2 or 3) (p=0.096). 
Twelve cases contained tissue from both primary and recurrent disease. All patients underwent 
three or six cycles of chemotherapy (Table 4). Comparison of staining scores showed no significant 
difference in FR-α expression (p=0.546), nor in low versus high expression (p=1.000). 
When combining scores from interval debulking surgery and surgery for recurrent disease, 37 
cases are matched for primary and postchemotherapy scores (postchemotherapy either directly at 
interval debulking or at surgery for recurrent disease). 
  Negative (0) Weak (1) Moderate (2) Strong (3) 
All primary (n=216) 28.2 47.2 19.9 4.7 
All interval (n=39) 10.3 43.5 38.5 7.7 
All recurrent (n=23) 26.1 34.8 21.7 17.4 
Serous primary (n=165) 18.2 53.3 23.0 5.5 
Serous interval (n=38) 7.9 44.7 39.5 7.9 
Serous recurrent (n=16) 18.8 43.8 25.0 12.5 
Other primary (n=51) 60.8 27.5 9.8 2.0 
Other interval (n=1) 100.0 0.0 0.0 0.0 
Other recurrent (n=7) 42.9 14.3 14.3 28.6 
	  
Table 2. FR-α expression subdivided into histology (top row, complete cohort; middle row, serous carcinoma; 
bottom row, non-serous carcinoma). Each group is subdivided into samples obtained at primary surgery, at interval 
debulking surgery or at surgery for recurrent disease. Expression scores are depicted as percentages.
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Wilcoxon Rank test did not show a difference in FR-α expression between these groups (p=0.109).
In the group of non-serous carcinomas, only one case was matched for primary and interval 
debulking surgery and four cases were matched for primary and recurrent disease. These numbers 
are considered too small to perform reliable statistical analyses on.
Survival analysis
As expected, univariate analysis in the cohort of 326 cases of known histology showed that 
advanced stage, age ≥ 58 years of age, residual tumor ≥ 2 cm, grade III/undifferentiated and 
serous histology were associated with shorter progression free survival (PFS) and overall survival 
(OS). FR-α expression (low vs. high), was not associated with PFS or OS. In multivariate 
analysis, advanced stage, serous histology and residual disease were significantly associated with 
PFS and OS, whereas age, grade and FR-α expression were not (Table 5). In the subgroup of 
serous carcinomas, advanced stage, residual disease ≥ 2 cm and high grade were associated with 
PFS and OS (data not shown). In the subgroup of non-serous tumors, univariate analysis showed 
associations between stage, age, residual disease and high grade with OS and between stage, 
residual disease and high grade and PFS. Only advanced stage was prognostic in multivariate 
analysis (data not shown). The influence of FR-α expression on PFS and OS is shown in survival 
curves (Figures 2A and 2B).
 




























































Missing 35       
	  
Table 3. FR-α expression in primary tumor samples subdivided into histologic subtype. Non-serous carcinomas are 
further subdivided; shown in italic. 
N; number of cases per group.
FR-α–; the number and percentage of samples showing no FR-α expression (negative).
FR-α+; the number and percentage of samples showing FR-α expression. These are further subdivided into weak (1), 
moderate (2) and strong (3) expression (right half of table).
*FR-α expression in serous compared to non-serous carcinomas: p<0.001
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  Primary & Postchemo Primary & Recurrent 
  n=28     n=12     
              
Age (mean, min-max, SD) 55.1 31-74 SD 9.3 49.8 31-68 SD 12.1 
              
Age; grouped n %   n %   
< 58 13 46.4   8 66.7   
≥ 58 15 53.6   4 33.3   
Missing 0 0.0   0 0.0   
              
FIGO n %   n %   
Stage I 0 0.0   1 8.3   
Stage II 1 3.6   2 16.7   
Stage III 22 78.6   8 66.7   
Stage IV 5 17.9   1 8.3   




































Rest tumor after primary surgery n %   n %   
Yes 28 100.0   4 33.3   
No 0 0.0   7 58.3   
Missing 0 0.0   1 8.3   
              
Size of rest tumor n %   n %   
< 2 cm 1 3.6   7 58.3   
≥ 2 cm 25 89.3   2 16.7   
Missing 2 7.1   3 25.0   
              
Chemotherapy n %   n %   
No chemo 0 0.0   1 8.3   
Platinum based 14 50.0   8 66.7   
Platinum / Taxane 13 46.4   3 25.0   
Missing 1 3.6   0 0.0   
              
Progression free survival (months)          
(mean, min-max, SD) 14.7 0-115 SD 21.1 46.6 11-124 SD 36.3 
              
FR-alpha expression (mean, median, SD) 
         
Primary tumor 1.29 1.0 SD 0.897 1.17 1.0 SD 1.03 
Interval debulking 1.54 2.0 SD 0.838     
Recurrent disease      1.42 1.0 SD 0.793 
     p=0.149   p=0.546 
              
FR-alpha expression low/high (mean, 
median, SD)          
Primary tumor 0.36 0.0 SD 0.488 0.4 0.0 0.515 
Interval debulking 0.52 1.0 SD 0.509     
Recurrent disease      0.36 0.0 0.505 
     p=0.096   p=1.000 
              
	  
Table 4. Patient characteristics of matched serous carcinoma samples. 
- Primary & Postchemo (middle column); cases containing both tumor tissue from primary surgery and from interval 
debulking surgery (n=28).
- Primary & Recurrent (right column); cases containing both tumor tissue from primary surgery and from surgery for 
recurrent disease (n=12).
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dIscussIon
We analyzed FR-α expression in 361 ovarian cancer tissue samples, of which 326 with known 
histology. We showed FR-α expression in 81.8% of serous carcinomas, versus 39.2% in non-
serous carcinomas (p<0.001). FR-α expression did not change significantly after chemotherapy, 
neither in vital tumor tissue obtained during interval debulking surgery (p=0.149) nor in tumor 
tissue obtained during surgery for recurrent ovarian cancer (p=0.546). Furthermore, FR-α 
expression in primary ovarian tumors was not associated with survival.
Several studies, summarized in Table 6, report FR-α expression in smaller patient cohorts.
Toffoli et al. reported overall expression of the folate binding protein (FBP) in 89.7% of 136 
patients, with a significant difference in expression between serous and mucinous tumors. FR-α 
expression was determined using cytofluorimetric analysis.17 Wu et al. described FR-α expression 
in gynecologic malignancies (n=23), measured with in situ hybridization histochemistry. Of 
23 malignant ovarian samples, 100% FR-α expression was seen in serous and endometrioid 
carcinoma (n=15), versus 0% expression in mucinous and clear-cell carcinoma (n=8).18 Bagnoli 
et al. analyzed 168 non-mucinous ovarian malignancies, in which an expression rate of 85.1% 
was found.19 Parker et al. compare expression rates in animal tissues and human tissues. Of 29 
ovarian tumor patient samples, 100% expression rates were seen in serous and endometrioid 
carcinoma and metastatic tissue. Only weak expression was seen in 36% of mucinous carcinoma.5 
Kalli et al. reported overall expression in 72% of primary ovarian tumors (n=186), with higher 
expression in serous carcinoma (81.7%) than in other histologic subtypes (59.8%), with lowest 
expression in mucinous tumors (22.2%).3 Markert et al. reported 97% expression in a series of 
104 malignant ovarian tumors, but did not specify percentages for histologic subtype.4
When comparing our data to these studies, FR-α expression in serous carcinoma appears 
comparable. Remarkable is the high expression rate reported by Markert et al. All studies are 
uniform in showing low expression rates in mucinous carcinoma, as do we.
The study by Kalli et al. is the only to report FR-α expression in 24 matched samples of both 
primary and recurrent tumors. No significant difference in expression was found.3 Our data 
support these findings. Moreover, by comparing primary surgery specimens to samples from 
interval debulking surgery as well as to recurrent tumors, we show that chemotherapy has neither 
a direct, nor a late effect on FR-α expression in remaining vital tumor tissue. 
Although our data are in general in line with the reported literature, a remarkable finding is the 
weak FR-α expression in the majority (53.3%) of the primary serous carcinomas. We observed 
‘moderate’ or ‘strong’ staining in only 28.5%. Numbers are slightly higher in interval debulking 
specimens and recurrent tumors, but do not exceed 50%. Little is known regarding the required 
intensity of FR-α expression for clinical application. Theoretically, lower expression rates may 
negatively influence the effectiveness of folate-based compounds. Since no data are available 
to confirm whether low expression implicates less effective tumor-targeting, further studies are 
warranted to elucidate this question. From the present study, we conclude that the strength of 
FR-α expression may be a relevant factor to be specifically addressed in future studies.
In summary, this study confirms previously found FR-α expression rates of ~82% in serous 
ovarian carcinoma, although strong expression was seen in a smaller proportion of tumors than 
earlier reported. FR-α was not associated with progression free survival, nor with overall survival. 
Furthermore, we show that chemotherapy does not affect FR-α expression in vital residual tumor 
tissue, thus strengthening the rationale for FR-α targeted diagnostic agents and drugs. 
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Figure 2 – Survival curves for serous tumors
A – Overall survival (follow-up in months); p=0.710. B – Progression free survival in months; p=0.755.
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Study No. of patients Method FR-α expression 
Toffoli (1997)17 136 Cytofluorimetric 89.7% 
Wu (1999)18 23 In situ hybridization 
histochemistry 
100% serous (n=10); 
80% endometrioid (n=5); 
0% mucinous (n=6); 
0% clear-cell (n=2) 
Bagnoli (2003)19 168 Immunohistochemistry 85.1% non-mucinous* 
Parker (2005)5 29 Radioligand binding assay 100% serous (n=7); 
100% endometrioid (n=4); 
36% mucinous (n=14)†; 
100% metastatic (n=4) 
Kalli (2008)3 186 Immunohistochemistry 81.7% serous (n=104); 
66.7% endometrioid (n=39); 
22.2% mucinous (n=9); 
63.3% clear-cell (n=30); 
50% mixed (n=4) 
Markert (2008)4 104 Immunohistochemistry 97% non-mucinous‡ 
	  
Table 6. Studies reporting FR-α expression in ovarian cancer.
* Serous, endometrioid and clear-cell carcinoma.
† Of 14 mucinous tumors, 36% showed only weak FR-α expression.
‡ Serous (n=8), serous-papillary (n=79) and papillary carcinoma (n=17).
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Background: The folate receptor alpha (FR-α) has been identified as a target for cancer 
therapy and imaging. FR-α is present on ~40% of human cancers. FR-β is known to be 
expressed on hematopoietic cancers and on activated macrophages, but currently little is 
known regarding FR-β expression in solid tumors. Additional or simultaneous expression 
of FR-β could help extend the indications for folate-based drugs and imaging agents. In this 
study, the expression pattern of FR-β is evaluated in a number of solid tumors. 
Methods: FR-β expression was analyzed by semi-quantitative scoring of immunohistochemical 
staining on tissue microarrays (TMAs) of 361 ovarian cancer patients, 449 breast cancer 
patients, on 20 slides of colorectal cancer samples and on 25 samples of diverticulitis.
Results: FR-β expression was seen in 21% of ovarian cancer samples, 9% of breast cancer 
samples, and 55% of colorectal cancer samples. Most expression was weak or moderate. Of 
the diverticulitis samples, 80% was positive for FR-β expression. FR-β status was neither 
correlated to known disease-related variables, nor showed association with overall survival 
and progression free survival in ovarian and breast cancer. In breast cancer, negative axillary 
status was significantly correlated to FR-β expression (p=0.022).
Conclusions: FR-β expression was low or absent in the majority of ovarian, breast and 
colorectal tumor samples. From the present study we conclude that the low FR-β expression 
in tumor tissue implicates limited practical use of this receptor in diagnostic imaging and 
therapeutic purposes.
IntroductIon 
The folate receptor (FR) has been proposed as a target in cancer therapy and imaging. The 
vitamin folate (B9) or its synthetic form folic acid is indispensable for nucleotide synthesis. Under 
physiologic conditions, uptake of folate occurs mostly through the reduced folate carrier (RFC), 
which is sufficient in healthy tissues despite its fairly low affinity for folate.1 Furthermore, some 
healthy tissues and a number of pathologic processes express the transmembrane FR which has 
in the past two decades attracted attention as a target for diagnostic and therapeutic compounds 
because of its much higher affinity for folate.2 
The FR gene family includes four isoforms; FR-α, FR-β, FR-δ and FR-γ. The latter two play a 
role in regulatory T-cells and fall outside the scope of this article. FR-α is expressed on the apical 
side of a number of epithelial cells and is present on ~40% of solid tumors. Expression varies 
between tumors showing high expression in serous ovarian cancer and renal carcinoma, versus 
low to moderate expression in breast, colorectal and lung cancer.3-5 The value of FR-α targeting 
in cancer diagnosis and therapy has been shown using folate-conjugated imaging agents as well 
as folate-based drugs.6-8
Little is known regarding the expression of FR-β in solid tumors. Studies using mRNA isolation 
and isolation of cellular membranes demonstrated expression on activated but not on resting 
macrophages and on the surfaces of malignant cells of hematopoietic origin such as acute 
leukemia.9,10 Targeting of FR-β has shown feasible in the visualization of inflammatory processes 
in rheumatoid arthritis and atherosclerosis.2,8,11
Thus far, it is largely unknown whether FR-β is also expressed on solid tumors, apart from one 
article stating that this may indeed be the case.6 
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However, one study indicates that FR-β mRNA can be found in tumors suggesting that FR-β 
may play a role in tumor cell growth and metastasis. It is suggested that the mechanism of action 
is mainly via infiltration of tumor-associated macrophages (TAMs), which are guided towards 
the tumor by cytokines and are thought to induce a more malignant tumor behavior.12 It has 
furthermore been suggested that folate-based immunotherapy for cancer may also exert its effect 
by targeting TAMs.
The overexpression of FR-α and/or FR-β on cancer cells and myelogenous cells allows for non-
invasive diagnostic imaging of FR-positive cancers and inflammatory processes and for subsequent 
treatment using folate-based drugs or FR-targeting antibodies. However, the limited and variable 
expression of FR-α on solid tumors is a major restriction for FR-targeted approaches. Additional 
or simultaneous expression of FR-β could help extend the indications. The aim of this study is to 
investigate the expression pattern of FR-β in solid tumors and thereby to evaluate the possibilities 
and limitations for cancer specific imaging and therapy.
materIals & methods
Patient tissue samples
All study specimens were collected from the databank of the Department of Pathology and 
Medical Biology at the University Medical Center Groningen (UMCG). Tissue microarrays 
(TMAs) of ovarian cancer (361 cases) and breast cancer (449 cases) were available from earlier 
studies, including full databases of anonymized patient data. All TMAs were constructed in the 
UMCG as described before13,14, and consisted of 4 cores per patient. Furthermore, twenty patient 
tumor samples of colorectal cancer were selected, all collected during cytoreductive surgery 
combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Twenty-five patient 
samples of diverticulitis were selected based on postoperative pathology reports. Patient data 
were retrieved from the electronic hospital patient data system and from the Dutch Pathology 
Registry (PALGA).
All patient data were anonymized and all performed study procedures were conducted in 
accordance with the rules and regulations posed by the Institutional Review Board (IRB) of the 
UMCG. 
Sample preparation and immunohistochemistry
FR-β expression was determined by immunohistochemistry (IHC). The antibody for FR-β 
staining (anti-human FR-β; Biotin-m909) was kindly provided by professor P.S. Low (Purdue 
University, West Lafayette, IN, USA). TMAs were cut into 3 µm sections and fixed on glass 
slides. All specimens were fixed by 10% formalin and embedded in paraffin. The samples were 
rinsed well in distilled water after the formalin-fixed, paraffin-embedded (FFPE) samples were 
deparaffinized with 3 changes of xylene and rehydrated in a series of alcohols. Antigen retrieval 
was achieved by placing the slices in a preheated Target Retrieval Solution (Dako, Glostrup, 
Denmark) for 5 minutes at 125°C then cooled in the buffer for 20 minutes to 90°C followed 
by a 5 minute rinse in running phosphate buffered saline (PBS). Subsequently, sections were 
incubated with 0.3% H2O2 in PBS for 30 minutes to inactivate the endogenous peroxidases. 
Slides were rinsed well and then incubated for 3 hours at room temperature with the biotinylated 
human anti-human FR-β at a 1:100. After washing with PBS, the sections were incubated with 
peroxidase labeled streptavidin (Thermo Scientific, Waltham, MA, USA and Dako) for 30 
minutes. 
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To visualize peroxidase activity, the sections were incubated in 3,3-diaminobenzidine (DAB+) 
for 10 minutes. Subsequently, sections were counterstained with haematoxylin, mounted with a 
permanent mounting media and coverslipped.
Five diverticulitis samples were stained using the anti-CD68 monoclonal antibody PGM 1. 
Activated macrophages, detected with CD68 PGM1 staining served as a positive control.
Histological analysis
All TMAs and slides were graded for FR-β staining using the following criteria: x = no tumor 
cells in the sample; 0 = no staining; 1 = weak staining; 2 = moderate staining; 3 = strong staining 
(Figure 1). The scoring was performed according to previously published studies.2,4 Only samples 
that showed staining in at least 25% of tumor cells were considered positive (score 1, 2 or 3). 
TMA samples were excluded in case of less than two representative cores. After judging of the 
cores separately, a mean score was appointed to each patient sample (consisting of four cores) 
based on the overall staining intensity observed in the sample. Colorectal cancer samples and 
diverticulitis samples were scored based on the dominant staining intensity. Last, for statistical 
purposes, all cases were divided into a ‘negative staining’ group (score 0) and a ‘positive staining’ 
group (score 1, 2 or 3). Scoring was performed by the researchers (LMAC, EDB, PK) after 
training by an experienced pathologist (JB) and all samples were confirmed by the pathologist. 
Scores were compared and in case of different grading, discussed until consensus was met.
Figure 1. FR-β expression in representative samples. A: weak expression (staining intensity 1). B: moderate expression 
(2). C: strong expression (3).
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Statistical analysis
All statistical analyses were performed by using SPSS 21.0 (SPSS Inc, Chicago, IL, USA). 
Descriptive statistics were calculated for variables of interest. The Chi-square test was applied to 
analyze correlations between FR-β staining and several disease-related variables. Survival analyses 
were performed for ovarian cancer and breast cancer. Due to small numbers, survival could not 
be calculated for colorectal cancer. Overall survival was defined as the time from diagnosis until 
the last follow-up alive or death due to the tumor (ovarian or breast, respectively). Progression-
free survival was defined as the time from primary surgery until progression of the disease, 
recurring disease or last follow-up. Survival curves were generated using Kaplan-Meier analysis. 
The prognostic influence of FR-β expression was tested in a Cox proportional hazards model. 
P-values <0.05 were considered statistically significant. 
Image capture
The images shown in this paper were acquired using a Leica DM4000B microscope and a Leica 




Baseline patient characteristics of the 361 patients included in the database are shown in Table 1 
and are summarized here. Histology was known in 326 of 361 cases. The total number of tumor 
samples obtained from these 326 patients was 386 (primary surgery n=295, interval debulking 
surgery n=63 and surgery for recurrent disease n=28). The majority of tumors consisted of 
serous carcinoma (n=210; 64.4%), followed by endometrioid (n=51; 15.6%) and mucinous 
adenocarcinoma (n=40; 12.3%). More than seventy percent of tumors were classified as FIGO 
stage III or IV (n=259; 71.8%). 
FR-β expression
Representative FR-β staining was obtained in 339 patient samples of which almost 80% showed 
no FR-β expression at all (n=269; 79.4%); 18.6% (n=63) showed weak staining and only 2.1% 
(n=7) showed moderate staining (Figure 2). None of the samples showed strong staining. 
FR-β expression was evaluated in regard to known risk factors in ovarian cancer, e.g. grade of 
differentiation, FIGO stage, histological subtype (serous vs. non-serous), age (<58 vs. ≥58) and 
residual disease >2 cm. None of these factors showed a significant correlation to FR-β status.
In a previous study, FR-α expression was analyzed using the same tumor samples and database.2 
The correlation found in the present study between FR-α and FR-β expression was weak, and 
not significant (p=0.098).
Survival analysis
All of the above factors were associated with reduced progression free survival (PFS) and overall 
survival (OS). In multivariate regression analysis, the only significant predictors of both PFS and 
OS were FIGO stage III-IV (p<0.000), residual tumor >2 cm (p<0.000) and serous histology 
(p=0.045). FR-β expression did not show any correlation with either PFS or OS. 
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Table 1. Characteristics ovarian cancer patients.




Baseline patient characteristics of all 449 patients included in the database are presented in Table 
2 and will here only be summarized. All patients were female, of whom 75% was over 50 years 
of age. Mean tumor size was 22.7 mm (1-140 mm). Ratios of breast-conserving surgical therapy 
and mastectomy were nearly equal (50.8% and 49.2%, respectively); 63.4% of patients received 
adjuvant radiotherapy and 49.7% received adjuvant chemotherapy. Nearly all tumors were 
diagnosed as either invasive ductal carcinoma (51.9%) or invasive ductal carcinoma with ductal 
carcinoma in situ (44.3%).
FR-β expression
FR-β scores could be obtained in 418 of 449 cases. The vast majority of tumor samples showed 
no FR-β staining (n=381; 91.1%), whereas 36 samples (8.6%) showed weak staining and only 
1 sample (0.002%) showed moderate staining (Figure 2). For statistical analyses, weak and 
moderate scores were combined into an ‘FR-β positive’ group, as compared to the ‘FR-β negative’ 
group. Low rates of positive staining were observed in invasive ductal carcinoma (n=20; 4.8%) 
and in invasive ductal carcinoma with ductal carcinoma in situ (n=17; 4.1%); there was no FR-β 
staining in other histological subtypes.
FR-β expression showed no significant correlation to age, differentiation grade, tumor size, 
relapse rate or HER2-neu status. Interestingly, axillary status showed a significant correlation 
with FR-β, with a higher expression rate in negative axillary lymph nodes compared to positive 
nodes (p=0.022)(Table 2). 
Figure 2. FR-β expression. A: ovarian cancer. B: breast cancer. C: colorectal cancer.




In multivariate regression analysis, differentiation grade III (p=0.009) was the only significant 
predictor for overall survival. A trend was observed for positive axillary status (p=0.080). 
Predictors for progression free survival were high differentiation grade (p=0.005), positive axillary 
status (p=0.024) and positive progesterone receptor status (p=0.017). FR-β status showed no 
correlation to either OS or PFS.
Colorectal cancer
Patient characteristics
Twenty tumor samples were stained for FR-β, all obtained during cytoreductive surgery for 
colorectal cancer combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Of 
these, thirteen were female and seven were male; mean age was 54.6 (range 34-75). Tumor 
differentiation was good in six patients, moderate in six patients and poor in eight patients. There 
were twelve mucinous adenocarcinomas, seven intestinal type adenocarcinomas and one singlet 
cell carcinoma. 
 N=449 
Age (mean, min-max, SD) 59.7 27-91 13.8 
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<58 years old 
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Table 2. Characteristics breast cancer patients.
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FR-β expression
Eleven of 20 (55%) tumor samples stained positive for FR-β, however, staining was predominantly 
focal and/or weak (Figure 2). Of the eleven positive samples, six tumors were classified as 
mucinous adenocarcinoma (50% of total number of this tumor subtype) and five were intestinal 
type adenocarcinoma (71% of total number of this tumor subtype). Most staining was seen at 
the apical side of the sample. In the surrounding adipose tissue, weak positive staining was seen 
in one sample while negative staining was observed in fifteen samples. All blood vessels were 
negative. Six samples contained smooth muscle cells, of which one sample scored positive and 
five scored negative. Healthy intestinal epithelium stained weakly in five samples and negative 
in two samples. Two samples contained ovarian tissue; both were negative for FR-β. One sample 




Seventeen of 25 patients included were female (68%). Mean age of all patients was 64 (range 
29-86). Most patients underwent a sigmoid resection because of diverticulosis or because of a 
suspected malignancy. One patient needed surgery because of widespread endometriosis. In all 
but two patients, active diverticulitis was confirmed by histopathology. 
FR-β expression
Of the 25 diverticulitis samples, 20 (80%) stained positive, of which moderate or strong FR-β 
expression was seen in nine samples (45%), and weak expression in eleven samples (55%) (Figure 
1). Co-expression of anti-CD68 and FR-β indicated activated macrophages in the inflammatory 
tissue (Figure 3). The five negative samples were diagnosed as a submucosal abscess, non-active 
colitis, endometriosis with a few diverticula, and in two cases active diverticulitis.
dIscussIon 
The aim of this study was to evaluate the expression of the FR-β in cancer. In summary, FR-β 
expression was low or absent in almost all tumor samples of ovarian, breast and colorectal cancer, 
with staining seen in respectively 21%, 9% and 55%. Furthermore, FR-β status showed no 
association with either OS or PFS in ovarian and breast cancer. 
Several studies report FR-β expression in myelogenous leukemias of hematopoietic origin.15,16 
Sega et al. reported FR-β expression on a variety of solid tumors of diverse origins, without going 
into detail.6 Conversely, our data show low or absent FR-β expression in most of the investigated 
solid tumor samples. 
The relationship between inflammation and cancer is widely appreciated.17 Chronic inflammation 
is thought to increase the risk of cancer and activated macrophages contribute to a worse prognosis 
by enhancing matrix degradation and metastasis.18,19 The role of TAMs cannot be supported by 
our study, as the presence of macrophages in tumor tissue was limited and no FR-β staining was 
observed, as would be expected in activated macrophages.
Previously, FR-α expression in ovarian cancer was analyzed using the same tumor tissue samples 
and database.2 No significant correlation could be detected between the FR-α and FR-β expression 
(p=0.098). 
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FR-β expression was also evaluated in regard to known risk factors in ovarian and breast cancer. 
None of the known risk factors for ovarian cancer showed a significant correlation to FR-β status. 
Likewise, FR-β expression showed no significant correlation to most known risk factors for breast 
cancer. Axillary status was the only factor that showed significant correlation to FR-β expression. 
A higher FR-β expression rate was seen in the tissue microarrays (TMAs) of breast cancer patients 
with negative axillary lymph nodes compared to positive nodes (P=0.022). A careful hypothesis 
might be that FR-β expression could be used as prognostic biomarker to indicate long-term 
outcome of breast cancer patients. However, the overall low expression rate of only 9% hampers 
further conclusions. 
The transmembrane folate receptor (FR) expressed by cancer cells, in particular the alpha subtype, 
has proven to be a useful target for non-invasive diagnostic imaging and therapy.2,7 From the 
present study we conclude that the low FR-β expression in tumor tissue implicates little practical 
use of this receptor in diagnostic imaging and for therapeutic purposes.
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taKe home messages
1. FR-β expression was found to be low or absent in the majority of ovarian, breast and  
 colorectal tumor samples.
2. We conclude that the low FR-β expression in tumor tissue implicates limited practical  
 use of this receptor for diagnostic imaging and therapeutic purposes.
3. A higher FR-β expression rate was seen in breast cancer tissue of patients with   
 negative  axillary lymph nodes. 
Figure 3. Co-expression of FR-β and anti-CD68 in activated macrophages in a diverticulitis sample. A: macrophage 
staining by anti-CD68. B: FR-β immunohistochemistry.
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Objective: To evaluate the expression of biomarkers in endometriotic tissue in order to 
determine the most promising molecules for targeted intraoperative imaging.
Methods: Tissue samples were obtained from 18 patients with endometriosis. The intensity and 
pattern of expression of the following biomarkers were assessed by immunohistochemistry: 
C-X-C chemokine receptor type 4 (CXCR4), epithelial cell adhesion molecule (EpCAM), 
estrogen receptor (ER), folate receptor-alpha (FR-α), hypoxia-inducible factor 1-alpha (HIF-
1α), progesterone receptor (PR), and vascular endothelial growth factor A (VEGF-A). The 
Target Selection Criteria scoring system was used to select the most promising biomarkers 
for intraoperative imaging.
Results: Expression of CXCR4, EpCAM, ER, PR, and VEGF-A was scored as strong in 
endometriotic epithelium. Expression of FR-α was detected in 94.4% of samples, whereas 
HIF-1α was expressed in just 5.6% of samples. Of note, CXCR4, ER, and VEGF-A were 
also expressed in surrounding healthy tissue, thus reducing the target-to-background ratio.
Conclusion: Of the 7 biomarkers assessed in the present study, EpCAM, FR-α, and VEGF-A 
seem the most promising for targeted intraoperative imaging of endometriosis. 
IntroductIon
Severe endometriosis is treated surgically, with the aim of removing as many lesions as possible.1 
However, postoperative symptomatic recurrences are frequent and repeat surgery is performed 
in more than 50% of all patients.2 Residual endometriosis after surgery contributes to a poor 
outcome.3 To minimize the contribution of residual disease to recurrent endometriosis, radical 
resection is required to excise all suspicious lesions. 
Enhanced intraoperative detection of endometriotic lesions may help to improve the success 
of radical excision, as is also the case in oncologic surgery.4 Furthermore, an imaging tool to 
specifically identify endometriotic lesions intraoperatively could spare normal structures and 
prevent surgical injury. Molecularly targeted intraoperative fluorescence imaging is an emerging 
technique in which a fluorescent agent aimed at a specific biomarker is used to visualize lesions or 
anatomic structures.5 For example, van Dam et al.6 reported a feasibility study for intraoperative 
detection of tumor lesions among patients with ovarian cancer by using a fluorescent probe 
targeting the folate receptor-alpha (FR-α).
Thus far, intraoperative fluorescence imaging has primarily been applied to oncology, but the 
concept could possibly be translated to benign conditions, such as endometriosis, provided that 
the lesions can be detected with an endometriosis-specific optical agent, that for example can 
be visualized by the use of a fluorescence imaging. However, little is currently known regarding 
biomarkers expressed in endometriotic tissue and an extensive survey of potential targets for 
intraoperative fluorescence imaging is lacking.
In assessing which of the broad spectrum of biomarkers might be promising for intraoperative 
imaging of endometriosis, the present study focused on molecules that have already been used 
for imaging in other diseases. The C-X-C chemokine receptor type 4 (CXCR4) is overexpressed 
in many types of cancer and has an important role in metastasis; expression has been identified 
on human epithelial cells and stromal endometriotic cells.7 Similarly, upregulation of hypoxia-
inducible factor-1alpha (HIF-1α) has been described in transplanted endometriosis-like lesions.8 
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Different studies have reported expression of vascular endothelial growth factor A (VEGF-A), the 
estrogen receptor (ER), and the progesterone receptor (PR) in human endometriotic lesions.9-12 
Epithelial cell adhesion molecule (EpCAM) and folate receptor-alpha (FR-α) are expressed on 
several epithelial cancers, including endometrial carcinoma.13-15 Nevertheless, further insight 
into biomarker expression is necessary for identification of the most suitable molecules for the 
development of targeted fluorescent imaging agents. In this regard, van Oosten et al.16 generated 
the Target Selection Criteria (TASC), a novel scoring system that can be used to identify potential 
targets for imaging purposes.
The aim of the present study was to analyze the expression CXCR4, EpCAM, ER, FR-α, HIF-
1α, PR, and VEGF-A in endometriosis and to evaluate the potential of these biomarkers for 
future intraoperative optical imaging purposes using the TASC scoring system.
materIals and methods
Tissue samples were selected from a prospective database created by the University Medical 
Center Groningen (UMCG), Groningen, Netherlands, comprising specimens from patients 
who had undergone surgery for endometriosis. Tissue samples from 18 consecutive patients who 
were operated on between November 11, 2009, and May 17, 2010, were used in the present 
study. The specimen archive of the Department of Pathology at the UMCG and the UMCG 
electronic hospital information system were used to create a database with general and histologic 
information about these 18 patients. All patient data were anonymized and the present study 
was conducted in accordance with the Declaration of Helsinki principles and with the rules and 
regulations posed by the Medical Ethical Research Board of the UMCG. Because all specimens 
were tissues left over after surgery and initial histopathologic diagnosis, no further informed 
consent was required after anonymization. 
The immunohistochemistry procedure is summarized in Table 1. Briefly, immunostaining for all 
7 biomarkers was performed on 3-μm thick, formalin-fixed, paraffin-embedded tissue sections. 
Immunostaining for ER was performed using a Ventana Benchmark Ultra full automatic slide 
staining machine (Roche-Ventana, Tuscon, Arizona, USA), while all the other biomarkers 
were stained as follows. Antigen retrieval was performed after deparaffinization, rehydration, 
and washing. Endogenous peroxidase was blocked in a 30% solution of hydrogen peroxide 
in phosphate buffered saline for 30 minutes. For HIF-1α and VEGF-A immunostaining, 
endogenous biotin was blocked with an avidin/biotin blocking kit (Sp-2001, Vector Laboratories, 
Burlingame, California, USA.). All sections were incubated with the primary, secondary, and 
tertiary antibodies as outlined in Table 1. Sections for FR-α immunostaining were incubated with 
anti-mouse immunoglobulin horse radish peroxidase, amplification reagent, and anti-fluorescein 
horse radish peroxidase. Peroxidase activity was visualized with 3,3’-diaminobenzidine. Slides 
were counterstained with hematoxylin, dehydrated, and mounted with coverslips.
Stained sections were viewed using an Olympus BX40 light microscope (Olympus company, 
Tokyo, Japan). The staining intensity was graded as follows: -, no staining in stromal or 
glandular endometriotic cells; +, weak staining; ++, moderate staining; and +++, strong staining. 
Immunostaining in stromal and epithelial cells was scored separately. The staining pattern 
was described as either diffuse or focal. In cases of focal staining, the percentage of positive 
endometriotic lesions was noted. Immunostaining was analyzed by 1 pathologist (J.B.) and 1 
PhD student (L.L.vdB.).
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Table 1. Summary of the immunohistochemistry procedure.
Abbreviations: ABC, avidin/biotin complex; CXCR4, C-X-C chemokine receptor type 4; EpCAM, epithelial cell 
adhesion molecule; ER, estrogen receptor; FR-α, folate receptor-α; GARbio, goat anti -rabbit-biotinylated antibody; 
GARPO, goat anti–rabbit peroxidase; HCL, hydrochloride; HIF-1α, hypoxia-inducible factor 1-α; HRP, horse radish 
peroxidase; PR, progesterone receptor; RAGPO, rabbit-anti-goat peroxidase ; RAMbio, rabbit anti-mouse biotinylated 
antibody ; RAMPO, rabbit-anti-mouse peroxidase; TE, Tris–ethylenediaminetetraacetic acid; TMA, tissue microarray; 
VEGF-A, vascular endothelial growth factor A. 
Manufacturer details are as follows: Abcam (Cambridge, Massachusets, USA); Dako (Glostrup, Hovedstaden, Denmark); 
Endocyte (West Lafayette, Indiana, USA); Neomarkers (Fremont, California, USA); Santa Cruz (Santa Cruz, California, 
USA); Ventana (Tucson, Arizona, USA). 
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results
Characteristics of the 18 patients included in the present study are shown in Table 2. All patients 
were diagnosed with endometriosis, with a clear indication for surgery with radical intent. The 
mean age was 30.4 ± 5.2 years. The results of the immunohistochemistry are shown by total study 
group (Table 3) and on a per-patient basis (Table 4). Representative immunostaining images are 
presented in Figure 1.
Positive CXCR4 immunostaining was found in the endometriotic epithelial cells in all 18 tissue 
samples; immunostaining was localized in the cytoplasm and the cell membrane (Table 3). Weak 
CXCR4 expression was detected in the cytoplasm of endometriotic stromal cells in 16 samples 
(88.9%), of which 8 showed a diffuse staining pattern. In all 18 samples, the surrounding healthy 
tissue showed CXCR4 immunostaining with almost the same intensity as the endometriotic 
lesions and extended to the borders of the tissue section.
Positive EpCAM immunostaining was found in the endometriotic epithelial cells of all 18 
samples and was localized to the cytoplasm and cell membrane (Table 3). No EpCAM expression 
was found in endometriotic stromal cells or surrounding healthy tissue.
Positive moderate to strong ER immunostaining was found in the endometriotic epithelial cells 
in all 18 samples; moderate immunostaining was found in the endometriotic stromal cells of 
all 18 samples (Table 3). In both cell types, immunostaining was localized to the nuclei, which 
corresponds to the known expression pattern of this receptor. In 4 samples (22.2%), some weak 
nuclear ER staining was found in surrounding healthy tissue, with a varying focal expression 
pattern.
Expression of FR-α was found in 17 (94.4%) samples in endometriotic epithelial cells and was 
mainly localized to the apical cell membrane (Table 3). The expression pattern was heterogeneous; 
in most samples staining was seen in only a fraction of the endometriotic cells, varying from 
10.0% to 100.0% of all lesions. No expression of FR-α was found in endometriotic stromal cells 
or surrounding healthy tissue.
A single sample (5.6%; patient 8) showed weak HIF-1α immunostaining in the endometriotic 
epithelial nuclei (Tables 3 and 4). No HIF-1α staining was seen in the endometriotic epithelial 
cytoplasm, nor in the endometriotic stromal cells or surrounding normal tissue.
Expression of PR was found in all 18 samples in the endometriotic epithelial cells; strong staining 
was localized to the nuclei whereas weak staining was seen in the cytoplasm and at the apical cell 
membrane (Table 3). Moderate-to-strong expression of PR was also found in the endometriotic 
stromal cells in 17 (94.4%) samples. Interestingly, the surrounding fibrotic tissue also showed 
heterogeneous expression of PR, whereas the surrounding healthy tissue did not. 
Positive VEGF-A immunostaining was found in the endometriotic epithelial cells of all 18 
samples and was localized in the cytoplasm and at, or close to, the cell membrane (Table 3). In 
1 sample (5.6%), weak expression was found in the endometriotic stromal cells. In 16 samples 
(88.9%), VEGF-A expression was found in surrounding healthy tissue, with a varying focal 
staining pattern; however, staining intensity was lower than in the endometriotic lesions (0–1 
vs. 3).
The TASC scoring system is based on 7 characteristics;16 a high TASC score indicates potential for 
use as a biomarker in targeted imaging. When applying TASC to the 7 biomarkers evaluated in 
the present study (Table 5), EpCAM seemed to have the greatest potential for imaging purposes 
(TASC score, 21). Other biomarkers with potential value were CXCR4, FR-α, and VEGF-A, 
with TASC scores of 18, 17, and 17, respectively. The remaining biomarkers (ER, PR, and HIF-
1α) had little potential value for intraoperative imaging.
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Location of endometriosis tissue section ASRM stagea 
1 37 Leuprorelin  G0 Sigmoid IV 
2 38 Leuprorelin, 
Tibolone 
G2 IVF Rectosigmoid IV 




Cyst in left adnex  IV 
4 30 N/A G0 Cyst in left adnex  III 
5 25 Leuprorelin G0 Mesocolon IV 
6 33 Leuprorelin G0 Left cardinal ligament IV 
7 26 Leuprorelin G0 IVF Rectovaginal septum and cardinal 
ligament  
IV 
8 29 Leuprorelin, 
Tibolone 
G0 ICSI Rectosigmoid IV 
9 37 Medroxyprogestero
ne 
G1 Left part of abdominal wall III 
10 27 Leuprorelin, 
Tibolone 
G0 Rectosigmoid IV 
11 21 Leuprorelin G0 Posterior vagina and left distal ureter IV 
12 34 Leuprorelin G0 Right part of peritoneum III 
13 24 Leuprorelin, 
Tibolone 
G0 Adipose tissue, muscle tissue, and 
connective tissue 
IV 
14 39 Leuprorelin, 
Tibolone 
G3 Left distal ureter IV 
15 32 Leuprorelin, 
Tibolone 
G0 Tuba and ovary IV 
16 32 Leuprorelin G1 IVF Uterus with left adnex and right tuba  IV 
17 28 Leuprorelin G0 IVF Vaginal top IV 
18 29 N/A G0 IVF Left adnex and hilus of the ovary  IV 
	  
Table 2. Patient characteristics. Abbreviations: ASRM, American Society for Reproductive Medicine; EUG, extra-
uterine gravidity; G, gravidity; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; N/A, not applicable. 
a The revised ASRM classification of endometriosis was used; I is the lowest stage while IV is the highest stage.26 
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dIscussIon
The present study aimed to identify molecules expressed by endometriotic tissue that might 
be suitable biomarkers for targeted intraoperative imaging. The intensity and pattern of 
immunostaining of CXCR4, EpCAM, ER, FR-α, HIF-1α, PR, and VEGF-A was assessed in 18 
samples comprising both endometriotic tissue and surrounding healthy tissue.
Immunohistochemistry revealed that CXCR4, EpCAM, ER, FR-α, PR, and VEGF-A were 
expressed in endometriotic tissue, whereas HIF-1α staining was shown in only one tissue sample. 
When using the TASC scoring system, and considering both intensity and pattern of expression, 
EpCAM, CXCR4, FR-α, and VEGF-A seemed the most promising biomarkers for targeted 
intraoperative imaging. 
The chemokine receptor CXCR4 guides the migration and adhesion of leukocytes to sites of 
inflammation and is also expressed on several tumors. Interestingly, the single natural ligand 
of CXCR4, namely CXCL12, is involved in angiogenesis and metastatic potential of tumors.17 
In the present study, CXCR4 was expressed in the cytoplasm and at the cell membrane of 
epithelial endometriotic cells. For most sections, CXCR4 was also expressed in stromal cells; 
however, the intensity of immunostaining was lower than in the epithelial cells. These results 
are in agreement with previously reported data.7 Given the finding that the staining intensity of 
the surrounding tissue was almost as high as that observed in endometriotic lesions, it may be 
difficult to distinguish such lesions from normal tissue with intraoperative fluorescence imaging. 
The low signal-to-background ratio reduces the potential of CXCR4 as a target for intraoperative 
imaging in endometriosis.
Biomarker Endometriotic tissue  Surrounding healthy 
tissue 
Epithelium Stroma  
Cytoplasm Nucleus Cell 
membrane  
CXCR4 18 (100.0) 0 (0.0) 18 (100.0) 16 (88.9) b 18 (100.0) 
EpCAM 15 (83.3) 0 (0.0) 18 (100.0) 0 (0.0) 0 (0.0) 
ER 0 (0.0) 18 (100.0) 0 (0.0) 18 (100.0) 4 (22.2) 
FR-α 2 (11.1) 0 (0.0) 17 (94.4) c 0 (0.0) 0 (0.0) 
HIF-1α 0 (0.0) 1 (5.6) 0 (0.0) 0 (0.0) 0 (0.0) 
PR 18 (100.0) 18 (100.0) 17 (94.4) 17 (94.4) 18 (100.0) d 
VEGF-A 15 (83.3) 0 (0.0) 18 (100.0) 1 (5.6) 16 (88.9) 
	  Table 3. Immunohistochemistry analysis of candidate biomarkers among the entire study group (n=18).a
Abbreviations: CXCR4, C-X-C chemokine receptor type 4; EpCAM, epithelial cell adhesion molecule; ER, estrogen 
receptor; FR-α, folate receptor α; HIF-1α, hypoxia-inducible factor 1-α; PR, progesterone receptor; VEGF-A, vascular 
endothelial growth factor A.
a Values are given as number of samples staining positive (percentage).
b A focal staining pattern was observed in 8 of 16 sections (50.0%).
c A focal staining pattern was observed in 15 of 17 sections (88.2 %).
d Staining was observed in the surrounding fibrotic tissue; however, staining intensity was lower than in the endometriotic 
tissue. No staining was observed in the surrounding healthy tissue. 
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CXCR4 EpCAM ER FR-α HIF-1α PR VEGF-A 
1 37 Leuprorelin +++ +++ +++ + – ++ ++ 
2 38 Leuprorelin, 
Tibolone 
+ +++ ++ + – ++ + 
3 27 Triptorelin + oral 
contraceptive 
+ +++ ++ – – + + 
4 30 N/A + + ++ + – + + 
5 25 Leuprorelin +++ ++ +++ + – +++ ++ 
6 33 Leuprorelin ++ +++ +++ + – ++ + 
7 26 Leuprorelin ++ ++ ++ ++ – ++ + 
8 29 Leuprorelin, 
Tibolone 
+++ +++ +++ + + ++ +++ 
9 37 Medroxyprogestero
ne 
++ + ++ + – + + 
10 27 Leuprorelin, 
Tibolone 
++ +++ +++ + – +++ +++ 
11 21 Leuprorelin + + +++ + – +++ + 
12 34 Leuprorelin + ++ ++ + – ++ + 
13 24 Leuprorelin, 
Tibolone 
+ ++ ++ + – ++ ++ 
14 39 Leuprorelin, 
Tibolone 
+ + ++ + – ++ + 
15 32 Leuprorelin, 
Tibolone 
++ ++ + + – ++ + 
16 32 Leuprorelin + ++ +++ ++ – ++ + 
17 28 Leuprorelin ++ +++ ++ + – +++ ++ 
18 29 N/A +++ +++ +++ + – +++ ++ 
	  
Table 4. Immunohistochemistry analysis of candidate biomarkers per patient.
Abbreviations: CXCR4, C-X-C chemokine receptor type 4; EpCAM, epithelial cell adhesion molecule; ER, estrogen 
receptor; FR-α, folate receptor-α; HIF-1α, hypoxia-inducible factor-1α; N/A, not applicable; PR, progesterone receptor; 
VEGF-A, vascular endothelial growth factor A.
Staining intensity was scored as follows: –, no staining; +, weak staining; ++, moderate staining; and +++, strong staining. 
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In addition to a role in cell adhesion, EpCAM functions in signal transduction, migration, 
proliferation, and differentiation.13,18 In the present study, EpCAM expression was found in the 
cytoplasm and at the membrane of epithelial endometriotic cells. Because EpCAM was expressed 
in all endometriotic lesions but not in the surrounding healthy tissue, it might be suitable for 
use as a biomarker in targeted intraoperative imaging. Although several anti-EpCAM antibodies 
have been developed,19-21 applying these for imaging in the clinical setting is not straightforward. 
Anti-EpCAM antibodies have not yet been used for imaging purposes; however, novel antibodies 
may have a place in targeted imaging of endometriotic lesions.
The presence of estrogen contributes to the activity of endometriotic lesions and expression of 
ER was therefore expected in the present study. Even though 16 of the patients were treated 
with anti-hormonal treatment before surgery, thus decreasing estrogen levels, ER expression was 
found in all endometriotic lesions. Little is known regarding fluorescence imaging of intracellular 
receptors, such as the ER, but this localization could challenge delivery of targeted fluorescent 
agents to the biomarker. Therefore, the suitability of ER for intraoperative imaging is currently 
debatable.
Figure 1. Representative endometriosis tissue samples. Hematoxylin and eosin staining is shown in (A) with a 
magnification of 20x. Immunohistochemical staining for the various biomarkers is shown in the remaining panels. (B) 
CXC chemokine receptor type 4 20x; (C) epithelial cell adhesion molecule 20x; (D) estrogen receptor 40x; (E) folate 
receptor-α with atrophic cells 2,5x; (F) folate receptor-α without atrophic cells 40x , (G) hypoxia-inducible factor-1α 
10x, (H) progesterone receptor 40x, and (I) vascular endothelial growth factor A 20x.
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Several types of cancer overexpress FR-α.14 Folate is required for the synthesis of nucleotide 
bases; as a consequence, cells that are rapidly dividing (e.g. cancer cells) use more folate for DNA 
replication than slowly dividing cells.15 In the present study, FR-α expression was detected at 
the apical membrane of endometriotic epithelial cells. As such expression was found in 17 of 
18 sections but not in surrounding healthy tissue, it seems that FR-α might be a suitable target 
for fluorescent imaging agents. However, the focal expression pattern may hinder imaging of 
all lesions and, as a consequence, endometriotic tissue may be overlooked. The heterogeneity of 
FR-α expression could be speculated to be a result of atrophy and diminished cell function of 
some endometriotic lesions owing to anti-hormonal therapy. Interestingly, estrogen is a negative 
regulator of FR-α and can downregulate its expression, which may influence the outcome 
of targeted intraoperative imaging.22,23 Thus far, no studies have been reported regarding the 
influence of anti-hormonal therapy on FR-α expression in patients with endometriosis. In 
contrast to all other biomarkers assessed in the present study, FR-α is the only molecule that has 
been described for intraoperative fluorescence imaging in a clinical setting.6 
Characteristic (score) CXCR4 EpCAM ER FR-  PR VEGF-A 
I. Extracellular protein localization 
    Bound to cell surface (5) 
    In close proximity to endometriotic cell (3) 
5 5 0 a 5 0 a 4 b  
II. Diuse expression through endometriotic tissue (4) 4 4 4 0 4 4 
III. T/N >10 (3) c 0 3 2 d 3 0 1 e 
IV. Percentage expression in tissue samples  
    >90% (6) 
    70–90% (5) 
    50–69% (3) 
    10–49% (0) 
6 6 6 6 6 6 
V. Previously imaged successfully in vivo (2)  2 2 2  2 0 2 
VI. Enzymatic activity (1) 0 0 0 0 0 0 
VII. Internalization (1) 1 1 1 1 1 0 
Total (maximum 22) 18 21 15 17 11 17 
H7 table 5.pdf   1   07-12-13   15:07
Table 5. Target Selection Criteria scores of the candidate biomarkers.16
Abbreviations: CXCR4, C-X-C chemokine receptor type 4; EpCAM, epithelial cell adhesion molecule; ER, estrogen 
receptor; FR-α, folate receptor-α; PR, progesterone receptor; T/N, target/normal tissue ratio; VEGF-A, vascular 
endothelial growth factor A.
a Expression of ER and PR are localized to the nuclei. 
b Score of 4 is awarded because VEGF is partly bound to cell surface and in close proximity to endometriotic cells. 
c Defined as the difference in expression intensity between the target tissue and normal tissue.
d ER staining was found in surrounding healthy tissue, however, this was weak staining with a varying focal expression 
pattern. Therefore, a score of 2 is awarded. 
e VEGF-staining was found in surrounding healthy tissue, with lower intensity and a focal expression pattern. Because of 
the signal-to-background ratio, a score of 1 is awarded.
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The finding that HIF-1α was not expressed in endometriotic tissue is in disagreement with a 
study reporting HIF-1α upregulation in a mouse model of endometriosis.8 However, in that 
particular study, endometriosis was surgically implanted and hypoxia and expression of HIF-
1α was shown in the endometriosis-like lesions only during the early stages of transplantation 
and invasion. The present finding that HIF-1α is not expressed in human endometriotic tissue 
suggests that hypoxia does not have an active role in the maintenance of endometriosis. The lack 
of HIF-1α expression in the 18 patient samples makes HIF-1α unsuitable as a biomarker for 
targeted intraoperative fluorescence imaging.
Expression of PR has previously been described in the glandular epithelium and stroma of normal 
endometrium, whereas expression of PR in normal pelvic peritoneum is unusual.11 By contrast, 
PR expression in the present study was detected in all endometriotic lesions, as well as some weak 
staining in surrounding fibrotic tissue. Similar to ER, the intracellular localization of PR makes 
it less than ideal as a biomarker for targeted intraoperative fluorescence imaging. 
Expression of VEGF-A in the present study was observed in the cytoplasm and at, or close 
to, the membrane of epithelial endometriotic cells, with minimal immunostaining in stromal 
tissue. These results confirm data from a previous study.9 VEGF-A functions in the formation of 
new blood vessels and seems to be overexpressed in endometriosis, contributing to the survival 
of endometriotic lesions. The fact that VEGF-A is also expressed in surrounding tissue is not 
expected to be a major problem in the imaging context. The intensity of immunostaining in 
the surrounding tissue was much lower than in the endometriotic lesions, yielding a signal-
to-background ratio that is most likely high enough for successful intraoperative fluorescence 
imaging. Combined with a diffuse and homogeneous staining pattern, VEGF-A seems a 
promising biomarker for imaging purposes. The monoclonal antibody bevacizumab has been 
clinically approved for several types of cancer, but is now also increasingly being used for imaging. 
Nagengast et al.24 demonstrated tumor visualization in a human ovarian tumor xenograft 
mouse model by injecting bevacizumab labeled with the positron emission tomography isotope 
89zirconium or 111indium. Imaging of intratumoral VEGF-A with ranibizumab labeled with 
the positron emission tomography isotope 89zirconium was also successful in visualizing the 
neoplastic lesion in a tumor xenograft mouse model.25 
Although the present study was limited by the small number of samples included in the analysis, 
the results obtained are clear and unambiguous. Furthermore, the source of the endometriosis 
tissue sections was diverse, with tissue from peritoneal implants, ovarian cysts, and deep 
infiltrating endometriosis. No differences in expression of the 7 biomarkers were found between 
these different anatomic locations.
In conclusion, evaluation of a panel of potential biomarkers indicates that EpCAM, FR-α, 
and VEGF-A are the most promising molecules for use in targeted intraoperative fluorescence 
imaging of endometriotic lesions owing to their favorable expression patterns and biomarker 
characteristics. Preclinical studies in a mouse model of endometriosis are necessary to confirm 
whether these biomarkers yield good results with the currently available targeted fluorescent 
agents. Subsequently, clinical proof-of-concept pilot studies for intraoperative fluorescence 
imaging of endometriotic lesions are required. 
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Bacterial infections are a frequently occurring, major issue in health care. Diagnosis is rarely 
straightforward and consequently treatment is often indefinite. Therefore, novel imaging 
modalities that can be clinically implemented are needed to accurately diagnose infections. 
Currently, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound 
(US) and positron emission tomography (PET) or single-photon emission computed 
tomography (SPECT) scanning, and scintigraphy are mainly used for this purpose. 
However, it has remained difficult to distinguish bacterial infections from other processes, 
such as sterile inflammation. The need to specifically image bacterial infections can be met 
by targeting bacteria with an imaging agent. This is exemplified by recent developments 
in molecular imaging and optical imaging where the antibiotic vancomycin labeled with 
a near-infrared fluorophore was used to image Gram-positive bacterial infections in real-
time. As highlighted by this ‘glowing’ antibiotic, the clinical implementation of specific 
real-time imaging of bacterial infections seems highly feasible. Here we review the current 
status of targeted imaging of bacterial infections, discuss advantages and disadvantages of 
the respective approaches, and present target selection criteria to evaluate potential bacterial 
targets and imaging agents for clinical implementation. We conclude that the full spectrum 
of targeted bacterial imaging ranges from diagnostic to therapeutic applications.
IntroductIon
Bacterial infections are a frequently occurring problem in almost all medical disciplines. The 
incidence is rising due to an increasingly ageing population, increased use of biomaterials, 
higher rate of organ transplantation and, especially, increased bacterial resistance to antibiotics. 
Infections vary in severity, from self-limiting to potentially life-threatening, resulting in major 
morbidity and mortality, and overall increasing health care costs. Fortunately, many infections 
can still be treated if diagnosed early, when the infectious process is still reversible and major 
damage has not yet occurred. However, for optimal treatment the correct diagnosis needs to be 
made quickly, based on sound and reliable information. Often diagnosis is based on anatomical 
imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI) 
and ultrasound (US), or functional imaging modalities like positron emission tomography 
(PET), single-photon emission computed tomography (SPECT) and scintigraphy. However, 
current imaging techniques are unable to distinguish sites of bacterial infection from sterile 
inflammation. Often the discrimination between bacterial infection and other pathologies, 
such as non-bacterial infections (e.g., viral or fungal infections), sterile inflammation, cancer, or 
wound healing is a major challenge.1-3
A potential solution to this problem may be found in a more specific methodology of bacteria-
targeted imaging. In the concept of targeted imaging, a contrast agent is conjugated to a molecule 
that specifically targets bacteria or other pathogens (i.e., the targeting moiety), theoretically 
resulting in selective binding or uptake at the site of infection.4 This potentially allows for specific 
imaging of infections, which is paramount. Targeted imaging has been described extensively for 
several modalities, mainly radionuclide-mediated, with varying success. In addition, targeted 
bacterial imaging would not only allow for specific non-invasive imaging of infection, but might 
also discriminate between different micro-organisms as the cause of infection in patients. 
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Most experience in targeted imaging has been gained in oncology over the past decades.5 For 
example, in bladder cancer and brain surgery, 5-aminolevulinic acid (5-ALA) is routinely used to 
improve visualization of the tumor intraoperatively, yielding better detection and more optimal 
resection margines.6,7 In a recent clinical trial, optical imaging targeting the folate receptor-alpha 
in ovarian carcinoma was shown to be feasible.8 So far, no targeted bacterial imaging techniques 
are routinely used in the clinic.
In this review we provide an overview of targeted imaging of bacterial infections for different 
imaging modalities. Furthermore, the possible combination of different imaging modalities 
and the potential of targeted therapy is briefly discussed. Lastly, we discuss how to determine 
guidelines to predict the suitability of a target, and methods to subsequently target bacteria for 
clinical purposes.
methods
A systematic literature search was performed using PubMed. The following search terms and 
variations thereof were used: bacterial, targeted, specific, imaging, detection, fluorescence, and 
radionuclide. MRI, CT and US were excluded from the search, because in a different search 
using the terms magnetic resonance imaging, computed tomography, ultrasound, bacterial, targeted, 
specific, detection, no articles describing in vivo bacteria-specific imaging in these modalities were 
found. The search was limited to publications in English, yielding a total number of around 
9000 publications. Of these publications we then selected those that were aimed at bacteria-
specific in vivo imaging in the period between January 1980 and December 2012. Furthermore, 
publications reporting only on the use of bioluminescence were excluded from this selection, 
as it seems currently not possible to implement bioluminescence in the clinic, apart from ex 
vivo diagnostic applications. This yielded 56 relevant publications. An additional 13 relevant 
publications were identified by following citations. Altogether, a total of 69 relevant publications 
were retrieved.
Table 1 summarizes all reported targets and imaging modalities mentioned in these 69 articles. 
The targets were grouped according to the mechanisms of targeting and the imaging modalities 
used (fluorescent or radionuclide-labeled). In referring to the literature, only the most relevant 
articles are mentioned, in terms of selective targeting, clinical translation and feasibility.
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current ImagIng modalItIes
The published imaging modalities can be subdivided into anatomical imaging, functional 
imaging and molecular imaging. 
Anatomical imaging - Anatomical imaging includes modalities, such as CT, MRI and US, all 
yielding information about anatomical structures. 
CT scanning provides detailed anatomic information of the entire body up to a resolution of 
about 50 µm.9 When using CT, infection is only visible if considerable anatomic damage has 
occurred. However, even then anatomic damage and distortion caused by infection can often not 
be discriminated from other causes of tissue damage due to the lack of specificity of the changes 
present.3 Furthermore, the interpretation of CT images can be hampered by the presence of 
metallic implants, which lead to dramatic scattering in the area of interest. As a consequence, a 
major drawback in the imaging of biomaterial-associated infections with CT is the disruption of 
images by metallic biomaterials.3 
MRI is often used as the preferred imaging modality for detection of bacterial infections. The 
major advantage with MRI is the high yield of contrast between soft tissue and bone-like 
structures compared to CT, resulting in extraordinarily detailed images with a resolution of up 
to 10 μm.9 Still, considerable anatomic change is needed before damage can be detected with 
MRI, and the destruction caused by infection can often not be discriminated from other causes 
of tissue damage.3 Importantly, due to the use of a strong magnetic fields, the presence of metallic 
biomaterials can impede MRI scanning, or even make it impossible.3
US allows highly sensitive real-time imaging with high spatial resolution. The major advantage 
of US is that it is a mobile, inexpensive and fast bed-side imaging modality.3,9,10 However, only 
local imaging with limited depth penetration is possible, and the sensitivity of US is strongly 
operator-dependent.5,10 
Functional imaging - Functional imaging includes PET, SPECT and scintigraphy. These 
modalities are based on the detection of uptake of an agent at particular sites of the body, thereby 
giving information about metabolic activities within specific tissues, even before substantial 
anatomic changes have occurred.11
A wide range of modalities and agents are available for imaging of infections and inflammation 
by functional imaging. Frequently used in diagnosis of infection is fluorodeoxyglucose (FDG) 
PET, in which radiolabeled glucose is used to visualize areas in the body with increased glucose 
uptake.1 This allows for the imaging of infections, but it is not possible to reliably discriminate 
infections from other areas with a higher glucose uptake, such as malignancies, physiological 
wound healing or sterile inflammation.2 Notably, PET is extremely useful in tracing the cause of 
fever of unknown origin, but other applications, such as the diagnosis of focal infections, remain 
challenging.2
Established alternatives to PET scanning in the imaging of infections are based on the use 
of radioactively labeled leukocytes, bone scintigraphy, or gallium-67 imaging. To prepare 
radioactively labeled leukocytes, autologous leukocytes are harvested from the patient and tagged 
in vitro with a radio-isotope. Upon administration of the radio-labeled leukocytes to the patient, 
they can be tracked to sites of inflammation. Bone scintigraphy, commonly executed with labeled 
methylene-diphosphonate (MDP), has proven to be very useful in imaging of skeletal processes. 
MDP is taken up by bone tissue and accumulates at sites where most active bone synthesis 
occurs. In this way active bone synthesis can be imaged, which can indicate osteomyelitis, bone 
fracture or tumor sites.1 The active molecule in gallium-67-mediated imaging is the Ga3+ ion, 
which is handled by the body as if it were an iron ion (Fe3+). 
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Accordingly, gallium-67 allows the visualization of areas of increased iron uptake, which occurs 
at sites of inflammation or increased cell division as encountered in malignant tissue, sites of 
infection and sterile inflammation. Therefore, gallium-67 can be employed in the visualization 
of cancer, infection and inflammation, but without the ability to discriminate between these 
different pathologies.1
Notably, different imaging modalities can be combined in order to yield a superior result. 
For example, PET/CT combines the high anatomical resolution of CT with the functional 
information of PET, which thereby greatly enhances accuracy in the detection of infections. Still, 
the resolution of the current clinical PET systems is relatively limited with a maximal resolution 
of 2 mm, and it remains problematic that sites of infection cannot be discriminated from other 
regions with increased uptake of the imaging agent (http://www.medical.siemens.com/siemens/
en_US/gg_nm_FBAs/files/multimedia/biograph/assets/pdf/biograph_technology.pdf, consulted 
June 14, 2013).3
Molecular imaging - The emergence of molecular imaging as a novel imaging approach related 
to physiological parameters, including perfusion and oxygenation, opens up new possibilities for 
infection-specific or targeted imaging. In molecular imaging, molecular biomarkers or pathways 
of interest are visualized using agents that specifically interact with a target. A wide spectrum of 
different approaches to target infection and/or inflammation is currently under investigation. 
Special interest is directed towards the discrimination of infection from sterile inflammation, 
which has thus far proved to be challenging, as pointed out above. Clearly, in pursuit of finding 
an imaging modality that is strictly confined to bacterial infection, it is necessary to use an 
imaging agent that is taken up or bound solely by bacteria and not by human cells. Therefore, 
this review is limited to the description of studies that report on bacteria-specific targeting agents. 
For other promising approaches, such as advanced leukocyte-mediated imaging and the targeting 
of other parts of the immune system, we refer to the review of Akhtar et al., which was published 
in 2012.12 
A relatively new molecular imaging modality in the clinic is optical (fluorescence) imaging. In 
this modality, a fluorophore is excited by an intense light source, such as a laser, set at a specific 
wavelength. The wavelength of this excitation light is subsequently shifted by the fluorophore 
(Stokes shift) so that the emitted light is significantly red shifted (longer wavelength). The shifted 
emission wavelength can be discriminated from the excitation wavelength using defined filters 
and/or electronic gating (especially when using a laser) and a sensitive charge-coupled device 
(CCD) camera. The goal of this approach is to visualize structures of interest in real-time by 
detection of a fluorescent signal. Hereto, a fluorescent agent is used that can be targeted to 
a specific site. Optical imaging allows for fast and non-invasive molecular imaging with high 
resolution. A further advantage is that radioactivity is not involved, allowing cheaper and more 
flexible imaging without the burden of ionization. Despite these advantages for bacteria-targeted 
imaging, optical imaging is currently mainly used in oncology.13 
It is important to note that, until recently, optical imaging could only be used to visualize 
a target located at a maximum depth of 1 cm within tissue. This was due to limited signal 
penetration based on light absorption by the respective tissue. However, with improvements in 
fluorescent dyes and CCD cameras, deeper signal penetration has become feasible. Moreover, 
the implementation of new technologies, such as optoacoustics, now allows imaging up to a 
theoretical maximum depth of around 11 cm in muscle tissue.14
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ImagIng agents
All relevant publications for radionuclide-mediated and optical imaging are listed in Table 1, and 
the respective targeting and signal molecules are summarized in Figure 1. 
Figure 1. Targeted probes and imaging modalities. A. Molecules used for bacteria-targeted imaging. B. Top: Modalities 
and correlated signaling molecules used in targeted imaging. Bacteria-targeted imaging in vivo has so far only been 
described for radioisotopes and fl uorophores. Bottom: Schematic representation of alternative bacteria-targeted imaging 
using activatable probes or multimodality probes.
Publications in this area mainly describe the use of targeted radioisotopes and, to a lesser extent, 
the use of fl uorescent agents. Importantly however, very promising results were recently reported 
concerning the distinction of bacterial infections from sterile infl ammation with the help of 
fl uorescent agents that are specifi cally targeted to bacteria (see: Nature News: http://www.nature.
com/news/glowing-antibiotics-reveal-infections-1.13943). Contrast agents are also used in both 
CT and MRI scanning, and in vivo successes have been reported concerning the targeting of 
these contrast agents in imaging applications that are not related to infection, i.e. for example 
the imaging of malignancies.58,59 However, no publications were found that report on the 
bacteria-specifi c targeting with MRI or CT contrast agents. Th e same applies to the so-called 
microbubbles. Microbubbles are gas fi lled bubbles that are used as contrast agents in US. Th e use 
of targeted microbubbles has for example been described in the imaging of tumor angiogenesis, 
where they were targeted to integrin αvβ3, endoglin or the vascular endothelial growth factor 
receptor 2 (VEGFR2).60 As microbubbles are relatively large entities that are mostly confi ned 
to the vascular system after intravenous administration, their potential for targeting bacteria is 
limited.60 
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Antibodies – One of the first reported options for bacteria-specific imaging was the use of 
antibodies and, essentially, two different approaches have been entertained so far. 
Most extensively described is the use of radiolabeled aspecific human immunoglobulin (HIG), 
which accumulates at sites of infection. It is arguable whether HIG is bacteria-specific, as at least 
three possible modes of action can be anticipated, namely: 1) binding to bacteria; 2) binding 
of the Fc part of the immunoglobulins to leukocytes; and 3) extravasation due to increased 
vascular permeability at sites of infection and inflammation.61 Thus, even if HIG is bacteria-
specific, it will also accumulate at sites of sterile inflammation due to the general properties 
of immunoglobulins. In a clinical trial, HIG was shown to have a specificity of only 77% for 
infection imaging, which is in line with the idea that HIG accumulation can potentially also be 
due to Fc-specific binding or extravasation caused by sterile inflammation.43
Alternatively, specific antibodies can be used that target subgroups of bacteria. Major advantages 
of targeted antibodies are their relatively straightforward synthesis and their long history of safe 
clinical use. It is relatively easy to develop specific antibodies to virtually any antigen present 
on the bacterial cell surface. Although specific antibody-mediated imaging is widely reported 
in oncology, only three publications were identified describing bacterial imaging using specific 
antibodies. Rubin et al. reported already in 1988 the specific imaging of Pseudomonas in rats using 
a murine monoclonal antibody targeting lipopolysaccharide.48 A few years later, Malpani et al. 
described Mycobacterium tuberculosis imaging in rabbits using a specific monoclonal antibody.47 
A major disadvantage of specific antibody-mediated imaging is that upon administration of the 
imaging agent, it takes up to 4-6 days to reach optimal target-to-normal tissue (T/N) ratios.48 This 
is highly unpractical when a rapid diagnosis is needed. To overcome this problem, radiolabeled 
antibody fragments were designed, allowing for much faster imaging. Lee et al. described in 1992 
the use of a radiolabeled antibody fragment targeting M. tuberculosis with good T/N ratios (T/N 
ratio of 2.51) after 24 hours.46
Antibiotics - Antibiotics represent the most extensively described group of agents used for 
bacteria-specific imaging. Most well-known in this group is 99mTc-labeled ciprofloxacin, which 
has been considered as an attractive imaging agent in patients for many years.62 In a large 
multicenter clinical trial including 879 patients with suspected infection, 99mTc-ciprofloxacin 
(Infecton®) was shown to have a sensitivity of 85.4% and a specificity of 81.7% in detecting 
bacterial infection.15 Although 99mTc-ciprofloxacin is reasoned to be bacteria-specific, this is 
not conclusive in vitro, and in both animal studies and clinical trials doubts have remained 
concerning its specificity.4,19,63 Another potential drawback of 99mTc-ciprofloxacin might 
be its limited applicability due to the widespread bacterial resistance to ciprofloxacin.64,65 
To overcome these issues, many attempts have been made to label other antibiotics, such as 
ceftriaxone, enrofloxacin, moxifloxacin, nitroimidazol, norfloxacin, rifampicin, sulfanilamide, 
pyrazinamid and vancomycin, with different rates of success (Table 1). So far however, no single 
antibiotic-based imaging agent has been shown to be exclusively taken-up in bacterial infections 
in multiple clinical studies. Nevertheless, we have recently obtained highly promising results 
using vancomycin labeled with the near-infrared fluorophore IRDye 800CW (vanco-800CW; 
Table 1).51 The application potential of vanco-800CW for real-time in vivo imaging of Gram-
positive bacterial infections was demonstrated in a murine myositis model and a human post-
mortem implant model (Figure 2). Importantly, vanco-800CW allowed the in vivo distinction 
between a Gram-positive bacterial infection and a Gram-negative bacterial infection or a sterile 
inflammation. Based on these findings, we concluded that vanco-800CW is a candidate tracer 
for enhanced non-invasive diagnosis of infections with Gram-positive bacteria, in particular in 
the case of soft tissue infections and biomaterial-associated infections.51 
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At the moment, vanco-800CW awaits appropriate toxicity testing and ‘good manufacturing 
practice’ synthesis according to Good Clinical Practice guidelines before it can actually be used 
for clinical trials in patients. We are currently conducting additional studies with alternative near-
infrared fluorophores that already have clinical approval, since these vancomycin derivatives may 
have an increased chance of being expedited for clinical trials.
Figure 2. Pre-clinical example of optical bacteria-targeted imaging. An osteosynthetic plate with a biofilm of 
Staphylococcus epidermidis cells was incubated with vanco-800CW and surgically applied onto the fibula of a post-mortem 
ankle. Subsequent non-invasive imaging with a clinical multispectral fluorescence camera clearly reveals the position of 
the plate with the biofilm.51 By contrast, the non-contaminated plate implanted on the right of the plate with the biofilm 
remains undetectable.
Antimicrobial peptides and proteins - As an alternative to antibiotics, the use of antimicrobial 
peptides and proteins has been explored for imaging purposes. Most successful in this group 
appears to be ubiquicidin (UBI), which is a microbicidal protein originally isolated from mouse 
macrophages. UBI was shown to bind specifically to Gram-positive bacteria, Gram-negative 
bacteria and fungi with minimal accumulation at sites of sterile inflammation.12,32,33 In small 
clinical trials, 99mTc-UBI showed 100% sensitivity and a specificity ranging from 80% to 100% 
in detecting bacterial and fungal infections.32-35 Other examples of antimicrobial proteins and 
peptides used for imaging bacteria, are human lactoferrin (hLF) and the human neutrophil 
peptide-1 (hNP-1) (Table 1).12 
Metabolizable compounds – Molecules that are specifically taken up by bacteria, for example 
as a source of energy, are attractive potential imaging agents. Due to basic metabolic differences 
between bacteria and human cells, many molecules are available for this purpose. For example, a 
N-acetylglucosamine derivate and maltodextrin have been described as metabolic substrates for 
imaging of bacterial infections with high specificity over sterile inflammation.37,52 Specifically, a 
maltodextrin-based fluorescent probe was shown to be taken up and metabolized by different 
bacteria, and this probe was successfully applied for specific in vivo infection imaging in mice.52 
Also, iron uptake has been exploited for this purpose, first in the conventional Gallium-67 scan. 
However, iron uptake is not strictly bacteria-related and, accordingly, uptake of Gallium-67 is 
also observed in inflammatory lesions.1 Later, the use of a Gallium-68-apotransferrin complex 
was described. However, it was not reported whether this complex allows a distinction between 
infection and sterile inflammation (Table 1).38 As an alternative approach, siderophores, high-
affinity iron-binding molecules produced by micro-organisms, can be labeled for imaging. 
However, the successful use of labeled siderophores was, thus far, only described for the detection 
of fungal infections.66 
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A special class of substrates in the group of metabolizable targeting agents is represented by 
nucleoside analogs that are specifically taken up by bacteria and incorporated into their 
DNA. Fialuridine (1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodouracil; FIAU), is such a 
nucleoside analogue. Fialuridine labeled with iodine-124 or iodine-125 was shown to be a very 
promising bacteria-specific imaging agent, both in a murine model and in patients (Table 1).40,41
Ligands - Two proteins of Staphylococcus aureus that promote coagulation, coagulase and the 
von Willebrand factor-binding protein, both activate prothrombin in a non-proteolytic manner 
by tightly binding to prothrombin. Panizzi et al. exploited this phenomenon by the use of 
radio-labeled or fluorescently labeled inactivated prothrombin to specifically target S. aureus. 
Indeed, this allowed for specific imaging of S. aureus-induced endocarditis in mice (Table 1).39 
Furthermore, several groups described the use of a bis zinc (II)-dipicolylamine complex to target 
the negatively charged membrane of bacteria. However, the specificity of this probe seems not 
limited to bacteria, as it targets all negatively charged areas, such as for example apoptotic cells.54
Bacteriophages – Intriguingly, virus particles that only infect bacteria and not human cells can 
also be exploited for imaging purposes. The proof-of-principle for this concept was reported by 
Rusckowski et al., who used radiolabeled bacteriophages to selectively image bacterial infections 
over sterile inflammation in mice (Table 1).49,50
duAL-mOdALITy	pRObES	
For optimal diagnostics, imaging modalities can be combined in order to make use of their most 
advantageous characteristics as was pointed out above for combinations of conventional imaging 
techniques. Accordingly, dual-modality probes have been designed by labeling a particular 
targeting molecule with two modality imaging agents, including different combinations of 
radionuclides, fluorophores, CT-contrast agents, MRI-agents or microbubbles (Figure 1).60 Such 
combinations allow for simultaneous imaging of the same target with, for example, PET-scanning 
as well as optical imaging, CT, MRI or US. In case of infection, this could be advantageous 
for non-invasively locating the infection grossly in the body and, subsequently, for invasively 
approaching the lesion under precise optical guidance. In the literature, multimodality imaging 
of components of the immune-system using dual-labeled probes is described.60,67 Examples are 
the targeting of CD20 on B-cells and the interleukin-11 receptor-α, which is expressed in breast 
tumors. Both were targeted with combinations of a radiotracer moiety and an optical dye.60,67 To 
the best of our knowledge, no infection-specific dual-labeled probes have been described so far.
smart actIVataBle proBes
A novel and exciting concept is the development of so-called smart activatable probes. This 
concept is based on the idea of switching the ‘off’ probe signal ‘on’ upon encountering the desired 
target. In fluorescence imaging, it is possible to quench the light-emitting fluorophore, resulting 
in silencing of the signal. When the quencher molecule is removed from the fluorophore, the 
signal can again be detected, the so-called ‘on’ status. A smart activatable imaging agent would, 
for example, be selectively cleaved at the site of infection by bacterial enzymes, resulting in a 
separation of the fluorophore from the quencher and signal activation (Figure 1). 
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This yields higher T/N ratios, due to the low background signal in untargeted tissue that lacks the 
required cleaving enzyme. Many variations of this concept were shown to be effective in oncology 
imaging, including the use of fluorescence resonance energy transfer (FRET), and molecular 
beacons and smart activatable probes in MRI.68 In bacterial imaging, only one example of a smart 
activatable probe has been reported so far. Kong et al. attached a fluorophore and a quencher 
on each side of a β-lactam ring. When this probe encounters bacteria that produce β-lactamases 
(i.e. enzymes that cleave the β-lactam ring), the quencher is separated from the fluorphore 
resulting in a strong fluorescent signal.53 Successful imaging was shown in a murine model with 
the β-lactamase-producing causative agent of tuberculosis, Mycobacterium tuberculosis (Table 1).
guIdelInes For target selectIon
Most experience with targeted imaging in vivo has so far been gained in oncology. With this 
particular disease, it is very challenging to pinpoint specific targets that are expressed exclusively 
on tumor cells at adequate density and homogeneity. To aid the systematic analysis of potential 
targets, Target Selection Criteria (TASC) were developed.69 This scoring system facilitates the 
assessment of favourable characteristics of a target, including expression rate, lack of expression 
in healthy tissue, internalisation ability of a target to favour signal accumulation, and enzymatic 
activity to facilitate the use of smart activatable probes. Targeting bacteria might be less 
complicated than targeting tumor tissue, as the bacterial cells (prokaryotic) are biochemically and 
structurally very different from human cells (eukaryotic). In particular, bacteria express a wide 
variety of potential targets that are not present on human cells. Nonetheless, targeted bacterial 
imaging may be complicated by the unwanted targeting of the human microbiome, mainly in the 
gut, the naso-pharynx, the upper respiratory tract and on the skin. Remarkably, the microbiome 
was so far not reported as a complicating factor in bacteria targeted imaging, suggesting that it 
may not be a major problem. On the other hand, this may relate to the particular model systems 
that were chosen to obtain proof-of-principle for the concept of bacteria-targeted imaging. 
Thus, further research involving a greater diversity in infectious disease animal models is needed 
before any conclusions can be drawn regarding the extent to which the human microbiome 
can influence the outcome of bacteria-targeted imaging. Potential problems can be foreseen for 
probes that can reach the gut. In this case, it may become somewhat challenging to modify these 
probes in such a way that they exclusively target the invasive bacteria causing infection as opposed 
to commensal gut bacteria. In this context, there is a clear need for objective criteria to select 
targets that discriminate between pathogenic bacteria and human cells or the microbiome. We 
have therefore evaluated whether the afore-mentioned TASC can be applied to the imaging of 
bacterial infections. The outcome of this evaluation is discussed below and illustrated in Figure 3.
Extracellular target localization (I) – In cancer imaging it is considered an advantage when 
a target is located on the outside of a cell, preferably on the cell membrane, as this allows easy 
accessibility. Conversely, in bacterial targeting, the majority of agents described need to be 
internalized by the bacteria. Some authors actually consider cellular uptake in bacterial imaging 
as an advantage, because it allows for signal accumulation.52 This difference can be explained in 
two ways. First, several of the tested targeting agents are based on clinically applied antibiotics 
that are active inside the bacterial cell. Clearly, these need to be taken up to bind to their target. 
Only a few groups of antibiotics applied for imaging, such as β-lactams and glycopeptides, act 
directly on the cell wall. Second, in contrast to cancer cells, compounds that can be metabolized 
are attractive targeting agents for bacteria. 
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Due to pronounced biochemical diff erences between bacterial and human cells, many substrates 
are available that are specifi cally taken up by bacteria but not by human cells, as exemplifi ed 
by maltodextrin.52 Due to the absence of specifi c data, it is currently hard to predict whether 
externally binding or internalized imaging probes will perform better in terms of ‘ignoring’ the 
human microbiota. Th is will require further research and clinical trials. 
Internalization (II) – Th e advantage of metabolizable compounds is that they can accumulate 
to high levels in the bacterial cells by which they are internalized. Th is will result in high T/N 
ratios as was demonstrated by the use of maltodextrin as an imaging agent, which yielded T/N 
ratios of up to 20.52 FIAU-based imaging showed the same results, resulting in T/N ratios of 14, 
which is higher than reported for most other probes (Table 1).41
Uptake by all lineages of the intended targeted species (III) – It is crucially important that 
all lineages of a microbial pathogen are targeted by the imaging agent that is to be used for the 
detection of infections caused by this particular species. Th is will ensure a minimal number of 
false negative results. It is conceivable that, as is the case with therapeutics, bacteria might become 
resistant to frequently used imaging agents over time, especially when antibiotics are used as 
targeting agents. Notably, antibiotic resistance is a problem of increasing clinical importance 
and it is presently not precisely known to what extent this will interfere with the eff ectivity of 
antibiotic-based imaging agents. Th is is clearly an area that needs further research. In theory, 
bacterial resistance due to decreased uptake or increased effl  ux of the antibiotic could reduce 
the imaging effi  ciency.65 On the other hand, in many cases the activity of the antibiotic is not 
needed for imaging. For example, DNA gyrase mutations leading to ciprofl oxacin resistance are 
not believed to interfere with ciprofl oxacin-mediated imaging, since this antibiotic is still taken 
up by the resistant bacteria.64 
Figure 3. Target Selection Criteria (TASC)69 adapted for bacteria-targeted imaging. I - Extracellular target localization, 
II – Internalization of the targeting agent, III - Uptake of the targeting agent by all lineages of the species that is to 
be targeted, IV - No uptake of the targeting agent in human tissue, V - Previously imaged with success in vivo, VI - 
Enzymatic activity.
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Moreover, ciprofloxacin resistance mediated by efflux pumps was shown not to alter uptake of 
99mTc-ciprofloxacin in vitro.70 Importantly, the chances that bacteria will develop resistance due 
to the use of antibiotic-based imaging agents seem rather small since such imaging agents will 
probably be administered in only a fraction of the therapeutic dose and, for diagnostic purposes, 
they will usually be administered only once. Accordingly, there will be no strong selective pressure 
favouring antibiotic resistant pathogens. Nevertheless, it can be argued that frequent exposure to 
sub-inhibitory doses of antibiotics may on the long term contribute to the accumulation of drug-
resistant species amongst the human microbiota. It will therefore be important to use imaging 
agents based on antibiotics wisely and with guidance through proper antibiotic stewardship.
No uptake or binding of the targeting agent in human tissue (IV) – Ideally, to yield a bacteria-
specific signal and high T/N ratios, it is important that the intended target is not expressed 
by human cells. As argued above, it is seemingly easy to meet this requirement due to the 
biochemical and structural differences between bacterial and human cells. However, a challenge 
that needs to be met is that the employed imaging agent must not be taken up aspecifically by 
leukocytes or any other human cells. This is crucial to distinguish bacterial infection from sterile 
inflammation. Unfortunately, it has thus far been difficult to predict whether an imaging agent 
will be specific or aspecific, as illustrated by the uptake of 99mTc-ciprofloxacin.4,63 The aspecific 
uptake of 99mTc-ciprofloxacin can be explained at least in part through the uptake of compounds 
foreign to the body by leukocytes.63 However, uptake was also seen in other areas of the body 
which is still unexplained.4,63 Furthermore, antibody-based probes have the intrinsic potential 
to bind to untargeted structures with their aspecific Fc-regions. A more complicated issue is the 
uptake or binding of targeting agents by the human microbiota. Here it may be wise to focus on 
agents that do not end up in the gut, which is the major reservoir of microbes in the human body. 
For example, the afore-mentioned vanco-800CW was shown to be excreted renally51, which is 
a major advantage as the kidneys of a healthy individual are sterile. Moreover, vanco-800CW 
accumulates only temporally in the bladder and is excreted in the urine.51
Previously imaged with success in vivo (V) – In cancer imaging, it has been difficult to identify 
targets that are exclusively expressed by tumor cells. Therefore, targeting agents or modalities 
that were previously described for in vivo imaging of other cancer types can be of importance 
for new applications. Thus, when a favourable target is found in one subtype of cancer, it is 
worth the effort to investigate whether it can also be applied for the imaging of other cancer 
subtypes. In bacterial imaging this is different, since finding appropriate targets is not the main 
difficulty. However, it is practical to use agents that have been clinically approved for the use in 
patients for other purposes, as is the case with antibiotics and humanized antibodies. Because 
the pharmaceutical characteristics and toxicity profiles are known for these agents, it is easier, 
faster and safer to introduce labeled derivatives into the clinic than to introduce completely 
novel imaging agents. On this basis, we believe that vanco-800CW is a promising candidate for 
early phase clinical trials. However, at present we cannot exclude the possibility that vancomycin 
labeled with other fluorochromes may be even better suited to fast-track into the clinic. 
Enzymatic activity (VI) – As mentioned before, smart activatable probes hold promise for highly 
specific fluorescence imaging of bacterial infections with minimized background signal. When 
designing a smart activatable fluorescent probe, it is therefore crucial that the envisaged target has 
the necessary enzymatic activity to remove the quencher from the fluorophore. This was shown 
to be the case for the mycobacterial β-lactamases that were capable of activating β-lactam-based 
smart activatable probes and this concept is worth exploring in more depth for bacteria-targeted 
imaging.53 




In line with targeted imaging, there are similar options for the selective treatment of infections. 
One modality is the application of photodynamic therapy (PDT), which combines diagnostics 
with therapy. In PDT, photosensitive molecules are brought in close proximity of the target, 
in this case bacteria. Subsequently, these photosensitizers are excited by a laser, leading to 
the generation of an optical signal as well as cytotoxic molecules that ultimately lead to the 
destruction of the targeted cell.71,72 In microbiology, this modality has been most widely explored 
in the treatment of dental plaques and skin infections.71,73 For a detailed description of PDT, 
we refer to the review of Kharkwal et al.73 A major disadvantage of PDT is that the uptake of 
photodynamic molecules is usually aspecific, which potentially leads to considerable damage 
of the surrounding healthy tissue. This is the main reason why the application of PDT was 
so far mainly limited to skin and dental infections. Nevertheless, the successful application of 
specifically targeted PDT in cancer treatment was recently described.72,74 In this case, tumor-
targeting monoclonal antibodies were labeled with a photosensitizer and administered to tumor-
bearing mice. After exposure to laser light of the appropriate wavelength, significant tumor 
reduction and improved survival was observed without major side effects. Tumors located up to 
1 cm below the surface of the skin can be reached this way. Apart from an improvement in the 
accuracy of treatment, targeted PDT also allows for the imaging of the targeted tissue, which 
will guide the localization of the respective lesion and residual disease. It is well conceivable that 
targeted PDT can also be translated to the treatment of bacterial infections or infections caused 
by other pathogens. However, due to the limited penetration depth of currently applied lasers, 
targeted PDT would be limited to localized, relatively easily accessible infections, such as soft 
tissue infections, endocarditis, and biomaterial infections. Such infections often relate to meshes 
or peripheral vascular devices that are readily colonized by opportunistic pathogens. To the best 
of our knowledge, no in vivo studies have thus far been conducted to explore the possibilities of 
targeted PDT in the imaging and treatment of infections. In vitro, it has however been shown 
that antibody-directed PDT in infections is a feasible approach.75,76 Besides antibody-mediated 
PDT, PDT using cationic charged photosensitizers has been described.76 However, it is currently 
not clear to what extent such imaging agents, like the cationic bis zinc(II) dicolylamine, are 
truly bacteria-specific. Interestingly, Suci et al. described Aggregatibacter actinomycetemcomitans-
targeted PDT in vitro using a biotinylated antibody specific for this bacterium and a biotinylated 
photosensitizer, which were coupled with streptavidin.77 The results obtained hold promise for 
the application of this approach in vivo to treat periodontal biofilms.77 Altogether, the published 
data indicate that targeted PDT could prove to be an interesting modality for the treatment of 
locoregional infections.
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conclusIon and Future perspectIVes
As outlined in this review, bacteria-specific (pre-)clinical molecular imaging is still in its infancy, 
but substantial progress has been made in several areas, especially the development of tracers 
and instrumentation. Currently it is difficult to predict which strategies will prove to be most 
appropriate for bacterial infections, but there are several promising options approaching the 
clinic at a rapid pace. Apart from the discovery of new targets in the field of molecular imaging, 
the emergence of new imaging modalities, such as optical imaging and optoacoustic imaging 
and technical improvements of current imaging modalities, are likely to promote the diagnosis 
of bacterial infections. Importantly, combinations of different modalities are likely to further 
improve diagnostic accuracy. Lastly, targeted imaging can be combined with therapy as novel 
theranostic agents, as is the case in targeted PDT, which has major implications for the treatment 
of bacterial infections in an era where close to untreatable antibiotic resistant pathogens threaten 
our health and well-being. It is thus very well conceivable that fluorescently labeled tracers 
suitable for PDT will become the ‘glowing antibiotics’ of the future.
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Invasive and biomaterial-associated infections in humans are often difficult to diagnose and 
treat. Here, guided by recent advances in clinically relevant optical imaging technologies, 
we explore the use of fluorescently labeled vancomycin (vanco-800CW) to specifically 
target and detect infections caused by Gram-positive bacteria. The application potential of 
vanco-800CW for real-time in vivo imaging of bacterial infections is assessed in a mouse 
myositis model and a human post-mortem implant model. We show that vanco-800CW 
can specifically detect Gram-positive bacterial infections in our mouse myositis model, 
discriminate bacterial infections from sterile inflammation in vivo, and detect biomaterial-
associated infections in the lower leg of a human cadaver. We conclude that vanco-800CW 
has a high potential for enhanced non-invasive diagnosis of infections with Gram-positive 
bacteria, and is a promising candidate for early phase clinical trials. 
IntroductIon 
Bacterial infections are of mounting medical and public concern. As human life expectancy 
continues to increase, so has the number of frail and immune-compromised individuals who 
are susceptible to bacterial infections. A major contributor to this trend is the proliferation of 
medical implants and devices, which are inherently vulnerable to bacterial contamination. To 
complicate matters further, current antimicrobial therapies face challenges from the emergence 
of omnipresent drug-resistant microbes such as methicillin-resistant Staphylococcus aureus 
(MRSA). Infections precipitated by implanted materials occur at high frequency and are difficult 
to diagnose and treat. For example, approximately 5% of the inserted internal fixation devices 
in bone fractures become infected. This number rises to ~30% after fixation of open fractures.1 
Apart from the clinical implications and burden on the patients’ quality of life, the costs for 
treating such severe complications can be as much as $107,000 per case.2
A major challenge in averting biomaterial-associated infections is the lack of a sensitive, specific, 
and non-invasive modality to detect early-stage bacterial infections, when treatment is most 
effective due to the absence of profound biofilm formation. Currently, only indirect imaging 
modalities are in clinical use, as exemplified by positron emission tomography (PET) with 
fluoro-deoxy-glucose (FDG), which visualizes increased glucose uptake by inflammatory cells.3 
Alternatively, sites of inflammation can be located by injection of radiolabeled leucocytes and 
subsequent scanning. Unfortunately, these approaches lack sufficient resolution, practicality, and 
cannot clearly discriminate between a bacterial infection and general inflammation. Therefore, 
clinical imaging tools that are easy-to-use, allow bedside monitoring, and directly target invasive 
bacteria are highly desirable. Radiolabeled antibiotics are attractive ligands that directly bind to 
pathogenic bacteria.4 However, their general use is hampered by inherent limitations in specificity 
and resolution (~0·5 cm) of the radiologic imaging modality4-7, and radioactivity itself. 
Optical imaging, in particular targeted fluorescent imaging (TFLI), is a relatively novel diagnostic 
approach that has attracted increasing support for both preclinical and clinical applications. TFLI 
is based on the administration of an exogenous targeting fluorophore that emits light outside the 
absorbance window of bodily tissues. Emitted signals are readily detected by a sensitive charge-
coupled device (CCD) camera. Clear advantages of TFLI include: (i) non-invasive real-time 
imaging, (ii) high resolution, (iii) absence of radiation-related risks, and (iv) relatively low costs. 
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Animal-based experiments have shown the feasibility of TFLI for detecting tumors. Moreover, 
the first proof-of-principle study for clinical use of TFLI in ovarian cancer surgery has recently 
been reported.8 
Recent pioneering studies have demonstrated the feasibility of TFLI for in vivo detection of 
bacteria.9-11 Prior to introducing this approach into the clinic, however, several essential 
steps need to be carried out including toxicity testing of the fluorescent probe for its clinical 
translation according to international guidelines and standards such as the Good Clinical 
Practice guidelines (http://www.ich.org/products/guidelines.html). With the afore-mentioned 
requirements in mind, we propose to use a novel fluorescent imaging agent derived from the drug 
vancomycin as a diagnostic tool for detecting infecting bacteria in vivo. Since vancomycin has 
been used clinically for over 50 years, there is widespread familiarity with the pharmacokinetics, 
biodistribution, and toxicity profile. For usage as an optical imaging agent to selectively target 
Gram-positive bacteria in vivo, we conjugated vancomycin to IRDye 800CW, a near-infrared 
fluorophore now in early clinical trial (NCT01508572) (Figure 1a). Vancomycin is a glycopeptide 
antibiotic drug that exhibits preferential activity against Gram-positive bacteria, which are the 
most prominent causative agents of soft tissue infections and biomaterial-associated infections 
(BAI). Vancomycin binds specifically to the D-Ala-D-Ala moiety present in bacterial cell walls 
(Figure 1b). Biodistribution of a vancomycin-based agent can be similar to that of unlabeled 
vancomycin, as shown by single photon emission computed tomography (SPECT) studies in 
rats.12 In the present study, we show that near-infrared (NIR) optical imaging with a bacteria-
specific vancomycin-based probe can detect both invasive infections in vivo and BAI post mortem.
methods
Synthesis of vancomycin-IRDye®800CW 
Vancomycin-IRDye®800CW (vanco-800CW) was synthesized by an adapted literature 
procedure.24 Vancomycin hydrochloride hydrate (3·0 mg, 2·0 μmol; Sigma-Aldrich) was added 
to a solution of IRDye®800CW-NHS ester (1·0 mg, 0·86 µmol; LI-COR Biosciences) and N,N-
diisopropylethylamine (2·0 μL, 11 μmol; Sigma-Aldrich) in dimethylsulfoxide (200 μL; Sigma-
Aldrich). The reaction progress was monitored by analytical reversed-phase HPLC on an Agilent 
Technologies 1100 series system with a Polaris C18-A column (100 X 3.0 mm; flow rate 0.5 
mL/min; manual injection of 10 μL samples; column temperature 30 ˚C). HPLC buffer A was 
50 mM triethylammonium acetate, 4% acetonitrile, pH 6.0, and HPLC buffer B was 50 mM 
triethylammonium acetate + 80% acetonitrile. The column was equilibrated at 0/100 Buffer B/
Buffer A, and the elution gradient was established from 0/100 to 100/0 Buffer B/Buffer A over 
10 min (5 min post-time to re-equilibrate column). The monitored wavelengths were 780, 680, 
280, and 230 nm. After overnight reaction at ambient temperature, the resulting bioconjugate 
was purified by preparative reverse-phase HPLC on an Agilent Technologies 1100 series system 
with a Zorbax C18 column (250 X 9.6 mm; flow rate 3.0 mL/min; manual injection of 100 μL 
samples, column temperature 40 ˚C). The column was equilibrated at 20/80 Buffer B/Buffer A, 
and the elution gradient was established from 20/80 to 35/65 Buffer B/Buffer A over 15 min (10 
min post-time to re-equilibrate column). The monitored wavelengths were 780, 680, 280, and 
230 nm. 
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Th e major peak was collected as two fractions, aliquots of which were checked by UV-Vis 
spectrometry (Supplementary Fig. S9) and low-resolution mass spectrometry (LR-MS) on 
an Agilent Technologies 1100 Series LC MSD Trap (Supplementary Fig. S10) to determine 
compound identity, and by analytical HPLC (Supplementary Fig. S11) to determine compound 
purity. Within the limits of HPLC detection, the fi nal product did not contain any unconjugated 
dye (detected at 780 nm), or unlabeled vancomycin (detected at 280 nm; Supplementary Fig. 
S12). Fractions containing pure vanco-800CW were pooled, concentrated in vacuo, redissolved 
in UltraPure water, and eluted through Amberlyte® IR-120 Ion Exchange Resin (sodium form). 
Th e bulk solution of ion-exchanged vanco-800CW was quantifi ed by UV-Vis spectrometry on 
an Agilent 8453 series spectrophotometer. Th e isolated yield for the product was determined to 
be 1.0 mg (46%, 396 nmol). Th e product was packaged as 25 nmol aliquots, frozen at -80°C, and 
lyophilized to aff ord a green fl occulent solid. UV/Vis (methanol) λmax = 778nm; Low Resolution 
Mass Spectrometry (ES/ammonium formate), m/z calculated for 2430·7 [M – H]–, found 810·6 
[M – 3H]3–. Prior to usage, the vanco-800CW was dissolved in phosphate-buff ered saline (PBS). 
Biofi lm formation
Th e American Type Culture Collection S. epidermidis strain 35984 was plated on agar containing 
5% sheep blood and cultured at 35˚C, 5% CO2. A colony was transferred to Tryptic Soy Broth 
(TSB) + 2·5% glucose and cells were cultivated at 35˚C for two days under shaking. Finally, a 
200-fold dilution of the S. epidermidis suspension was incubated with an osteosynthetic device 
(i.e. one-third tubular plate) in TSB + 2·5% glucose medium overnight at 35˚C.
Figure 1. Vancomycin-IRDye 800CW and the experimental approach. (a) Structure of vanco-800CW. (b) Schematic 
representation of the experimental approach for imaging mice injected with either S. aureus (‘S. aureus myositis’), E. 
coli (‘E. coli myositis’) or Cytodex® beads (‘sterile myositis’) and subsequent detection of S. aureus with vanco-800CW.
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Incubation with vancomycin-IRDye800CW 
Bacteria or biofilm-bearing biomaterials were incubated with TSB+2·5% glucose medium 
containing vanco-800CW (0.14 nmol/mL) for two h at 35˚C, 5% CO2. Subsequently, the 
incubated material was washed twice with PBS. For bacterial suspensions, the materials were 
centrifuged (8 min at 16873 RCF) and the supernatants were removed. The pellets were 
resuspended in PBS or TSB. In vitro imaging analyses were performed using an IVIS Spectrum 
(Caliper LS, Hopkinton MA, USA).
Clinical isolates
Samples of bacterial infections related to orthopedic biomaterial, occurring over one year at 
the UMCG, were collected (2010-2011, 32 patients with 150 isolates). A selection of variably 
occurring species was prepared to mimic microbial populations associated with BAI. Selected 
isolates (38 from 19 different patients) were thawed and cultured on blood agar plates (5% 
sheep blood) for three days at 35˚C, 5% CO2. Suspensions at an optical density of 3·5-4·2 
McFarland were prepared, incubated with vanco-800CW and washed twice with PBS. Samples 
were centrifuged, and pellets were resuspended in 200 µL PBS and pipetted into 96-well plates 
(BD Falcon, black). Imaging was performed with the IVIS Spectrum, using afore-mentioned 
settings. The experiment was performed twice in duplicate.
Limit of bacterial detection
To determine the limit of bacterial detection, a clinical isolate of S. aureus was suspended in TSB 
+ 2·5% glucose medium (4 McFarland in 2 mL). The suspension was incubated with vanco-
800CW, washed twice with PBS, and resuspended in PBS. Numbers of bacteria were calculated 
using a cell counting-chamber (Bürker), at a 200-fold dilution and optical enhancement with 
safranin 0·1%. Counting was done independently by two researchers. A series of dilutions in 180 
µL PBS was prepared in black 96-well plates. The experiment was performed thrice in duplicate 
with non-treated S. aureus as a negative control. Imaging analysis was performed with the IVIS 
Spectrum. After analysis, incubated S. aureus and non-treated S. aureus were plated on blood 
agar and cultured overnight at 35˚C, 5% CO2 to determine whether vanco-800CW at the used 
dosage would impair viability.
Mouse experiments
Bioluminescent S. aureus (Xen29; Caliper LS) was used to induce a hind limb myositis in 12 
Naval Medical Research Institute (NMRI) mice.25 The applied dose of 5x107 colony-forming 
units (CFU) per injection was the minimum dose at which a readily detectable myositis 
developed (Supplementary Fig. S13). Two days post-infection, vanco-800CW was intravenously 
administered (0·1-5 mg/kg) to six infected mice and six non-infected mice. After 24 h, the 12 
infected and six non-infected mice were euthanized and imaged with an IVIS Lumina II (Caliper 
LS) to detect fluorescence and bacterial bioluminescence. In co-infection experiments, NMRI 
mice were infected with bioluminescent S. aureus (Xen36) and E. coli (Xen16; Caliper LS) 
at 5x107 CFU per injection. Low-dose Micro-Computed Tomography (µ-CT) was performed 
with a Quantum FX microCT Imaging System within the IVIS SpectrumCT (Caliper LS). 
Infected muscle tissue was excised and subsequently imaged with the IVIS Lumina II or the 
IVIS SpectrumCT. Infected tissue was homogenized and cultured or stored at -80⁰C. Bacterial 
presence in excised tissue was visualized either by fluorescence microscopy or by Giemsa staining 
and light microscopy. For NIR fluorescence microscopy, tissues were fixed overnight with 4% 
paraformaldehyde in PBS (pH 7.5), and washed thrice in PBS (10 min), twice in 70% ethanol 
(1 h), and twice in 95% ethanol (1 h). 
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Fixed tissue was embedded in paraffin and 5µm-thick sections were cut. Deparaffinization and 
rehydration of tissue slides were performed by washing in xylene (5 min, thrice), 100% ethanol 
(2 min, twice), 96% ethanol (2 min), 80% ethanol (2 min), 70% ethanol (2 min), 50% ethanol 
(2 min), distilled water (2 min) and PBS (5 min). Mounting medium with DAPI (Vectashield, 
Burlingame, CA) was added and a coverslip was placed. Fluorescence imaging was performed 
with the Nuance EX multispectral CCD camera (PerkinElmer, Hopkinton, MA) and an Eclipse 
E400 microscope (Nikon, Japan). For Giemsa staining, frozen tissue sections were made (6 µm 
thickness) and mounted on slides. The sections were fixed in methanol for 1 min, rinsed with 
water, treated with 2·5% Giemsa dilution in PBS for 30 min, and rinsed with water. FISH 
with an EUB-fluorescein isothiocyanate (FITC) probe was performed to confirm the presence of 
bacteria.26 Briefly, sections were fixed with methanol and dried on a hot plate. Next, sections were 
treated with permeabilization buffer, rinsed with methanol, and dried on a hot plate. EUB-FITC 
probe dissolved in urea buffer (10 ng/µL) was added to the sections, followed by incubation 
for 20 min on a hot plate.27 The sections were washed twice, covered with Vectashield (Vector 
Laboratories), and coverslipped. Analysis was performed using fluorescence microscopy (Leica 
CTR5500, Leica Microsystems BV, Rijswijk, The Netherlands).
To induce a sterile inflammation, Cytodex® beads (1 mg in 50 μL; Sigma-Aldrich, St. Louis, USA) 
were injected in the upper leg muscle of four NMRI mice.28 Vanco-800CW was intravenously 
administered (1mg/kg) to two mice. To compare the sterile inflammation with bacterial myositis, 
S. aureus (Xen29) was introduced to the left hind limbs of six mice whereas Cytodex® beads were 
introduced into their contralateral right hind limbs. Three mice were treated with vanco-800CW 
(1 mg/kg) and compared with three negative controls. Imaging was performed with the IVIS 
Lumina II, and tissues were collected as described above. Frozen tissue sections were made and 
Giemsa-stained to confirm leukocyte infiltration. To determine the staphylococcal burden of 
infected muscles, tissue was aseptically harvested at indicated time points and homogenized in 2 
mL of sterile PBS using Dispomix (Bio-Budget Technologies GmbH, Krefeld, Germany). Serial 
dilutions of the homogenates were cultured on mannitol salt-phenol red agar plates for at least 
48 h at 37°C. Colonies were counted and staphylococcal burden was calculated as total CFU/
excised tissue. Bioluminescence signal was determined using the IVIS Lumina II.
Human post-mortem implant model
Biofilms were formed on two osteosynthetic devices (one-third tubular plates) by incubation 
with S. epidermidis ATCC 35984. Subsequently, biofilm-coated plates and uncoated control 
plates were incubated with vanco-800CW as mentioned above and washed twice with PBS. The 
three differently treated osteosynthetic devices were implanted on the distal fibula in a human 
cadaver ankle and the skin was subsequently sutured (Ethilon 3-0, Ethicon Somerville, New 
Jersey, USA). Imaging was performed using an intraoperative clinical multispectral fluorescence 
camera (T3-imaging system, SurgOptix BV, Groningen, The Netherlands) and the IVIS 
Spectrum.8, 16 The experiment was performed twice with the lower legs of two human cadavers. 
For dose-response measurements, dilution series of vanco-800CW-treated S. aureus SH1000 
or S. epidermidis ATCC35984 were spotted on Whatman 3MM paper strips (ranging from 
2·5x104 to 2·5x108 CFU/mm2, or from 1·5x104 to 1·5x108 CFU/mm2, respectively). These were 
subsequently implanted on the medial site of the distal tibia in a human cadaver ankle, and 
imaging was performed with the T3 intraoperative clinical multispectral fluorescence camera. 
The post-mortem experiments were conducted according to institutional guidelines with prior 
approval from the scientific review committee of the Skills Center of the University Medical 
Center Groningen, the Netherlands. 
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All individuals involved in the human post-mortem studies have provided informed written 
consent for the use of their bodies for scientific research and teaching.
Software
Results obtained with the IVIS systems were analyzed with Living Image 4·2 (Caliper LS). 
Optimal detection limits were set to the lowest signal at which positive signal was effortlessly 
discriminated from negative controls. Signal intensity was determined by drawing regions of 
interests (ROI’s) and measuring average counts in these regions. The signal was corrected for 
background by subtracting the background signal from the signal of interest, referred to in the 
text as net counts. 
Statistics
Fluorescence imaging data derived by the IVIS systems are expressed in counts as mean ± 2 
standard deviations (SD) in the ROI. For determining statistical relationships among bacterial 
infection, sterile inflammation or negative controls, either the paired or unpaired two-sample 
Student t-test (p < 0·05) was used.
results
Detection of clinical bacterial isolates in vitro
To determine the binding specificity of vanco-800CW, bacterial isolates from infected 
orthopedic material of 19 patients at the University Medical Center Groningen were cultured, 
incubated with vanco-800CW, and subsequently imaged with an IVIS Spectrum. Notably, 
these isolates form a representative display of the microorganisms encountered in biomaterial-
associated infections, including S. aureus, Staphylococcus epidermidis, Corynebacterium species, 
Streptococcus or closely related bacterial species (Group G Streptococcus species, Streptococcus mitis, 
and Granulicatella adiacens), Dermabacter hominis, Escherichia coli, Klebsiella species, Enterobacter 
species and Pseudomonas species. By this ex vivo fluorescence imaging approach, all of the 18 tested 
Staphylococcus isolates were detected, and 21 of the 25 tested Gram-positive bacterial isolates 
(84%; Supplementary Fig. S1a). The Gram-positive isolates with a fluorescent signal below the 
preset detection limit (i.e. intensity: 105 net counts) mainly consisted of Corynebacterium species 
(4/6). Additionally, ten out of 11 Gram-negative bacterial isolates (91%) were undetectable using 
the above parameters, as expected based on the pharmacological preference of vancomycin for 
targeting Gram-positive bacteria.
To determine the minimal number of bacteria detectable by TFLI, a dilution series was 
performed using a S. aureus isolate derived from a clinical sample, labeled with vanco-
800CW. The bacteria were then counted using a counting chamber. In the dilution 
series, the minimum fluorescence detection level approximated 1·2x104 net counts. 
After incubation with vanco-800CW, approximately 5x106 staphylococci were detected 
in 200μL, corresponding to 2·5 x104 staphylococci per mm3 (Supplementary Fig. S1b). 
Bacterial myositis in mice
The in vivo applicability of vanco-800CW was subsequently tested in immunocompetent mice 
that had myositis in the left hind limb induced by intramuscular (i.m.) injection of luciferase-
engineered S. aureus. 
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The S. aureus strain’s constitutive bioluminescence facilitates localization of live bacteria by 
simultaneous imaging of the fluorescence signal derived from vanco-800CW and luciferase 
bioluminescence. Two days after i.m. inoculation with S. aureus, 6 mice were intravenously 
injected with vanco-800CW (at 0.1, 1, 3 or 5 mg/kg, in which 1 mg/kg was administered in 
several mice since this was the expected optimal targeting dose). After an additional 24 h, both 
bioluminescence and fluorescence imaging were performed with an IVIS Lumina II imaging system. 
A strong near-infrared fluorescence (NIRF) signal, attributed to vanco-800CW, was observed to 
co-localize with the bioluminescence signal in all administered doses (i.e. an intensity of 3·7x105 
± 9·8x104 counts ex vivo at a dose of 1mg/kg) (Supplementary Fig. S2a). In addition, the bladder 
gave a strong signal, which was no longer detectable after draining (Supplementary Fig. S3a). No 
NIRF signal was observed in infected mice that did not receive vanco-800CW. Importantly, in 
a co-infection experiment where mice were injected with luciferase-engineered S. aureus in one 
hind limb and luciferase-engineered E. coli in the other, a vanco-800CW-specific fluorescent 
signal was only observed for the staphylococcal myositis (Figure 2a). Ex vivo, the fluorescence 
signal also co-localized with the bioluminescence signal (Figure 2b and Supplementary Fig. S2b). 
A significant increase in fluorescence signal was observed for the infected muscle in comparison 
to the contralateral non-infected hind limb (1·0x105 ± 4·2x104 counts; p=0·007). Infected tissue 
yielded a target-to-background ratio (TBR) of 4·2 corrected for background signal, over the non-
infected tissue in the contralateral leg ex vivo. Notably, while we observed large overlaps between 
the bioluminescence and fluorescence signals, the match between both signals was not 100% 
(Figure 2c and Supplementary Fig. S4). We attribute this to a combination of factors, including 
(i) different threshold settings in the bioluminescence and fluorescence imaging, (ii) differences 
in wavelengths of the light emitted through bioluminescence (luciferase peak at 490 nm) and 
NIR fluorescence (IRDye800CW peak at 800 nm) which result in significantly different tissue 
scattering and absorption properties, and (iii) the fact that only exponentially growing cells are 
bioluminescent (Supplementary Fig. S5) while staining with vanco-800CW is independent of 
the growth phase. Fluorescence microscopy demonstrated that the fluorescence in the 800 nm 
channel was directly related to the presence of vanco-800CW-labeled staphylococci (Figure 2d 
and Supplementary Fig. S6), as also detected by Giemsa staining and confirmed by Fluorescent 
In Situ Hybridization microscopy (FISH; Supplementary Fig. S2c,d). In contrast, no NIR 
signal was observed for the E. coli cells (Figure 2d and Supplementary Fig. S6). Culturing of 
homogenized infected muscle tissue after macroscopic optical imaging revealed the presence of S. 
aureus (~6·4 x 107 CFU), which was confirmed by ex vivo bioluminescence imaging. After autopsy, 
fluorescence signal was also detected in the kidneys, liver and urine of vanco-800CW-treated 
mice (Supplementary Fig. S3b and S7), which is consistent with the strong in vivo bladder signal 
(Supplementary Fig. S3a) and the known pharmacokinetic profiles of unlabeled vancomycin and 
unmodified IRDye 800CW (both eliminated by the kidneys).13-15 Heart, spleen, normal muscle 
and bowel showed no fluorescence signal above background levels (Supplementary Fig. S7). 
Non-bacterial Inflammatory Myositis in Mice
To discriminate a bacterial infection from a sterile foreign body reaction or aseptic inflammation, 
the fluorescence signal detected after intravenous injection of vanco-800CW in mice with S. 
aureus-induced myositis (n=6) was compared to that in mice with sterile myositis induced by 
implanted Cytodex beads (n=6). Three of the mice injected with vanco-800CW had S. aureus 
myositis in the left hind limb, as well as contralateral sterile myositis in order to reliably compare 
signals within the same animal. 
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Ex vivo, the muscle tissue with sterile infl ammation showed fl uorescent signals (1·8x102 ± 0·8 
x102 counts) comparable to those of healthy tissue (1·2x102 ± 0·1x102 counts, p=0·06, not 
signifi cant; Figure 3). Again, muscle tissue infected with the luciferase-engineered S. aureus 
emitted signifi cantly higher fl uorescence signals (4·1x102 ± 2·6x102 counts) in comparison to 
non-infected contralateral healthy muscle tissue (p=0·008) and tissue with sterile infl ammation 
(p=0·01) (Figure 3a). Furthermore, upon correction for background signal, the staphylococcal 
myositis signal was 2.4-fold stronger than the sterile myositis signal (SD 0·15; CI 95% 2·1-2·7; 
Figure 3c). Th e presence of sterile infl ammation following bead implantation was confi rmed by 
Giemsa staining and light microscopy, which showed accumulation of leukocytes around the 
beads and absence of leukocytes in healthy muscle tissue (Figure 3b). No bioluminescent bacteria 
were found in cultures from either the non-infected or sterilely infl amed muscle tissue.
Figure 2. In vivo imaging of bacterial myositis. (a) Imaging of a mouse with E. coli (Xen16)-induced myositis in the 
left hind limb and S. aureus (Xen36)-induced myositis in the right hind limb was performed with the IVIS SpectrumCT 
Imaging System at 8 and 24 h after intravenous administration of 1.8 mg/kg vanco-800CW. Left side: bioluminescence 
imaging (open fi lter, FOV 12.8 cm, f1, 30 s acquisition time); right side: fl uorescence imaging (excitation 745 nm, 
emission 840 nm, FOV 12.8 cm, f-stop 2, 0.5 s acquisition time). (b) Excised muscle tissue of the E. coli-infected left leg 
(left) and the S. aureus-infected right leg (right) of the mouse shown in panel a. (c) Micro-Computed Tomography (μ-
CT) imaging of the mouse shown in panel a with bioluminescence (BLI; rainbow scale) and fl uorescence (FLI; red-yellow 
scale) co-registration. A fl uorescent signal from the bladder is detectable behind the spine. See Supplementary Figure S4 
for the separate BLI and FLI images. (d) Fluorescence microscopy of infected muscle tissue. A cluster of vanco-800CW-
labeled Gram-positive cocci (i.e. S. aureus) is indicated in the right panel (red), and a chain of Gram-negative rods (i.e. 
E. coli) is indicated in the left panel (green). DAPI-stained cell nuclei are labeled green. Vanco-800CW imaging: excitation 
710 nm, emission >785nm; DAPI imaging: excitation 360 nm and emission >458 nm. See also Supplementary Figure 
S6.
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Biofi lm Detection in a Human Post-mortem Implant Model 
To investigate whether vanco-800CW could be employed for non-invasive optical imaging of 
bacterial biofi lms on superfi cially implanted medical devices, we performed human cadaver TFLI 
experiments (n=2) with bacteria-contaminated implants. A three-hole osteosynthesis plate (i.e. 
a one-third tubular plate) was coated with a S. epidermidis biofi lm and subsequently incubated 
with vanco-800CW (plate 1). Plates without biofi lm treated with vanco-800CW (plate 2), or 
plates containing biofi lm without vanco-800CW incubation (plate 3) were used as controls. Th e 
plates were surgically implanted on the fi bula of a human cadaver, followed by standard skin 
suturing. Subsequently, the lower leg was imaged in both pseudocolor and fl uorescence modes 
with a clinical intraoperative multispectral fl uorescence camera system.8,16 A strong fl uorescence 
signal from plate 1 was detected through the skin, whereas neither plate 2 nor plate 3 showed 
any signifi cant fl uorescence signal compared to background (Figure 4a). Corroborating data were 
obtained with the IVIS Spectrum imaging system (Supplementary Fig. S8). Subsequent dose-
response analyses with vanco-800CW-preincubated S. aureus or S. epidermidis cells spotted onto 
fi lter paper and applied to the distal tibia of the left leg of a human cadaver showed that the 
detection limits for these bacteria were 1·25x108 or 1·5x108 CFU/mm2, respectively (Figure 4b). 
In this case, the bacteria were covered with about 8 mm of tissue upon skin suturing. 
Figure 3. In vivo imaging of bacterial myositis and sterile myositis. (a) Imaging of excised tissue was performed with 
the IVIS Lumina II. Upper panel, left: bioluminescence detection of bacterial myositis induced with S. aureus Xen29 
after injection with vanco-800CW (+/+); upper panel, right: bioluminescence detection of sterile myositis after injection 
with vanco-800CW (-/+); lower panel, left: NIR detection of bacterial myositis induced with S. aureus Xen29 after 
injection of vanco-800CW (+/+); lower panel, right: NIR detection of sterile myositis after injection of vanco-800CW 
(-/+). Settings for fl uorescence measurements: excitation: 745nm, fi lter: ICG; acquisition time 3 s, binning 4, F-stop 2, 
FOV12·5; settings for bioluminescence measurements: excitation block, fi lter open, acquisition time 300 s, binning 4, 
F-stop 1, FOV12·5). (b) Confi rmation of the presence of leukocytes by microscopy (Giemsa staining). b1: non-infected 
tissue; b2 and b3: sterile infl ammation with Cytodex (*) beads (leucocytes are indicated by black arrows). Scale bars in 
b1 and b2 mark 200 µm; the scale bar in b3 marks 20 µm. (c) Quantifi cation of ex vivo fl uorescence signals in tissue of 
bacterial myositis, sterile myositis, and heart tissue with the IVIS Lumina II (settings as in a). Bars represent the mean of 
3 mice, error bars display the standard deviation (SD). Mice treated with vanco-800CW (1 mg/kg; n=3) are represented 
by red bars and control non-injected mice (n=3) are represented by yellow bars. Infected tissue yielded a signifi cantly 
higher signal than sterile infl ammation (*, p=0·01).
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dIscussIon
Detecting bacterial infections in patients remains a challenging clinical problem, with potentially 
devastating consequences arising from fulminant infections and sepsis. Current non-invasive 
diagnostic imaging techniques are handicapped by low resolution and specifi city due to 
their shared inability to discriminate between bacterial infection and sterile (non-bacterial) 
infl ammation.4,7 Moreover, these techniques harbor inherent disadvantages that preclude their 
incorporation in bedside monitoring devices for repetitive clinical application in individual 
patients. Optical imaging, in particular TFLI imaging, has shown great potential in applications 
ranging from cancer detection to image-guided surgery.8,17,18 Both epi-illumination techniques 
and novel developments like opto-acoustics off er highly promising methods for early detection of 
bacterial infections. Th ree studies have so far been published describing in vivo optical imaging of 
bacterial infections using fl uorescent agents.9-11
Ning et al. used a maltodextrin-IR786 conjugate to detect E. coli, S. aureus, P. aeruginosa, and 
Bacillus subtilis.9 Th e conjugate yielded strong bacteria-specifi c signals in rats after intravenous 
administration (TBR ratios of 26). Th e maltodextrin-IR786 probe was also able to discriminate 
E. coli infection from LPS-induced sterile infl ammation. However, this probe tends to accumulate 
only in metabolically active bacteria. 
Figure 4. Human post-mortem implant model. (a) Osteosynthetic devices were either uncoated (2) or coated with an 
S. epidermidis biofi lm (1 and 3). Plates 1 and 2 were incubated with vanco-800CW prior to surgically applying each plate 
onto the fi bula of a post-mortem ankle. Subsequent non-invasive examination of the ankle was performed with a clinical 
multispectral fl uorescence camera. (b) Vanco-800CW-labeled S. aureus cells were spotted onto a Whatman paper strip, 
which was imaged as in a, either prior (left fl uorescence panel) or after surgical application onto the distal tibia of a post-
mortem ankle (right fl uorescence panel). Th e tested amounts of S. aureus applied to the Whatman paper were: a, 0·63 
x108 CFU/mm2; b, 1·25x108 CFU/mm2; c, 2·5x108 CFU/mm2.
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Although the authors described biofilm detection using maltodextrin-IR786, this probe might 
not detect infections containing metabolically inactive bacteria. Furthermore, IR786 has not 
undergone extensive animal toxicity studies, nor is clinical good manufacturing practice (GMP) 
material available. Although maltodextrin is a common food additive, no intravenous data are 
available for humans.
Panizzi et al. reported specific S. aureus endocarditis detection in mice using fluorescently labeled 
prothrombin (prothrombin-AF680).10 This agent binds to the staphylococcal-coagulase produced 
by S. aureus on heart valves, enabling good visualization of S. aureus-induced endocarditis. 
Prothrombin-AF680 was pharmacologically inactive and no signal was observed in areas of sterile 
endothelial damage. This suggests that it could be clinically applicable. Nevertheless, prothrombin 
may not be completely S. aureus-specific, as it is involved in physiological processes, potentially 
leading to false-positive results.19 Another potential pitfall of this agent is that staphylococcal 
coagulase was shown to be expressed only on the borders of mature vegetation, which may 
yield inadequate signal. Importantly, prothrombin will only reveal coagulase-positive bacteria, 
which severely limits the spectrum of detectable bacteria. Although there is experience with the 
intravenous use of prothrombin in humans, AF680 also has not yet undergone extensive animal 
toxicity studies.
Kong et al. demonstrated in vivo detection of Mycobacterium tuberculosis with a “smart” activatable 
probe.11 This probe consisted of a β-lactam moiety linking a fluorophore to a fluorescence 
quencher. After cleavage of the β-lactam ring by β-lactamase, an enzyme endogenously produced 
by M. tuberculosis and some other bacteria, the fluorophore was separated from the quencher and 
emitted a signal. Although such smart activatable probes can potentially deliver higher TBRs 
in optical imaging, not all bacteria produce β-lactamase. Additionally, none of the dyes used in 
this study have undergone extensive animal toxicity studies, which limits their translational use.
We have shown here that vanco-800CW enables specific detection of the main Gram-positive 
bacteria that cause soft tissue and biomaterial-associated infections. Treatment of the latter is 
most effective during early stages, before extensive biofilm formation has occurred. Therefore, 
early detection could improve patient outcome and reduce healthcare costs. Vanco-800CW 
could be ideally used in combination with a multispectral near-infrared clinical imaging camera 
as exemplified in our human post-mortem implant experiments. This provides high TBRs due to 
reduced tissue auto-fluorescence and optimal tissue penetration.20
In vitro analyses showed highly specific binding of vanco-800CW to all tested clinical BAI isolates 
of S. aureus and coagulase-negative staphylococci. Variable detection of less common causes of 
BAI was observed, with good detection of Streptococcus and Dermabacter species and a lesser 
detection of corynebacteria. As expected, Gram-negative bacteria like E. coli or P. aeruginosa were 
not detectable. For S. aureus, the in vitro limit of detection was estimated to be 2·5x104 bacteria 
per mm3. Notably, we were able to isolate ~6·4 x 107 CFU of S. aureus from ~300-400 mg 
homogenized tissue taken from the imaged myositic tissue. It has been shown that the majority 
of soft tissue infections and abscesses caused by Gram-positive cocci contain more than 107 CFU/
mL, corresponding to 104 CFU/mm3.21 Therefore, vanco-800CW should allow detection of the 
vast majority of clinically relevant Gram-positive bacterial infections in vivo, making it more 
widely applicable than prothrombin-AF680 or β-lactamase-specific smart activatable probes. 
The in vivo efficacy of vanco-800CW was demonstrated in a mouse model of myositis induced 
by bioluminescent S. aureus. The vanco-800CW-specific signal colocalized with the intrinsic 
bioluminescence of the staphylococcal strain and was able to discriminate S. aureus-induced 
infection from E. coli-induced infection or sterile inflammation. In terms of biodistribution, 
strong fluorescence signals were detected in the kidney and urine; a minor signal was detected 
in the liver. 
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These signals suggested that vanco-800CW was metabolized by the liver into renally excreted 
products. It is long known that native vancomycin is mainly eliminated from the body by renal 
excretion.13 Unconjugated IRDye 800CW is also known to be excreted by the kidneys.14,15 
Importantly, the signals emitted from infection sites were clearly distinguishable from the kidney, 
bladder and liver signals. No significant signal was detected in other organs. As expected, no 
bowel signal was observed since vancomycin is unable to penetrate the bowel. Therefore, the gut 
microbiota should not interfere with imaging of bacterial infections. 
A post-mortem study using contaminated implants was performed as a clinical simulation to 
assess the feasibility of BAI detection. S. epidermidis-containing implants stained with vanco-
800CW were visible through the cadavers’ skin. Furthermore, vanco-800CW-labeled S. aureus 
or S. epidermidis cells spotted onto implanted paper strips were detectable at levels of 1·25x108 or 
1·5x108 CFU/mm2, respectively. Although this detection limit may seem high, it should be noted 
that the bacteria were present in a two-dimensional layer covered by ~8 mm of sutured tissue, 
which mimics the situation in an early-stage biofilm. In a progressive BAI, bacteria will grow 
in three dimensions, which is likely to be more readily detectable, as was the case in our mouse 
myositis model. Altogether, our findings imply that detection of early-stage biofilm formation on 
implants using vanco-800CW is feasible. Nevertheless, limited tissue penetration might pose a 
challenge in detecting deeper infections arising from hip prosthesis or endocarditis, as the current 
maximum penetration depth of near-infrared fluorescence is around one centimeter.22 Another 
challenge could be that the vascularity around synthetic joint implants may be limited. However, 
new techniques such as opto-acoustic imaging may allow deeper tissue penetration to a depth of 
several centimeters and at greater sensitivity, potentially allowing detection of bacterial infections 
deeper seated in the human body.22 
Vancomycin has been extensively applied in the clinic for over fifty years. Using this clinically 
approved drug as a targeting agent coupled with IRDye 800CW, which has undergone GLP 
toxicity testing and is being used in a clinical trial (NCT01508572, UMCG), is likely to expedite 
the translation of the vanco-800CW agent into clinical use after appropriate toxicity testing and 
GMP production according to Good Clinical Practice guidelines.23 In our mouse model, a strong 
fluorescence signal emanated from the site of bacterial infection with an intravenous dose of 
1mg/kg vanco-800CW, which is ten-fold lower than the therapeutic dose in humans 
(10 mg/kg). Besides, for most clinical imaging indications, only one single bolus injection 
of imaging agent will be administered. Accordingly, unwanted side effects such as toxicity or 
induction of vancomycin resistance in bacteria are unlikely. 
In summary, we have shown that specific detection of Gram-positive bacterial infections can 
be achieved with optical imaging using vanco-800CW in vivo in a mouse myositis model. We 
have also tested vanco-800CW in a human post-mortem BAI implant model, with the intent of 
developing a novel bedside tool for detecting soft tissue infections and BAI. Based on the present 
findings, we consider vanco-800CW as a very promising clinical optical imaging agent for 
detection of Gram-positive bacterial infections. Furthermore, we anticipate that optical imaging 
will gain a place in day-to-day clinical practice in the fight against severe bacterial infections. 
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Supplementary Figure S1. In vitro determination of the detection limit of vanco-800CW. (a) Specifi city of vanco-
800CW for diff erent clinical bacterial isolates. Th e in vitro imaging analyses were performed using an IVIS Spectrum 
(Caliper LS, Hopkinton MA, USA; excitation 710 nm, emission 800 nm, acquisition time 1-60 s, binning 4, F-stop 1 or 
2, fi eld of view 12·8). Th e cutoff  for a positive result was 105 net counts. (b) Determination of the lower limit of detection 
of S. aureus per mm3 by fl uorescence imaging. Th e cutoff  for a positive reaction was set at 1·2x104 net counts. Open dots 
(○) represent six replicate measurements, with the mean depicted by fi lled squares (■). 
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Supplementary Figure S2. In vivo imaging of bacterial myositis. Bioluminescent S. aureus Xen29 was used to induce 
a hind limb myositis in NMRI mice by injection of 5x107 CFU per mouse. Two days post-infection, 1 mg/kg vanco-
800CW was intravenously administered to infected mice and non-infected mice. After 24 h, infected and non-infected 
mice were euthanized and imaged with an IVIS Lumina II to detect fl uorescence (excitation 710 nm; fi lter: ICG; 
acquisition time 1-10 s, binning 2, F-stop 2, FOV12·5) and bacterial bioluminescence (excitation block, fi lter open, 
acquisition time 300 s, binning 2, F-stop 1, FOV12·5). (a) Upper panel, left side: Bioluminescence imaging of a mouse 
with S. aureus-induced myositis after injection with vanco-800CW (+/+); upper panel, right side: uninfected mouse 
after injection with vanco-800CW (-/+). Lower panel, left: NIR detection of S. aureus (Xen29)-induced myositis after 
injection with vanco-800CW; lower panel, right side: uninfected mouse after injection with vanco-800CW. (b) Excised 
muscle tissue of infected (left) and non-infected mice (right) as in panel a. (c) Light microscopy of infected muscle tissue 
(Giemsa staining). An individual S. aureus cell is indicated by the black arrow. (d) Fluorescence microscopy of infected 
muscle tissue after fl uorescent in situ hybridization (FISH) with an EUB-fl uorescein isothiocyanate (FITC) probe. An 
individual S. aureus cell is indicated by the red arrow.












Supplementary Figure S3. Bladder and urine signals. (a) Ventral images of a mouse 24 h after administration of 1.8 
mg/kg vanco-800CW were recorded with the IVIS SpectrumCT Imaging System as in Figure 2a (excitation 745 nm, 
emission 840 nm, FOV 12.8 cm, f-stop 2, 0.5 s acquisition time). A clear fl uorescence signal was observed at the position 
of the bladder (left image), which disappeared upon bladder draining (right image). (b) Upon euthanasia, urine was 
collected from mice treated with or without vanco-800CW and imaged with the IVIS Spectrum (excitation 710 nm, 
emission 800 nm; acquisition time 60 s; binning 4; F-stop 1; FOV 12·8). Left: urine from a mouse intravenously injected 
with vanco-800CW (+). Right: urine from a mouse without vanco-800CW (-).














Supplementary Figure S4. Co-registration of bioluminescence and fl uorescence. Micro-Computed Tomography (μ-
CT) imaging of a mouse with E. coli (Xen16)-induced myositis in the left hind limb and S. aureus (Xen36)-induced 
myositis in the right hind limb 24 h after intravenous administration of 1.8 mg/kg vanco-800CW. Imaging was 
performed as described for Figure 2c. Left panel, bioluminescence (rainbow scale); middle panel, fl uorescence (red-yellow 
scale; excitation 745 nm, emission 800 nm); right panel, bioluminescence (BLI) and fl uorescence (FLI) co-registration. 
A fl uorescent signal from the bladder is detectable behind the spine (middle panel).
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Supplementary Figure S5. Bioluminescence of S. aureus Xen29 during growth in vitro. Overnight cultures of S. 
aureus Xen29 were diluted into fresh TSB medium to an OD600 of 0.05 and grown for 24 h at 37°C under vigorous 
shaking (220 rpm). Samples were collected at hourly intervals for the fi rst 8 h of growth and after 24 h to measure the 
bioluminescence (solid line) and the optical densitiy at 600 nm (OD600, dashed line). After 7-8 h, when the cells entered 
the stationary growth phase, bioluminescence was no longer observed. Data represent the mean of three independent 
experiments ± the standard deviation (SD). Bioluminescence was measured with a luminometer LB 9501 (Berthold, Bad 
Wildbad, Germany).
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Supplementary Figure S6. Microscopic analysis of bacterial myositis. A mouse with S. aureus (Xen36)-induced 
myositis in the right hind limb and E. coli (Xen16)-induced myositis in the left hind limb was intravenously administered 
1.8 mg/kg vanco-800CW as shown in Figure 2 of the main manuscript. 24 h after the vanco-800CW administration, the 
mouse was imaged (Figures 2 and S4) and sacrifi ced. Fluorescence microscopy of infected muscle tissue was performed as 
in Figure 2d. Slides with fi xed muscle tissue were prepared for NIR fl uorescence microscopy, as described in the Methods 
section. Th e left panels show slides with 5µm-thick tissue sections as imaged with the IVIS SpectrumCT (excitation 745 
nm, emission 800 nm, FOV 6.6 cm, f2, 50 s acquisition time). Note the strong fl uorescent signal of tissue infected with 
S. aureus (upper left panel) in contrast to the background noise observed for the tissue infected with E. coli (lower left 
panel). Clusters of vanco-800CW-labeled Gram-positive cocci are detectable upon fl uorescence microscopy of the S. 
aureus-infected tissue (upper right panel; red stain), while no vanco-800CW-labled bacteria are detectable in the tissue 
infected with E. coli (lower right panel). DAPI-stained cell nuclei are labeled green. Settings for fl uorescence microscopy: 
vanco-800CW - excitation 710 nm, emission >785 nm; DAPI - excitation 360 nm and emission >458 nm.























































Supplementary Figure S7. Tissue distribution of vanco-800CW. 
Th e diagram shows the intensities of the fl uorescence signals of ex vivo analyzed tissues 24 h after administration of vanco-
800CW (1 mg/kg) to mice with S. aureus (Xen29)-induced myositis. Fluorescence intensities were determined with the 
IVIS Lumina II as described for Figure S2 (n=5; 5x107 CFU per mouse). Mice were sacrifi ced, and muscle tissue and 
peripheral organs were harvested aseptically. Note that only muscle tissue was infected, while all other examined tissues 
remained non-infected. Mean signal intensity (-)± 2SD (♦) is given.
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Supplementary Figure S8. IVIS Spectrum analysis of the human post-mortem implant model. 
Two osteosynthesis plates (1 and 3) bearing S. epidermidis biofi lms and one plate without biofi lm (2) were surgically 
applied onto the fi bula of a post-mortem ankle. Plates 1 and 2 were treated with vanco-800CW prior attachment to 
the fi bula. Before imaging with a clinical camera system, the fl uorescence signal from plate 1 was imaged with the IVIS 
Spectrum (excitation: 710 nm, emission: 800 nm, acquisition time 5 s, binning 4, F-stop 2, FOV 21·2). Th e plates 
without biofi lm or vanco-800CW treatment (2 and 3, respectively) showed no fl uorescence signal.
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Supplementary Figure S9. UV-Vis spectral overlay of diluted aliquots from preparative HPLC purifi cation of de 
novo synthesized vanco-800CW. 
LLC-652-079 and LLC-652-079B denote consecutively collected HPLC fractions. Net absorbances were obtained by 
background subtraction over the range of 900 to 910 nm. Average net absorbances were used to determine the product 
concentration in respective HPLC fractions.
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Supplementary Figure S10. Low-Resolution Mass Spectrum (electrospray ionization) of purifi ed de novo 
synthesized vanco-800CW. 
Th e purifi ed product was more readily detected in the negative rather than positive ion channel. Th e strongest m/z signal 
was deconvoluted by the instrument software and found to correspond to the triple-anion of the parent compound.
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Supplementary Figure S11. Analytical HPLC data for purifi ed vanco-800CW. 
Th e compound shows absorbance signals at 780, 680, 280, and 230 nm, indicating the presence of IRDye 800CW. Th e 
peak height ratios of the absorbance intensities are consistent with the full UV-Vis spectrum in Supplementary Fig. S9.
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Supplementary Figure S12. Analytical HPLC of unlabeled vancomycin. 
Absorbance signals were only detectable at 280 and 230 nm, indicating the absence of IRDye 800CW. Th e unlabeled 
ligand eluted at an earlier retention time (tR = 4.10 minutes) than the dye-labeled compound (see Supplementary Fig. 
S11; tR = 5.58 minutes). Th is was expected as the dye confers additional hydrophobic surface area to interact with the 
reverse-phase column.




Supplementary Figure S13. Dose-response analysis for S. aureus limb myositis in mice. 
Bioluminescent S. aureus Xen29 was used to induce a hind limb myositis in immunocompetent NMRI mice by injection 
with 1x106, 1x107 or 1x108 CFU per mouse. Bioluminescent images were taken at 2 h, and 1 to 6 days (d) post infection, 
using the IVIS Lumina II with exposure time of 60 sec and medium binning. Radiance is indicated in p/sec/cm2/sr. Th e 
depicted mice are representative for the particular cohorts (n =3). Th e minimal dose to reproducibly induce a hind limb 
myositis was determined at 5x107 CFU. 
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Imaging has since long an established place in the surgical work field. However, the use of 
targeted imaging is relatively new and rapidly developing. Targeted imaging could substantially 
increase the sensitivity and specificity of detection of disease. Fluorescence imaging, and especially 
near-infrared fluorescence (NIRF) imaging, is an attractive modality for targeted imaging, due 
to its high resolution, high signal-to-background ratio and real-time applicability. This thesis 
provides an overview of the current status of NIRF imaging in surgery for colorectal and ovarian 
peritoneal carcinomatosis (PC) and endometriosis (part I) and, in the peri-operative setting, for 
bacterial infections (part II). The focus has been put on the identification of potential targets 
and the investigation of the feasibility of targeted fluorescence imaging using animal models. The 
first chapter of part I, gives an outline of the necessity of intraoperative tumor-targeted imaging 
in peritoneal disseminated colorectal carcinoma (peritoneal carcinomatosis; PC), and provides a 
systematic search to find the most ideal biomarkers for targeting (chapter 2). For this purpose, 
the ‘target selection criteria’ (TASC) scoring system is presented that allows the evaluation of a 
potential target based on: I) extracellular biomarker localization, either on the cell membrane 
or in close proximity of the tumor cell; II) expression pattern; III) tumor-to-healthy tissue ratio 
(T/N); IV) percentage of positive tumors; V) reported successful use of the biomarker in in vivo 
imaging studies; VI) enzymatic activity; and VII) internalization. It is proposed that a potential 
target should score preferably 18 points or higher, with a maximum score of 22 points. Future 
research should prove whether TASC is indeed useful and whether further calibration of TASC 
might be required.
Based on a previously published study, out of 128 genes known to be upregulated in colorectal 
cancer, 16 were selected that encode proteins known to be present at elevated levels as judged by 
immunohistochemistry (IHC). These 16 proteins were considered as potential targets for targeted 
imaging approaches. Another 13 proteins were added to this list, because they had already been 
described as suitable imaging targets in the literature. Of these 29 proteins, the epithelial cell 
adhesion molecule (EpCAM), CXC chemokine receptor 4 (CXCR4), mucin 1 (Muc1), matrix 
metalloproteinases (MMPs), epidermal growth factor receptor (EGFR), and carcinoembryonic 
antigen (CEA) scored best in TASC and were thus identified as the most promising candidate 
targets for imaging of colorectal carcinoma.
Biomarker expression has mainly been investigated for colorectal carcinoma in general, and to 
a lesser extent in the specific situation of colorectal PC. Therefore, colorectal PC samples of 
14 patients were immunohistochemically analyzed for expression of CXCR4, EGFR, EpCAM, 
folate receptor-alpha (FR-α), hypoxia inducible factor-1alpha (HIF-1α) and vascular endothelial 
growth factor-A (VEGF-A) as described in chapter 3 of this thesis. For the biomarkers with 
most optimal expression in patient tissue, i.e. CXCR4, EGFR, EpCAM and VEGF-A, all having 
TASC scores of 17 or higher, targeted imaging was tested in vivo using intravenously administered 
antibody-based fluorescent probes in mice with colorectal PC xenografts. CXCR4, EpCAM and 
VEGF-A appeared to be the most promising biomarkers for targeted imaging in colorectal PC, 
according to their TASC scores and in vivo feasibility.
Chapter 4 provides an introduction to the concept of intraoperative fluorescence imaging in 
epithelial ovarian cancer (EOC). Emphasis is put on target finding in EOC with special focus on 
those targets that are closest to clinical introduction. Folate receptor-alpha (FR-α) was found to 
be the most promising target for clinical fluorescence imaging in EOC. FR-α is upregulated in 
the vast majority of serous ovarian tumors (72-97%), both in primary tumors and in metastatic 
tissue, with hardly any expression in healthy tissue. 
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Furthermore, FR-α is easily targeted by folate, which is known to have little toxicity, and the 
clinically approved therapeutic FR-α-specific antibody Farletuzumab (MORAb-003) is available. 
At the time, FR-α was the only marker for which targeted fluorescence imaging in patients had 
been shown feasible. CXCR4, EGFR and VEGF are also upregulated in EOC and clinically 
approved ligands are available. These markers have all been imaged previously in vivo, but are not 
yet investigated for fluorescence imaging in patients.1 MMPs show overexpression in EOC and 
preclinical imaging studies have been conducted using these markers.1 However, MMP-targeted 
probes are not yet suitable for clinical use which, for now, complicates clinical MMP-targeted 
imaging. 
As discussed in chapter 4, FR-α is one of the most suitable targets for intraoperative fluorescence 
imaging in patients with EOC. At the start of the research presented in this thesis, it was known 
that FR-α is expressed in the vast majority of EOC, but little was known about FR-α expression 
after chemotherapy. Since many patients with ovarian cancer are treated with chemotherapy 
before surgery, the FR-α status after chemotherapy is of major relevance in intraoperative FR-
α-targeting. Therefore, the influence of chemotherapy on FR-α expression in epithelial ovarian 
cancer (EOC) was investigated as described in chapter 5. Tissue microarrays (TMAs) of 361 
patients with EOC were immunohistochemically analyzed for FR-α expression and this was 
correlated to previous chemotherapeutic treatment. FR-α expression was found in 82% of the 
serous carcinomas and 39% of the non-serous carcinomas, consistent with other studies. FR-α 
expression was shown not to be altered by chemotherapy, and the FR-α status was not related to 
overall patient survival.
Although FR-α was identified as a potential target for imaging in at least EOC, little was known 
regarding expression of folate receptor-beta (FR-β) in solid tumors. FR-β is mainly known 
for its expression in activated macrophages and hematopoietic cancers and serves as a target 
for inflammatory diseases, such as rheumatoid arthritis and atherosclerotic plaques.2,3 It was 
hypothesized that FR-β expression besides FR-α upregulation in solid tumors could broaden 
the indication of FR-targeted imaging probes in cancer. Therefore, as reported in chapter 6, 
the FR-β status was assessed for 361 ovarian cancer TMAs, 449 breast cancer TMAs and 20 
samples of colorectal PC using IHC. Additionally, 25 samples of diverticulitis were investigated 
as positive controls. FR-β expression was found in 21% of the ovarian cancer samples, 9% of the 
breast cancer samples and 55% of the samples of colorectal PC. In most cases, the expression was 
weak and it was, therefore, concluded that FR-β is probably of limited use in targeted imaging 
of solid tumors.
Apart from malignant disease, intraoperative imaging could also be of substantial use in benign 
conditions, such as endometriosis, where optimal surgical resection of lesions is also pivotal. 
With this goal, potential biomarkers for targeted imaging in endometriosis were investigated and 
the results are documented in chapter 7. Tissue samples of 18 patients were analyzed using IHC. 
Expression of CXCR4, EpCAM, estrogen receptor (ER), FR-α, HIF-1α, progesterone receptor 
(PR) and VEGF-A were investigated and these biomarkers were scored using TASC. EpCAM 
scored best with a TASC score of 21 and 83% of moderate to strong expression in the investigated 
samples. CXCR4 scored 18 points, still sufficient for potential imaging qualities, and expression 
was found in all tissue samples (18/18). However, moderate to strong expression was found in 
only 44% of the samples and equal staining intensity was found in surrounding tissue, likely 
limiting the quality of imaging. VEGF-A and FR-α both scored 17 points, and these biomarkers 
are especially attractive since clinically approved fluorescent probes are available. However, the 
intensity of VEGF-A and FR-α expression was mainly weak. Future research will have to prove 
whether the signal-to-background ratio is still high enough for adequate intraoperative imaging. 
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The other markers scored less than 17 points, and were therefore not considered as potentially 
useful markers for targeting.
In part II of this thesis, translation of fluorescence imaging was made to bacterial infections in 
the surgical work field.
To provide an introduction to the concept of bacteria-targeted imaging, the current status for 
both fluorescence imaging and radionuclide-mediated imaging is discussed in chapter 8. Most 
advanced is the use of the radiolabeled antibiotic ciprofloxacin, i.e. 99mTechnetium –ciprofloxacin 
(99mTc-ciprofloxacin; Infecton©) for imaging of bacterial infections. However, it is doubtful 
whether 99mTc-ciprofloxacin is strictly bacteria-specific, since this agent had a specificity of 
only 82% in a large clinical trial, and even less in smaller trials. Other targeting agents may 
be more promising, such as the radiolabeled form of the antimicrobial peptide ubiquicidin or 
the nucleoside analogue fialuridine (FIAU). However, specificity of these agents has yet to be 
proven in larger clinical trials. Bacteria-targeted fluorescence imaging is still in its infancy and 
has thus far not been performed in patients. However, this concept seems promising according 
to a limited number of animal studies, using imaging agents based on I) maltodextrin which 
is taken up by bacteria as a metabolic agent, II) prothrombin which targets the coagulases of 
Staphylococcus aureus, III) a beta-lactam which acts as a substrate for the enzyme β-lactamase, and 
IV) Bis(Zinc(II)-dicolylamine) that binds to the negatively charged cell membranes of bacteria.
To specifically image Gram-positive bacterial infections in vivo, the antibiotic vancomycin was 
labeled with the NIRF fluorophore IRDye800CW (vanco-800CW) as reported in chapter 
9.4 This probe allowed the specific detection of Staphylococcus aureus infection over sterile 
inflammation or Gram-negative bacterial infection in mice. Furthermore, biomaterial infection 
could be detected in a post-mortem model using vanco-800CW in combination with a clinically 
approved charge-coupled device (CCD) camera. Translation of this probe to clinical use is 
expected to be feasible, since vancomycin and IRDye800CW both have shown to be non-toxic 
to patients.4
conclusIons
This thesis describes the application of targeted fluorescence imaging in surgery with the emphasis 
on target finding and in vivo feasibility of fluorescence imaging in cancer surgery and the fight 
against bacterial infections.
Target finding for intraoperative imaging
The characteristics that are of importance to make a particular biomarker a suitable target for 
imaging were aggregated in the TArget Selection Criteria (TASC) scheme as presented in this 
thesis (chapter 2), to provide a guideline in the selection of potential targets for imaging in 
malignancies. 
In colorectal PC, the CXC chemokine receptor 4 (CXCR4), epidermal growth factor receptor 
(EGFR), epithelial cell adhesion molecule (EpCAM) and vascular endothelial growth factor-A 
(VEGF-A) yielded a TASC score of 17 or higher, making them attractive for imaging (chapter 
3). In addition to a high TASC score, the availability of a clinically approved ligand is attractive, 
allowing easy conversion of the ligand into an imaging agent suitable for safe clinical introduction. 
For CXCR4, EGFR, EpCAM and VEGF-A, clinically approved ligands are indeed available, 
such as AMD3100, cetuximab, edrecolomab and bevacizumab, respectively. 
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Intraoperative fluorescence imaging of these markers was shown feasible in an intra-abdominal 
colorectal xenograft model in mice (chapter 3). Other studies reported successful targeting of 
CXCR4, EGFR and VEGF-A in vivo using probes based on the respective clinically approved 
ligands.5-7 Currently, fluorescently labeled bevacizumab (bevacizumab-IRDye800CW) is in 
clinical trial in patients with breast cancer. It is therefore expected that a clinical trial testing 
VEGF-A targeting in colorectal PC, using bevacizumab-IRDye800CW, will be executed in the 
near future (www.clinicaltrials.gov NCT01508572).
Not investigated in the present PhD research, but a highly promising imaging target in colorectal 
cancer is the carcinoembryonic antigen (CEA). This marker has a TASC score of 19 points and, 
in patients, radionuclide-mediated imaging has been described to be successful (chapter 2).8 
Specifically, Kaushal et al. showed feasibility of intraoperative fluorescence imaging of CEA in 
mice.9
In ovarian PC, the folate receptor-alpha (FR-α) seems the most suitable target, with the shortest 
path to clinical introduction (chapter 4). Expression of FR-α was found in the vast majority of 
the serous epithelial ovarian carcinomas and chemotherapy treatment did not seem to alter the 
expression (chapter 5). Indeed, targeted intraoperative imaging of FR-α was proven to be feasible 
in patients with ovarian PC.10 No major role was found for the folate receptor-beta (FR-β) in 
colorectal or ovarian PC (chapter 6).
EpCAM, FR-α and VEGF-A might be attractive targets for imaging in endometriosis (chapter 
7). Fluorescent probes directed to FR-α and to VEGF-A are clinically available, and could be 
translated to this disease (www.clinicaltrials.gov NCT01508572).10
Peri-operative imaging of bacterial infections
Compared to oncology, targeted imaging in bacterial imaging is still lagging behind. To date, 
99mTechnetium-ciprofloxacin is the only bacterial-targeted imaging agent that was proven to be 
reasonably sensitive and specific in a large clinical trial.11 However, other promising bacteria-
targeted radionuclide-mediated imaging agents are emerging, such as ubiquicidin- and fialuridine 
(FIAU)-based imaging agents (chapter 8). In contrast to radionuclide-mediated imaging, 
fluorescence imaging in bacterial infections is described in only a few animal studies, but with 
promising results.12-15 At the start of the present PhD research, no bacteria-targeted fluorescence 
imaging agent had been described that can easily be translated to clinical use. Therefore, the 
possible use of vancomycin-IRDye800CW (vanco-800CW) was explored for the in vivo 
detection of Gram-positive bacterial infections (chapter 9). From the results it is concluded that 
vanco-800CW allows the specific detection of staphylococcal infection in mice and in a human 
post-mortem model for biomaterial infection using a clinically approved CCD-camera. Since 
both vancomycin and the IRDye800CW are clinically approved compounds, it is anticipated 
that vanco-800CW can also be safely introduced for clinical use. However, this awaits the good 
manufacturing practice (GMP)/good laboratory practice (GLP) synthesis of vanco-800CW and 
the necessary toxicity testing.
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Future perspectIVes: technIcal adVances In ImagIng 
optImIZatIon
The major limitation of fluorescence imaging is that this type of imaging is currently restricted 
to surface imaging, since the available CCD cameras allow detection of signal to a maximum 
depth of approximately 1-2 cm. Recently however, a new technique was described in the form of 
optoacoustics, allowing detection of fluorescence signals to a maximum depth of 11 cm.16 This 
new approach will significantly enhance the detection of disease in patients, and could be of 
substantial use especially in the peri-operative detection of bacterial infections. 
The currently investigated approaches for intraoperative fluorescence imaging make use of 
a single probe. However, it is conceivable that in the future probes might not target a single 
receptor specifically expressed by tumors or bacteria. Instead, a cocktail of probes could be 
administered targeting multiple receptors for a more complete coverage of tumor or infected 
tissue. Alternatively, probes could be designed that emit both a fluorescent signal and a second 
signal that can be imaged through another modality, for example positron emission tomography 
(PET) or magnetic resonance imaging (MRI).17,18 The use of such multimodality probes would 
allow pre-operative staging and intraoperative detection of tumor and infected tissue, while the 
patient only needs to be injected with one single probe. 
Finally, the efficiency of fluorescence imaging might be substantially optimized by the use of 
“smart” activatable probes. In this concept, a quenching molecule is brought in close proximity 
to the targeted fluorophore. This will quench the fluorescent signal until the fluorophore is 
separated from the quencher upon encountering its target. In this way, greater T/N ratios can be 
achieved. The use of smart activatable probes has been described for tumor targeting as well as 
for bacterial targeting.14,19
In conclusion, targeted fluorescence imaging can significantly aid in intraoperative disease 
detection and peri-operative diagnostics. Selection of suitable targets is of crucial importance 
and, for this purpose, several factors should be taken into account. In oncology, clinical testing 
of intraoperative imaging is currently in progress for ovarian PC and on the verge of being tested 
in colorectal PC. Translations to other diseases will most likely be made soon. Furthermore, peri-
operative targeted fluorescence imaging has a high potential for improved detection of bacterial 
infections. As documented in this thesis, vanco-800CW is a promising candidate for this goal, 
but many others might follow. Altogether, it can be concluded that the future of targeted 
fluorescence imaging appears bright and shiny.
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In de chirurgie wordt een rijke verscheidenheid aan beeldvormingstechnieken gebruikt, zowel 
voor diagnostiek voorafgaand aan een operatie, als begeleidende beeldvorming tijdens een 
operatie (intra-operatief ) en beeldvorming voor follow-up doeleinden na operatie. Voorbeelden 
van veelgebruikte beeldvormingstechnieken in de kliniek zijn standaard röntgendiagnostiek, 
computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography 
(PET), single-photon emission computed tomography (SPECT) en echografie. Deze technieken 
zijn over de jaren sterk verbeterd en hebben elk hun eigen voordelen en beperkingen. Geen van 
deze beeldvormende technieken is echter in staat om specifiek tumorweefsel of bacteriële infecties 
van gezond of overliggend weefsel te onderscheiden of zelfs van fysiologische processen, zoals 
wondgenezing na een operatie. Er is daarom dringend behoefte aan een beeldvormingstechniek 
die betrouwbaar, gericht en met hoge gevoeligheid verschillende ziekteprocessen en gezonde 
weefsels van elkaar kan onderscheiden.
Vergeleken met de peri-operatieve beeldvorming voor of na een operatie staat de intra-operatieve 
beeldvorming tijdens operaties nog in de kinderschoenen. Tot op heden vertrouwt de chirurg 
met name op direct zichtbare en voelbare veranderingen in het lichaam van de patiënt. Hierdoor 
is het vaak lastig om tijdens operaties bij patiënten met kanker de tumorgrenzen betrouwbaar 
vast te stellen en ‘microscopische ziekte’, bijvoorbeeld in lymfeklieren, wordt dientengevolge 
bij het verwijderen van een tumor vaak gemist. Door middel van vriescoupes is het weliswaar 
mogelijk om tijdens een operatie te beoordelen of de resectie radicaal is geweest, maar dit is een 
indirecte methode die enkel informatie geeft over het kleine gedeelte van de snijvlakken waaruit 
een biopsie genomen is. De ontwikkeling van methoden om beeldvorming tijdens een operatie 
te verbeteren is daarom zeer gewenst, aangezien dit kan resulteren in een betere detectie van 
tumoren of geïnfecteerde weefsels. Dit zou dan kunnen leiden tot een preciezere en meer radicale 
resectie, wat uiteindelijk een betere prognose voor de patiënt zou kunnen opleveren.
Doelgerichte fluorescentiebeeldvorming biedt interessante mogelijkheden om de peri-operatieve 
diagnostiek en de intra-operatieve precisie in de chirurgie te verbeteren. Fluorescentiebeeldvorming, 
ook wel optische beeldvorming genoemd, is een elegante beeldvormingstechniek die zich op het 
moment snel ontwikkelt. Het onderliggende principe is als volgt: elektronen in een fluorescent 
molecuul (een zogenaamde fluorofoor) raken geëxciteerd wanneer dit molecuul blootgesteld 
wordt aan licht van een bepaalde golflengte. Wanneer de geëxciteerde elektronen vervolgens 
terugvallen in hun normale energiestaat, zendt het molecuul licht uit van een net iets hogere 
golflengte. Dit licht kan worden opgevangen met een speciale camera. Hoewel menselijk weefsel 
van nature auto-fluorescent is (vooral in het spectrum van 400-600 nm) kan met bepaalde sterke 
fluoroforen die licht uitzenden van een geschikte golflente (vooral in het nabij-infrarode spectrum 
tussen 700-1000 nm) het uitgezonden signaal onderscheiden worden van de fluorescentie van 
het omliggende weefsel. Daarnaast heeft het signaal van nabij-infrarood fluorescente moleculen 
een optimale weefselpenetratie.1 Verder heeft fluorescentiebeeldvorming een aantal gunstige 
eigenschappen in vergelijking tot andere beeldvormende technieken, zoals een hoge resolutie, 
de afwezigheid van radioactieve straling, relatief lage kosten en de mogelijkheid om real-time 
beeldvorming te kunnen doen.1
Fluorescentiebeeldvorming is met name goed te gebruiken voor beeldvorming van oppervlakkig 
gelegen structuren, bijvoorbeeld tijdens operaties waarbij de chirurg het zieke weefsel benadert door 
het omliggende weefsel in te snijden of te verwijderen.2 Het nadeel van fluorescentiebeeldvorming 
is dat het fluorescente signaal slechts door maximaal 1-2 cm weefsel is waar te nemen. 
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Ondanks dat er veel fluoroforen beschikbaar zijn, zijn er slechts enkele goedgekeurd en getest 
voor gebruik in patiënten, waaronder fluoresceïne isothiocyanaat (FITC; 518 nm), indocyanine 
groen (ICG; 790 nm) en IRDye® 800CW (800 nm).
In doelgerichte beeldvorming wordt een contrastmiddel gebruikt, dat specifiek opgenomen 
of gebonden wordt door het zieke weefsel. Op deze manier is het mogelijk om specifiek 
ziekteprocessen te identificeren en te lokaliseren. Een specifiek en doelgericht contrastmiddel 
kan gevormd worden door een beeldvormingsmolecuul (bijvoorbeeld een radionuclide of een 
fluorofoor) te conjugeren aan een molecuul, dat specifiek bindt aan een kenmerkende target voor 
een bepaald ziekteproces. De target kan bijvoorbeeld een receptoreiwit op een kankercel zijn of 
een specifiek molecuul in de celwand van een bacterie.
Doelgerichte beeldvorming kan zowel met fluorescentiebeeldvorming als met PET/SPECT, CT, 
MRI en echografie uitgevoerd worden.3-5 De sensitiviteit en de specificiteit hangt af van het 
contrastmiddel en het detectieapparaat, maar vooral ook van de target die gekozen wordt. De 
mate en het patroon van de expressie van een gekozen target in ziek en gezond weefsel hebben 
sterke invloed op de zogenaamde “target-to-normal tissue ratio” (T/N ratio) van het signaal. Hoe 
hoger deze ratio, des te sterker de signaal/ruis verhouding. Derhalve is het belangrijk de target te 
identificeren die de beste T/N ratio oplevert. 
Doelgerichte fluorescentiebeeldvorming is zowel peri-operatief als intra-operatief te gebruiken. 
Met behulp van fluorescent gelabelde stoffen die specifiek gericht zijn op targets die verhoogd tot 
expressie komen bij ziekte en een gevoelige camera die het uitgezonden signaal kan opvangen en 
omzetten in een beeld op een beeldscherm, kan een behandelend arts van specifieke informatie 
over de locatie van het zieke weefsel worden voorzien. Tijdens de operatie kan de chirurg zijn 
visuele informatie op deze manier zodanig uitbreiden, dat hij tumor-spots met een grootte van 
0.3 mm kan waarnemen.6,7 Recent is de werk- en haalbaarheid van dit concept aangetoond 
in patiënten met eierstokkanker en klinische implementatie is bewerkstelligd voor patiënten 
met blaaskanker en in de hersenchirurgie.8-11 Peri-operatief kan het gebruik van doelgerichte 
fluorescentiebeeldvorming helpen om op een niet-invasieve manier infecties te detecteren. Door 
de hoge resolutie van de fluorescentie en de hoge sensitiviteit en specificiteit van het doelgerichte 
contrastmiddel, zouden infecties eerder opgespoord kunnen worden dan nu het geval is, zodat 
patiënten sneller en efficiënter behandeld kunnen worden en de schade aan gezond weefsel 
minimaal blijft.
samenVattIng Van dIt proeFschrIFt
In dit proefschrift wordt een overzicht gegeven van de huidige status van doelgerichte 
fluorescentiebeeldvorming voor de operatieve behandeling van darmkanker, eierstokkanker 
en endometriose (deel I) en voor de peri- en intra-operatieve detectie van bacteriële infecties 
(deel II). Het beschreven onderzoek is met name gericht op de identificatie van nieuwe targets 
voor doelgerichte beeldvorming en op de preklinische ontwikkeling van nieuwe fluorescente 
contrastmiddelen met als uiteindelijk doel deze in de kliniek te gaan gebruiken. Het eerste 
hoofdstuk van deel I (hoofdstuk 2) beschrijft de noodzaak van intra-operatieve doelgerichte 
fluorescentiebeeldvorming bij patiënten met uitgezaaide darmkanker in de buikholte (peritonitis 
carcinomatosa; PC). Voor de systematische identificatie van geschikte darmkanker-targets bij PC 
zijn zogenaamde TArget Selectie Criteria (TASC) opgesteld die ook gebruikt kunnen worden 
om potentiële targets voor beeldvorming van andere ziekteprocessen snel en effectief op hun 
geschiktheid te beoordelen. 
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TASC beoordeelt targets op: I) een extracellulaire lokalisatie; II) het patroon van expressie; III) de 
tumor-normaal weefsel ratio; IV) het percentage positieve tumoren bij verschillende patiënten; 
V) een eerdere beschrijving van succesvol gebruik in beeldvorming; VI) enzymatische activiteit 
van de target; en VII) internalisatie van het molecuul na binding aan de target. Een veelbelovende 
target zou 18 TASC-punten of hoger moeten scoren op een schaal van maximaal 22 punten. 
Verder onderzoek moet uitwijzen of TASC inderdaad in de praktijk bruikbaar is en of nog verdere 
aanpassing en verfijning vereist is. Het TASC-systeem is specifiek getoetst aan darmkanker. 
Hierbij werden de hoogste scores toegekend aan het epitheliale celadhesiemolecuul (EpCAM), de 
CXC chemokine-receptor 4 (CXCR4), het mucin1 (MUC1) eiwit, de matrix metalloproteinases 
(MMPs), de epidermale groeifactorreceptor (EGFR) en het carcinoembryonaalantigeen (CEA). 
Deze targets werden aldus geïdentificeerd als de meest veelbelovende targets voor doelgerichte 
moleculaire beeldvorming in darmkanker.
De expressie van biomarkers is in het verleden met name onderzocht voor darmkanker in het 
algemeen en in mindere mate voor het specifieke geval van PC bij darmkanker. Daarom werd 
bij het onderzoek beschreven in hoofdstuk 3 de expressie van de biomarkers CXCR4, EGFR, 
EpCAM, de folaat-receptor alpha (FR-α), de hypoxie-induceerbare factor-1alpha (HIF-1α) en 
de vasculair-endotheliale-groeifactor-A (VEGF-A) onderzocht in weefsels van 14 darmkanker-
patiënten met PC. Van de biomarkers met de meest optimale expressie en de hoogste TASC scores, 
namelijk CXCR4, EGFR, EpCAM en VEGF-A, werd doelgerichte optische beeldvorming getest 
in muizen met darmtumoren. Hiertoe werd gebruik gemaakt van nabij-infrarode fluorescente 
probes gebaseerd op antilichamen die in de bloedbaan geïnjecteerd werden. Op grond van de 
resultaten kan geconcludeerd worden dat CXCR4, EpCAM en VEGF-A de meest veelbelovende 
targets voor optische beeldvorming van tumoren in darmkanker-patiënten met PC zijn.
Hoofdstuk 4 geeft een introductie van de mogelijkheden voor intra-operatieve 
fluorescentiebeeldvorming in eierstokkanker (epitheliaal ovariumcarcinoom; EOC). Nadruk 
wordt gelegd op het vinden van de meest geschikte targets in EOC voor klinische toepassing. 
FR-α bleek de meest veelbelovende target te zijn voor klinische fluorescentiebeeldvorming 
in EOC. FR-α komt namelijk verhoogd tot expressie in de overgrote meerderheid van de 
eierstoktumoren (72-97%), zowel in primaire tumoren als in metastatisch weefsel, met vrijwel 
geen expressie in normaal omliggend weefsel. Daarnaast is het betrekkelijk eenvoudig om de op 
het tumorceloppervlak gelokaliseerde FR-α receptor te bereiken met de stof folaat, waarvan al 
bekend is dat hij weinig toxisch is. Een alternatief voor het gebruik van folaat als FR-α-specifieke 
targeting-factor in een optisch contrastmiddel is het klinisch goedgekeurde FR-α-specifieke 
antilichaam Farletuzumab. Naast FR-α worden CXCR4, EGFR en VEGF verhoogd tot expressie 
gebracht in EOC. Voor de desbetreffende targets zijn antilichamen of peptides beschikbaar die in 
de kliniek reeds als therapeuticum ingezet worden. De desbetreffende antilichamen en peptides 
zijn al in sub-therapeutische doseringen goed te gebruiken als optisch contrastmiddel.12 De 
eerder genoemde MMPs komen ook verhoogd tot expressie in EOC en deze biomarkers zijn al in 
dierproeven als targets voor beeldvorming getest.13 Voor MMPs zijn op dit moment echter nog 
geen klinisch toepasbare probes beschikbaar.
Zoals in hoofdstuk 4 beschreven, is FR-α een van de meest geschikte targets voor intra-operatieve 
beeldvorming in patiënten met EOC. Het is bekend dat FR-α verhoogd tot expressie komt in de 
overgrote meerderheid van patiënten met EOC, maar er was weinig bekend over FR-α-expressie 
in eierstoktumoren wanneer patiënten reeds chemotherapie hadden ondergaan. Aangezien 
patiënten met eierstokkanker vaak chemotherapie krijgen voorafgaand aan een operatie is het 
belangrijk om zeker te weten dat de chemotherapie geen negatieve invloed heeft op de FR-α-
status, want anders is intra-operatieve FR-α-specifieke beeldvorming niet zinvol. 
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In hoofdstuk 5 wordt de FR-α-expressie in weefsels van 361 patiënten met EOC beschreven en 
gecorreleerd aan eerdere chemotherapeutische behandeling. FR-α-expressie werd waargenomen 
in 82% van de patiënten met sereuze tumoren, en in 39% van de patiënten met niet-
sereuze tumoren, wat overeenkomt met eerdere studies. FR-α-expressie was niet anders na 
chemotherapeutische behandeling en was niet gecorreleerd aan de overleving van patiënten. 
Hoewel FR-α geïdentificeerd is als geschikte target voor beeldvorming in EOC, is er weinig 
bekend over de folaat receptor-beta (FR-β) in solide tumoren. FR-β is vooral bekend vanwege 
zijn expressie in geactiveerde macrofagen en hematopoietische kanker en wordt gebruikt als target 
in inflammatoire ziekten, zoals reumatoïde artritis en atherosclerotische plaques.14,15 Het was 
denkbaar, dat FR-β naast FR-α als target voor doelgerichte beeldvorming van solide tumoren zou 
kunnen fungeren. In het onderzoek beschreven in hoofdstuk 6 is daarom de FR-β-status bepaald 
in tumorweefsel van 361 patiënten met eierstokkanker, 449 patiënten met borstkanker en 20 
patiënten met PC bij darmkanker. FR-β-expressie werd waargenomen in 21% van de patiënten 
met eierstokkanker, 9% van de patiënten met borstkanker en 55% van de patiënten met PC bij 
darmkanker. In de meeste gevallen was de expressie zwak en derhalve is geconcludeerd, dat FR-β 
vermoedelijk van weinig toegevoegde waarde is in doelgerichte moleculaire beeldvorming van 
solide tumoren.
Naast kanker zou doelgerichte moleculaire beeldvorming ook van substantiële toegevoegde 
waarde kunnen zijn voor de detectie van “goedaardige” aandoeningen, zoals endometriose, waar 
een zo optimaal mogelijke chirurgische detectie en resectie ook van cruciaal belang is voor een 
volledige genezing van de patiënt. Om dit te onderzoeken zijn potentiële targets geanalyseerd 
in endometriose-weefsel en de verkregen resultaten zijn beschreven in hoofdstuk 7. Weefsel 
van 18 patiënten met endometriose is onderzocht op expressie van CXCR4, EpCAM, de 
oestrogeenreceptor (ER), FR-α, HIF-1α, de progesteronreceptor (PR) en VEGF-A en van deze 
potentiële targets werd de TASC score berekend. EpCAM scoorde het best met in 83% van 
de gevallen een matig tot sterke expressie. CXCR4 scoorde ook voldoende als potentiële target 
voor beeldvormingsdoeleinden. Hierbij moet de kanttekening geplaatst worden, dat CXCR4-
expressie weliswaar aantoonbaar was in alle onderzochte weefsels (18/18), maar dat slechts in 
44% van deze weefsels een matig tot sterke expressie waargenomen kon worden. Daarnaast werd 
in het omliggende gezonde weefsel veelal een vergelijkbare expressie van CXCR4 gevonden. Dit 
zal de bruikbaarheid van CXCR4 voor doelgerichte beeldvorming waarschijnlijk aanzienlijk 
beperken, omdat in dit geval het achtergrond-signaal te hoog is en daardoor de T/N ratio te laag. 
VEGF-A en FR-α scoorden beide 17 TASC-punten. Deze twee targets zijn bijzonder interessant, 
omdat er reeds klinisch toepasbare nabij-infrarode optische contrastmiddelen tegen beschikbaar 
zijn (www.clinicaltrials.gov NCT01508572).8 Toekomstig klinisch onderzoek moet uitwijzen of 
de respectievelijke T/N ratio’s hoog genoeg zijn voor accurate intra-operatieve beeldvorming. 
De overige biomarkers hadden lage TASC-scores en werden derhalve niet als geschikte targets 
beschouwd.
In deel II van dit proefschrift wordt de vertaalslag gemaakt van doelgerichte moleculaire 
beeldvorming van solide tumoren naar bacteriële infecties.
In hoofdstuk 8 wordt een introductie gegeven over het concept van bacterie-specifieke gerichte 
moleculaire beeldvorming. Tevens worden de voor- en nadelen van de gebruikte methodiek 
beschreven. De ontwikkeling van het radioactief gelabelde antibioticum ciprofloxacine (99mTc-
ciprofloxacine; Infecton©) voor de specifieke detectie van bacteriële infecties is het meest 
vergevorderd. 
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Er bestaat echter enige twijfel of 99mTc-ciprofloxacine wel strikt bacteriespecifiek is, aangezien 
deze stof in een grote klinische trial een specificiteit van ‘slechts’ 82% bleek te hebben. Andere 
veelbelovende bacterie-gerichte contrastmiddelen, zoals de radioactief gelabelde vorm van 
het antimicrobiële peptide ubiquicidin of het nucleoside-analoog fialuridine (FIAU), zijn 
in ontwikkeling. De diagnostische accuratesse van deze probes in termen van sensitiviteit 
en specificiteit moet echter nog in grotere klinische trials aangetoond worden. Ook de 
bacteriespecifieke fluorescentiebeeldvorming staat nog in de kinderschoenen van preklinische 
ontwikkeling en wordt tot dusver nog niet in patiënten toegepast. Het is echter wel een 
veelbelovend concept zoals recente studies met verschillende probes hebben laten zien. Deze 
probes waren gebaseerd op: I) maltodextrine dat door bacteriën als voedingsstof opgenomen 
wordt; II) protrombine dat aan het coagulase van Staphylococcus aureus bindt; III) een β-lactam 
dat dient als substraat voor het bacteriële enzym β-lactamase; en IV) de stof Bis(Zinc(II)-
dicolylamine) die zich hecht aan de negatief geladen celmembranen van bacteriën.
Om specifieke moleculaire beeldvorming te verkrijgen van infecties veroorzaakt door Gram-
positieve bacteriën is het antibioticum vancomycine gelabeld met het nabij-infrarode 
fluorofoor IRDye800CW (vanco-800CW), zoals beschreven in hoofdstuk 9. Met dit optische 
contrastmiddel was het mogelijk om een S. aureus infectie in een in vivo muizenmodel te detecteren 
en te onderscheiden van een steriele ontsteking of een infectie met de Gram-negatieve bacterie 
Escherichia coli. Bovendien kon een bacteriële biofilm op een metalen implantaat gedetecteerd 
worden in een humaan post-mortem model door middel van vanco-800CW gecombineerd met 
een klinisch-goedgekeurde intra-operatieve infraroodcamera. Translatie van deze probe naar de 
kliniek is naar verwachting goed haalbaar, aangezien zowel vancomycine als IRDye800CW veilig 
in mensen gebruikt kunnen worden.16
conclusIe
Dit proefschrift beschrijft de toepassing van doelgerichte fluorescentiebeeldvorming in 
de chirurgie met nadruk op (I) het vinden van geschikte targets en (II) de haalbaarheid van 
fluorescentiebeeldvorming voor de detectie van solide tumoren en bacteriële infecties.
Het vinden van targets voor intra-operatieve beeldvorming.
De eigenschappen die van belang zijn om van een bepaalde biomarker een geschikte target voor 
beeldvorming te maken zijn vastgelegd in de zogenaamde TArget Selectie Criteria (TASC), zoals 
beschreven in dit proefschrift (hoofdstuk 2). De TASCs zijn een hulpmiddel voor de selectie van 
geschikte targets voor moleculaire beeldvorming in solide tumoren.
In PC bij darmkanker zijn CXCR4, EGFR, EpCAM en VEGF-A de biomarkers met de 
hoogste TASC-scores. Deze eiwitten vormen derhalve aantrekkelijke targets voor moleculaire 
beeldvorming (hoofdstuk 3). Naast een hoge TASC-score is de beschikbaarheid van klinisch 
goedgekeurde medicamenten die specifiek aan de desbetreffende targets binden van groot 
voordeel, omdat een medicament vaak op betrekkelijk eenvoudige wijze aangepast kan worden 
tot een contrastmiddel, dat geschikt is voor gebruik in patiënten. Voor CXCR4, EGFR, EpCAM 
en VEGF-A zijn klinisch-goedgekeurde medicamenten beschikbaar, zoals respectievelijk 
AMD3100, cetuximab, edrecolomab en bevacizumab. Intra-operatieve beeldvorming door 
middel van targeting van deze biomarkers bleek goed uitvoerbaar, zoals getoond in een PC model 
op basis van darmkanker in muizen (hoofdstuk 3). 
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Andere studies hebben succesvolle in vivo moleculaire beeldvorming door middel van targeting van 
CXCR4, EGFR en VEGF-A laten zien met behulp van klinisch beschikbare medicamenten.17-19 
Op dit moment wordt fluorescent gelabelde bevacizumab (bevacizumab-IRDye800CW) getest 
in patiënten met borstkanker (www.clinicaltrials.gov NCT01508572). Het ligt daarom in de 
lijn der verwachting, dat in de nabije toekomst bevacizumab-IRDye800CW getest zal worden 
voor intra-operatieve fluorescentiebeeldvorming in patiënten met PC bij darmkanker. Niet 
onderzocht in de studies beschreven in dit proefschrift, maar wel zeer veelbelovend als target voor 
beeldvorming in darmkanker, is CEA. Deze biomarker heeft een TASC-score van 19 en het is reeds 
in de literatuur beschreven, dat CEA-gerichte beeldvorming succesvol in patiënten is getest. 20 
Daarnaast lieten Kaushal et al. zien, dat ook specifiek intra-operatieve fluorescentiebeeldvorming 
gericht op CEA mogelijk is in muizen.21 
In PC bij eierstokkanker lijkt FR-α de meest geschikte target te zijn, met een hoge kans op 
klinische introductie (hoofdstuk 4). Expressie van FR-α werd aangetoond in de overgrote 
meerderheid van de sereuze ovariumtumoren en bovendien had chemotherapie geen invloed op 
de FR-α-status in vitale tumorcellen die nog aanwezig waren na chemotherapie (hoofdstuk 5). 
Intra-operatieve beeldvorming gericht op FR-α bleek inderdaad mogelijk in patiënten met PC bij 
eierstokkanker.8 Noch voor PC bij darmkanker, noch voor eierstokkanker werd een significante 
rol gevonden voor FR-β als target voor beeldvorming (hoofdstuk 6). Tenslotte lijken EpCAM, 
FR-α en VEGF-A aantrekkelijke targets voor beeldvorming van endometriose (hoofdstuk 7). 
Fluorescente probes gericht op FR-α en VEGF-A zijn klinisch getest en zouden ook toegepast 
kunnen worden voor de detectie van endometriose tijdens laparoscopische procedures.
Peri-operatieve beeldvorming van bacteriële infecties
In vergelijking met de oncologie is doelgerichte moleculaire beeldvorming voor de detectie 
van bacteriële infecties aanzienlijk minder ver gevorderd. Op dit moment is 99mTechnetium-
ciprofloxacine de enige uitgebreid klinisch-geteste bacteriegerichte radiotracer die een redelijke 
sensitiviteit en specificiteit lijkt te hebben voor bacteriële infecties.22 Er zijn echter ook andere 
veelbelovende bacteriegerichte probes in opkomst, waaronder ubiquicidine- en FIAU-gebaseerde 
probes (hoofdstuk 8). Recentelijk zijn in enkele dierstudies ook zeer goede resultaten behaald bij 
fluorescentiebeeldvorming van bacteriële infecties.23-26 Bij aanvang van dit promotieonderzoek 
was nog geen enkele bacteriegerichte fluorescente probe beschreven die eenvoudig naar de 
kliniek vertaald kan worden. Daarom is in het onderhavige promotieonderzoek de mogelijke 
toepasbaarheid van vancomycine-IRDye800CW (vanco-800CW) onderzocht voor de in vivo 
detectie van Gram-positieve bacteriële infecties (hoofdstuk 9). Hieruit kon geconcludeerd 
worden, dat specifieke detectie van stafylokokkeninfecties met vanco-800CW mogelijk is, 
zowel in muizen als in een humaan post-mortem model. Aangezien zowel vancomycine als 
IRDye800CW klinisch goedgekeurde bestanddelen zijn, zal naar verwachting vanco-800CW 
veilig in de kliniek geïntroduceerd kunnen worden, uiteraard na zorgvuldige GMP synthese en 
de noodzakelijke toxiciteitstesten.




Een grote beperking van fluorescentiebeeldvorming is dat op dit moment enkel oppervlakkige 
beeldvorming mogelijk is, doordat de beschikbare camera’s fluorescent signaal slechts tot een 
weefseldiepte van maximaal 1-2 cm kunnen detecteren. Hierdoor is deze vorm van detectie 
slechts toepasbaar voor oppervlakkig-gelegen infecties, zoals het geval is bij wekedeleninfecties of 
oppervlakkige implantaat-infecties. Recent is echter een nieuwe opto-akoestische detectietechniek 
beschreven, waarmee in potentie de detectie van een fluorescent signaal op een weefseldiepte van 
11 cm mogelijk is.27 Deze nieuwe methodiek kan de detectie van dieper gelegen ziekteprocessen 
in patiënten aanzienlijk verbeteren, hetgeen met name van nut kan zijn voor de peri-operatieve 
detectie van bijvoorbeeld bacteriële infecties van heupimplantaten of endocarditis.
De tot dusver onderzochte strategieën voor intra-operatieve beeldvorming maken gebruik van 
een optisch contrast middel gericht tegen één specifieke target. Het is echter goed denkbaar, 
dat in de toekomst een contrastmiddel niet alleen maar gericht is op één enkele biomarker, 
maar dat een cocktail van targeting-moleculen toegediend wordt die gericht is op verschillende 
targets. Dit zou kunnen leiden tot een verbeterde detectie van tumoren of geïnfecteerde weefsels. 
Anderzijds zouden contrastmiddelen dusdanig ontworpen kunnen worden, dat ze in staat zijn 
om zowel een fluorescent signaal uit te zenden als een signaal dat gedetecteerd kan worden met 
een andere beeldvormingsmodaliteit (bijvoorbeeld PET-scan of MRI).28,29 Dergelijke hybride of 
multimodaliteit-contrastmiddelen zouden het mogelijk maken om voorafgaand aan een operatie 
de ziekte precies te lokaliseren en ze zouden vervolgens intra-operatief de chirurg in staat stellen 
een optimale resectie te verrichten. 
De fluorescentiebeeldvorming kan mogelijk aanzienlijk verbeterd worden door het gebruik 
van zogenaamde “slimme” activeerbare contrastmiddelen. In dit geval wordt een fluorescentie 
dovend molecuul – de “quencher” - in de directe nabijheid van een gerichte fluorofoor gebracht. 
Hierdoor is de fluorofoor niet meer in staat een fluorescent signaal uit te zenden. Wanneer 
de fluorofoor-quencher combinatie vervolgens zijn target bereikt, wordt de quencher van de 
fluorofoor gescheiden, hetgeen leidt tot uitzending van een fluorescent signaal door de fluorofoor. 
Op deze manier kunnen hogere T/N ratio’s bereikt worden. Het gebruik van dergelijke “slimme” 
activeerbare probes is reeds beschreven voor beeldvorming van zowel tumoren als bacteriën, maar 
vooralsnog alleen in dierstudies.25,30,31
Concluderend kan gesteld worden, dat doelgerichte fluorescentiebeeldvorming substantieel 
kan bijdragen aan intra-operatieve ziektedetectie en peri-operatieve diagnostiek. De selectie 
van de meest geschikte targets is van cruciaal belang en met dit doel voor ogen moet, zoals 
beschreven in dit proefschrift, met meerdere (TASC) factoren rekening gehouden worden. In 
de oncologie is intra-operatieve doelgerichte fluorescentiebeeldvorming reeds getest in patiënten 
met PC bij eierstokkanker en worden momenteel studies opgezet of uitgevoerd in patiënten 
met borstkanker, PC bij darmkanker en endometriose. Daarnaast is peri-operatieve doelgerichte 
fluorescentiebeeldvorming veelbelovend voor een verbeterde detectie van bacteriële infecties. 
Zoals in dit proefschrift is beschreven, is vanco-800CW een potentiële kandidaat voor dit doel, 
maar andere types van contrastmiddelen zullen mogelijk volgen. Al met al kan geconcludeerd 
worden, dat doelgerichte fluorescentiebeeldvorming een sprankelende toekomst tegemoet gaat.
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Marleen van Oosten werd op 14 november 1984 geboren te Winschoten. Haar middelbare school 
doorliep zij aan het Dollard College in Winschoten, waar zij in 2003 haar gymnasiumdiploma 
behaalde. Vervolgens startte zij de opleiding Geneeskunde aan de Rijksuniversiteit Groningen. 
In 2006 raakte Marleen betrokken bij de onderzoeksgroep van prof. dr. G.M. van Dam met 
als aandachtsgebied fluorescente beeldvorming bij chirurgische ingrepen. Zij combineerde het 
doen van onderzoek met haar co-schappen. Na haar afstuderen in 2009 heeft dit geresulteerd 
in een promotietraject met de focus op het onderwerp fluorescente tumorspecifieke intra-
operatieve beeldvorming in darmkanker. Dit onderzoek combineerde zij met haar aanstelling als 
arts-assistent niet-in-opleiding bij de afdeling Chirurgie in het Universitair Medisch Centrum 
Groningen. In 2011 startte Marleen met de opleiding tot arts-microbioloog en heeft toen tevens 
haar onderzoek vertaald van oncologie naar infecties. Dit leidde tot een nauwe samenwerking 
tussen de Medische Microbiologie en de Chirurgie en onder leiding van prof. van Dam en prof. 
dr. J.M. van Dijl van de afdeling Medische Microbiologie, resulteerde dit in de totstandkoming 
van dit proefschrift.
Marleen van Oosten was born in Winschoten, the Netherlands, on 14 November 1984. In 2003 
she graduated from high school in Winschoten and started medical school at the University 
of Groningen. In 2006, Marleen was introduced to the research group of prof. dr. G.M. van 
Dam, with the focus on fluorescence imaging during surgery. She combined research with her 
clinical internships. After obtaining her M.D. degree in 2009, this research resulted in a PhD 
track with the emphasis on fluorescence targeted intraoperative imaging in colorectal cancer. The 
research was combined with a residency in the department of Surgery. In 2011, Marleen started 
the training to become a medical microbiologist and translated her research from oncology 
to bacterial infections. This led to a close collaboration between the departments of Medical 
Microbiology and Surgery, which resulted in this thesis, under the supervision of prof. van Dam 
and prof. dr. J.M. van Dijl.
Proefschrift Marleen 18-12-2013.indd   215 18-12-13   20:06
Proefschrift Marleen 18-12-2013.indd   216 18-12-13   20:06
13DanKWoord
Proefschrift Marleen 18-12-2013.indd   217 18-12-13   20:06
218
Proefschrift Marleen 18-12-2013.indd   218 18-12-13   20:06
219 13
danKWoord
Tijdens mijn studie geneeskunde kwam ik in aanraking met fluorescentiebeeldvorming 
in de chirurgie. Wat startte als een vrijblijvende verrichting van hand-en-spandiensten in de 
onderzoeksgroep, heeft uiteindelijk geresulteerd in dit proefschrift. De weg naar dit proefschrift 
was enerzijds inspirerend en motiverend, maar anderzijds soms ook zwaar en frustrerend. Hoewel 
mijn eerste intentie was om chirurg te worden, ben ik halverwege mijn onderzoekstraject begonnen 
aan de opleiding Medische Microbiologie, wat ook in dit proefschrift terug te vinden is in de 
verandering van focus op fluorescentiebeeldvorming in kanker naar bacteriële infecties. Achteraf 
is gebleken, dat dat ook onderzoekstechnisch een zeer goede keuze geweest is, resulterend in een 
publicatie in het blad Nature Communications.
Mede gezien het grootste gedeelte van dit proefschrift in de avonduren, weekenden en vakanties 
tot stand is gekomen, kan ik in alle eerlijkheid zeggen dat dat zonder de hulp van een groot aantal 
mensen niet gelukt zou zijn. Enkele van deze mensen wil ik graag in de volgende bladzijden 
persoonlijk bedanken.
Promotores prof. G.M. van Dam, prof. J.M. van Dijl en prof. T. Wiggers.
Beste Go, bedankt voor je begeleiding de afgelopen jaren. Je enthousiasme en ideeën waren erg 
inspirerend, en hebben me er toe gedreven door te gaan wanneer we op een dood spoor leken te 
zitten. We hebben zeker “out of the box” onderzoek verricht.
Beste Jan Maarten, het was een genoegen om samen met jou dit proefschrift tot een einde te 
brengen. Je was een bijzonder goede toevoeging aan het team dat al stond en ik heb bewondering 
voor je professionele en wetenschappelijke inzichten.
Beste Theo, ik waardeer erg hoe je mij van een afstand gesteund hebt bij het afronden van mijn 
proefschrift. Dank je voor je flexibele en meedenkende rol hierbij.
Mijn dank gaat bovendien uit naar de leescommissie, prof. Borel Rinkes, prof. Hollema en 
prof. Götz voor het beoordelen van mijn proefschrift.
Vervolgens wil ik allereerst mijn onderzoeksgroep bedanken. Lucy Crane, Niels Harlaar, Rick 
Pleijhuis, Tim Buddingh, Esther de Boer en Brenda Samaniego Cameron, het was erg leuk 
om met jullie samen te werken. Ook onze weekendprojectjes waren altijd bijzonder gezellig. Ik 
wens jullie allen veel succes met jullie verdere onderzoekstrajecten en specialisaties.
Bedankt aan alle medewerkers bij de chirurgie, waaronder het chirurgisch onderzoekslaboratorium. 
Uit deze groep wil ik in het bijzonder bedanken Jacco Zwaagstra en Douwe Samplonius, 
vanwege hun hulp en expertise. Marco de Bruijn en Theo Bijma, jullie ook bedankt voor het 
mij wegwijs maken op het lab en ook voor de gezelligheid natuurlijk.
Thanks to all researchers within the department of Medical Microbiology, in particular those of 
the Molecular Bacteriology. 
Thank you, Tina Schäfer. I had an excellent time with you in Würzburg. I wish you the best of 
luck with your further research career.
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Bedankt opleiders, zowel prof. Degener en dr. Manson, als prof. Friedrich en dr. Riezebos. 
Jullie zijn altijd enthousiast en faciliterend geweest ten aanzien van mijn onderzoek en dit waardeer 
ik zeer. Dit geldt ook voor de opleiders en stafleden van het Laboratorium voor Infectieziekten. 
In het bijzonder uit deze groep, bedankt dr. Benne en bedankt dr. Möller.
Bedankt collega-(oud-)AIOS, Yanka Kyuchukova, Xuewei Zhou, Lieke van Balen, Edwina 
Doting, Janette Rahamat, Marleen van der Vusse, Felix Geeraerdts, Julia Kovaleva, Júlia da 
Silva en Sulaiman Surie, voor de fijne samenwerking en de gezelligheid!
En uiteraard bedankt aan alle andere medewerkers van de Medische Microbiologie, stafleden, 
analisten en administratieve medewerkers, zowel van het UMCG als het Laboratorium voor 
Infectieziekten. In het bijzonder nog uit deze groep: Ank Vugteveen, de steun en toeverlaat van 
de AIOS, dankjewel!
Het doen van onderzoek heeft veel impact gehad op mijn privéleven. Daarom bedankt aan alle 
familie en vrienden die hier een bijzondere rol in gehad hebben. Pap, mam en Ester en Ate, dank 
jullie wel! Schoonpapa, dank u wel voor uw interesse en ondersteuning de afgelopen jaren. Jullie 
zijn geweldig! Robert en Marjo, beste vrienden die ik mij in kan denken, Chris, Ludwig en 
Sandra, bedankt voor alles! En alle andere vrienden, die ik verder niet bij naam zal noemen maar 
die niet minder belangrijk waren. De belangrijkste les die ik uit mijn onderzoek geleerd heb, 
is dat goede vrienden en familie alles zijn! Ik hoop dat ik vanaf nu meer tijd voor jullie heb. J
Lucy en Ludwig, bedankt voor jullie hulp bij het voltooien van dit boekje.
Lucy, we hebben een hechte band ontwikkeld gedurende onze beide onderzoekstrajecten en ik 
heb veel steun aan je gehad, waarvoor mijn dank. Hoogtepunt: Japan! High five!
Ludwig, je hebt je taak als paranimf heel serieus genomen en bij het ontwerpen van dit boekje 
vakwerk afgeleverd. Dank je!
Tot slot, Hans en Elise, de twee belangrijkste personen uit mijn leven. Hans, dankjewel dat je er 
voor mij was de afgelopen jaren. Ik hou van je! Elise, kleine meid, je bent het beste wat ik gedaan 
heb in mijn leven en ik hou met heel mijn hart van je!
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